CLINICAL TRIAL PROTOCOL

A PHASE 2/3, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE SAFETY AND IMMUNOGENICITY OF COVOVAX [SARS-CoV-2 RECOMBINANT SPIKE PROTEIN NANOPARTICLE VACCINE (SARS-CoV-2 rS) WITH MATRIX-M1™ ADJUVANT] IN INDIAN ADULTS

Protocol number:	ICMR/SII-COVOVAX
Version:	6.0
Date:	18 May 2021
Amendment:	5
Investigational Products:	Test product: COVOVAX [SII-SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] and Reference (control) product: Novavax-SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant

SPONSOR

SERUM INSTITUTE OF INDIA
CYRUS POONAWALLA GROUP

SERUM INSTITUTE OF INDIA PRIVATE LIMITED (SIIPL)
212/2, Off Soli Poonawalla Road, Hadapsar, Pune-411028, INDIA

CO-SPONSOR

icmr
INDIAN COUNCIL OF MEDICAL RESEARCH

INDIAN COUNCIL OF MEDICAL RESEARCH
V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi – 110029, INDIA

CONFIDENTIAL

TABLE OF CONTENTS

LIST OF ABBREVIATIONS

ACE2	Angiotensin-Converting Enzyme 2
ADE	Antibody Dependent Enhancement
AE	Adverse event
AESI	Adverse event of special interest
CI	Confidence interval
CLIA	Chemiluminescence Immunoassay
CMI	Cell Mediated Immunity
CoV	Coronavirus
COVID-19	Coronavirus Disease 2019
CRF	Case report form
CRO	Contract research organization
CTRI	Clinical trials registry of India
DS	Drug Substance
DP	Drug Product
DCGI	Drugs controller general of India
DSMB	Data Safety Monitoring Board
E	Envelope protein
ELISA	Enzyme-linked Immunosorbent Assay
ELISpot	Enzyme- linked Immunospot
GCP	Good Clinical Practices
GCLP	Good Clinical Laboratory Practices
GMEUs	Geometric Mean ELISA Units
GMTs	Geometric mean titers
IcEv	Intercurrent Events
ICF	Informed consent form
ICMR	Indian Council of Medical Research
ICU	Intensive Care Unit
IEC	Institutional Ethics Committee
IFN-γ	Interferon-gamma
IM	Intramuscular
M	Membrane protein
MAAE	Medically Attended Adverse Event
MedDRA	Medical Dictionary for Regulatory Activities
MERS-CoV	Middle East Respiratory Syndrome-Coronavirus
N	Nucleocapsid protein

Nab	Neutralising Antibody
NARI	National AIDS Research Institute
NHPs	Non-Human Primates
RT-PCR	Reverse transcription Polymerase Chain Reaction
PI	Principal Investigator
PIMMCs	Potential immune mediated medical conditions
PSRT	Protocol Safety Review Team
PT	Preferred term
RBD	Receptor Binding Domain
rS	Recombinant spike protein
S	Spike glycoprotein
SAE	Serious adverse event
SARS-CoV	Severe Acute Respiratory Syndrome-Coronavirus
SIIPL	Serum Institute of India Private Limited.
SOC	System Organ Class
SOP	Standard Operating Procedure
UPT	Urine Pregnancy Test
WHO	World Health Organization

PROTOCOL SUMMARY

Title	A phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults
Protocol number	ICMR/SII-COVOVAX
Phase	2/3
Study rationale	The COVID-19 epidemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Containment measures have failed to stop the spread of virus, which has reached pandemic levels. There are currently no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. Novavax has developed SARS-CoV-2 rS Nanoparticle Vaccine with Matrix adjuvant. It has been already administered in more than 30000 adults across ongoing Phase 1/2, Phase 2 and Phase 3 studies in Australia, South Africa, UK, USA and Mexico without any serious safety concerns. The UK Phase 3 study enrolled more than 15,000 participants between 18-84 years of age. The primary efficacy endpoint (PCR-confirmed symptomatic COVID-19 with onset at least 7 days after the second vaccination) demonstrated an overall vaccine efficacy of 89.7%. The South Africa Phase 2b study enrolled more than 4,000 participants between 18-84 years of age. The primary efficacy endpoint demonstrated an overall vaccine efficacy of 49.4%. Post-hoc vaccine efficacy against B.1.351 strain (South African variant) was 51.0%.Considering the large safety and efficacy data available from these studies, we have planned this Phase 2/3 safety and immunogenicity study in Indian population for licensure in India.
Population	1600 healthy individuals ≥ 18 years of age
Participation Duration	Approximately 6 months
Study duration	Approximately 9 months: 1.5 months for recruitment and 6 months of follow up

Description of study vaccine (s)	**Phase 2 part:** • **Test Vaccine** COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] is available as a ready to use liquid formulation in a single dose (0.5 mL) vial containing 5 µg antigen and 50 µg Matrix-M1 adjuvant. The other ingredients are 25 mM phosphate buffer (pH 7.2), 300 mM sodium chloride, and 0.01% (v/v) polysorbate 80. Manufacturer: Drug Substance (DS) is manufactured by Novavax and is imported for further formulation and fill finished at Serum Institute of India Pvt. Ltd. (SIIPL). • **Comparator product (Placebo):** Placebo: 0.9% Normal saline (Sodium chloride) for injection Manufacturer: Serum Institute of India Pvt. Ltd. **Phase 3 part:** • **Test Vaccine** COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] is available as a ready to use liquid formulation in a single dose (0.5 mL) vial containing 5 µg antigen and 50 µg Matrix-M1 adjuvant. The other ingredients are 25 mM phosphate buffer (pH 7.2), 300 mM sodium chloride, and 0.01% (v/v) polysorbate 80. Manufacturer: Serum Institute of India Pvt. Ltd. • **Active comparator vaccine (Control vaccine)** Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ Adjuvant is available as a ready to use liquid formulation in a 10-dose vial with each dose of 0.5 mL containing 5 µg antigen and 50 µg Matrix-M1 adjuvant. The other ingredients are 25 mM phosphate buffer (pH 7.2), 300 mM sodium chloride, and 0.01% (v/v) polysorbate 80. Manufacturer: Novavax, 21 First field Road, Gaithersburg,

<table>
<tr><td></td><td colspan="2">MD20878, USA
All the study vaccines (COVOVAX / Control vaccine / Placebo) will be administered intramuscularly (IM) as two doses of 0.5 ml each with 21 days interval between doses. The preferred site for injection is deltoid muscle.</td></tr>
<tr><td rowspan="8">Objectives and endpoints:</td><td colspan="2">Initially, SIIPL had received DS manufactured by Novavax which was fill finished (DP) at SIIPL and used as test vaccine (COVOVAX) in the Phase 2 part of the study. Subsequently SIIPL manufactured both DS and DP which will be used as test vaccine (COVOVAX) in the Phase 3 part of the study. Therefore, the data from Phase 2 and Phase 3 parts of the study will be analyzed separately.</td></tr>
<tr><td>Objectives</td><td>Endpoints</td></tr>
<tr><td colspan="2">Primary</td></tr>
<tr><td>To assess the safety of COVOVAX</td><td>Occurrence of causally related serious adverse events (SAEs) throughout the study duration following vaccination</td></tr>
<tr><td colspan="2">Co-Primary</td></tr>
<tr><td>To assess immunogenicity of COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) by IgG ELISA assay</td><td>Ratio of Geometric Mean ELISA Units (GMEUs) of anti-Spike (S) protein IgG at 14 days after second vaccination (35 days post first dose vaccination)</td></tr>
<tr><td colspan="2">Secondary</td></tr>
<tr><td>To assess the tolerability and reactogenicity profile of COVOVAX in comparison with Placebo (for Phase 2 part) AND COVOVAX with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part)</td><td>a) Occurrence of solicited local and systemic adverse events (AEs) for 7 days following each dose (Reactogenicity cohort)
b) Occurrence of unsolicited adverse events including medically attended adverse events (MAAEs) for 35 days post first dose vaccination
c) Occurrence of SAEs, related MAAEs, and adverse events of</td></tr>
</table>

		special interest (AESI) which encompasses potential immune-mediated medical conditions (PIMMCs) and AESIs relevant to COVID-19 throughout the study duration following vaccination
	To assess immunogenicity of COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) by IgG ELISA and neutralizing antibody assays	a. GMEUs of anti-S IgG antibodies at baseline, 21, 35 and 179 days post first dose vaccination. b. Seroconversion (defined as at least four-fold increase in antibody titres from baseline) for anti-S IgG at 21, 35 and 179 days post first dose vaccination. c. GMTs of virus neutralizing antibodies (NAb) at baseline and 35 days post first dose vaccination. d. Proportion with seroconversion (defined as at least four-fold increase in titres from baseline) for neutralizing antibodies at 35 days post first dose vaccination.
	Exploratory	
	To assess immunogenicity of the COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)	a. GMTs of virus neutralizing antibodies (NAb) at 21- and 179-days post first dose vaccination. b. Proportion with seroconversion for NAb at 21- and 179-days post first dose vaccination. c. Mean of change from baseline (Day 1) in the cell-mediated immune responses (for example, as

		measured by enzyme-linked immune absorbent spot (ELISpot) ± intracellular cytokine staining) on, Day 36 and Day 180.
	To assess the incidence SARS-CoV-2 infection between COVOVAX and Placebo (for Phase 2 part) AND between COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part)	a. Virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19 which occur from 14 days after each vaccination until the end of the study Visit 6 - Day 180 (+28)
		b. Laboratory confirmed (RT-PCR and /or Anti-Nucleocapsid IgG) asymptomatic cases of COVID-19 which occur 14 days after each vaccination until the end of the study Visit 6 - Day 180 (+28)
		c. Laboratory confirmed (RT-PCR and /or Anti-Nucleocapsid IgG) SARS-CoV-2 cases (symptomatic as well as asymptomatic) which occur 14 days after each vaccination until the end of the study Visit 6 - Day 180 (+28)
	To assess the incidence of severe COVID-19 disease between COVOVAX and Placebo (for Phase 2 part) AND between COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part)	a) Severe virologically confirmed COVID-19 infection b) Intensive care unit (ICU) admissions associated with virologically confirmed COVID-19 infection c) All cause deaths in virologically confirmed COVID-19 infection

Study Design:	This is a Phase 2/3, observer-blinded, randomised, controlled study in adults ≥ 18 years of age in India, to evaluate the safety of COVOVAX in comparison with Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) and Placebo; and for comparison of the immunogenicity of COVOVAX in comparison with Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant). A total of 1600 eligible participants of ≥ 18 years of age will be enrolled in this study. Of these 460 participants will be part of immunogenicity cohort. The remaining 1140 participants will be part of safety cohort. All eligible participants (n=1600) will receive two doses of 0.5 ml each of either COVOVAX or Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) or Placebo on Day 1 and Day 22 as per randomization. Post vaccination site visits are planned on Day 22, Day 36, Day 85 and Day 180. All participants will also be contacted telephonically on Day 120 for safety follow up. The study will be conducted in two parts as below: **Phase 2 part:** Initial 200 participants have been enrolled in the Safety cohort with 3:1 allocation to COVOVAX (n=150) or Placebo (n=50). There was a telephonic contact at 7 days after first dose for safety assessment. The independent Data Safety Monitoring Board (DSMB) reviewed this safety data and recommended to continue the recruitment in the Phase 3 part of the study. This interim safety data and DSMB recommendation was submitted to DCGI. DCGI issued permission to continue the study for recruitment in the Phase 3 part. On or after Day 85 visit, unblinding will be done for all the participants and those in the Placebo group will be offered COVOVAX (test vaccine that is being used in Phase 3 part i.e. both DS and DP manufactured by SIIPL). If they agree to receive COVOVAX, then COVOVAX will be administered as two dose schedule (Each dose of 0.5 ml intramuscularly with minimum interval of 21 days between the doses). Even after unblinding all the participants will be continued in the study till Day 180 visit.

Phase 3 part: Enrolment of remaining 1400 participants (940 from the Safety cohort and 460 from the Immunogenicity and Reactogenicity cohort) will be done.

Treatment allocation for the Phase 3 part:

Safety cohort (n=940)	COVOVAX	705
	Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant)	235
Reactogenicity and Immunogenicity cohort (n=460)	COVOVAX	345
	Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant)	115

Immunogenicity and Reactogenicity cohort: In the 460 participants [345 in the COVOVAX group and 115 in the Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) group] who agree to give blood for immunogenicity testing, approximately 10 ml blood sample will be collected at baseline (Day 1), Day 22, Day 36 and Day 180. Additionally, up to 20 ml blood sample may be collected from subset of 28 participants for assessment of cell mediated immune (CMI) responses at baseline, Day 36 and Day 180. Of these 460 participants, 120 participants of ≥ 60 years of age will be enrolled.

In the same cohort, data of solicited local and systemic adverse events through 7 days after each dose will be collected using participant diary cards. These participants will receive a digital thermometer, measuring scale and a diary.

Treatment allocation			
Age group	**COVOVAX**	**Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)**	**Total**
18-59 years	255	85	340
≥ 60 years*	90	30	120
Total	345	115	460

**Since the majority of population ≥ 60 years of age may have already received COVID-19 vaccination, there may be difficulty in recruiting these numbers. If this is not achieved, any shortfall in these numbers will be recruited in 18-59 years age group.*

	Safety Cohort: 940 participants in this cohort will receive either COVOVAX (n=705) or Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (n=235) as per randomization. Post first dose vaccination site visits are planned on Day 22, Day 36, Day 85 and Day 180. All participants will also be contacted telephonically on Day 120 for safety follow up.
Inclusion and Exclusion Criteria	**Inclusion criteria:** Eligible participants must meet all of the below criteria at the time of enrolment: 1. Adults aged ≥ 18 years of either sex 2. Written informed consent by participants 3. The participant is resident of the study area and is willing to comply with study protocol requirements, including availability for all scheduled visits of the study 4. Healthy, as determined by medical history and physical examination 5. Sexually active female participants of childbearing potential* must have practiced adequate contraception** for 28 days prior to study vaccine administration and agree to continue adequate contraception until completion of their Day 36 visit * Females can be considered not of childbearing potential only if they have undergone bilateral tubal ligation or occlusion, or hysterectomy, or bilateral oophorectomy, or are post- menopausal (defined as continuous amenorrhea for 12 months) ** Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label as follows: • Combined estrogen and progesterone oral contraceptives • Injectable progestogen • Implants of etenogestrel or levonorgestrel • Contraceptive vaginal ring • Percutaneous contraceptive patches • Intrauterine device or intrauterine system • Male partner (sole partner for participant) sterilized

- Male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository), and/or progesterone alone oral contraceptive

6. Female participants of childbearing potential must have a negative urine pregnancy test within 24 hours prior to study vaccine administration

Exclusion criteria:

Participants meeting any of the below criteria at the time of enrolment will be ineligible to participate in the trial:

1. Acute illness including COVID-19 with or without fever at the time of study vaccine administration
2. History of laboratory confirmed (by PCR or serology to SARS-CoV-2) COVID-19 disease
3. History of severe allergic reactions after previous vaccinations or hypersensitivity to any component of study vaccines
4. Any confirmed or suspected condition with impaired/altered function of immune system (e.g. immunodeficient or autoimmune conditions)

   Note: Stable endocrine disorders that have a confirmed autoimmune etiology (e.g., thyroid, pancreatic) are allowed.
5. Have any bleeding disorder which is considered as a contraindication to intramuscular injection or blood draw
6. Suspected or known current alcohol or drug dependence
7. Chronic administration (defined as more than 14 continuous days) of immunosuppressant or other immune-modifying drugs within three months prior to the study vaccination or planned use throughout the study period (For corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg per day. Inhaled, intranasal and topical steroids are allowed, use of Hydroxychloroquine prophylaxis is allowed)
8. Administration of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 3 months or planned use throughout the study period
9. Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e.

	apixaban, rivaroxaban, dabigatran and edoxaban etc) **Note:** The use of ≤ 325 mg of aspirin per day with or without any other antiplatelet drugs like clopidogrel, prasugrel, ticagrelor is permitted 10. Administration of any vaccine within 28 days prior to enrolment in the study or planned administration of any vaccine for until 28 days after second study vaccination 11. Prior receipt of an investigational or licensed vaccine likely to impact interpretation of the trial data 12. Prior receipt of a COVID-19 vaccine or planning to receive a COVID-19 vaccine during the course of the study 13. Current or planned participation in prophylactic drug trials for the duration of the study 14. Use of any investigational or non-registered drug or vaccine within 30 days prior to the administration of study vaccines or planned during the study 15. Pregnant or breast-feeding 16. Individuals who are part of study team or close family members of individuals conducting this study 17. Participants who are having any current workup of undiagnosed illness within the last 8 weeks that is either participant-reported or has been clinician-assessed, which could lead to a new condition or diagnosis 18. Acute or chronic, clinically significant pulmonary, cardiovascular, endocrine, metabolic, gastrointestinal, neurological, hepatic, renal functional abnormality or any other systemic disorder, that are assessed by the investigator (based on medical history or physical examination) as being clinically unstable within the prior 4 weeks as evidenced by: a. Hospitalisation for the condition, including day surgical interventions. b. New significant organ function deterioration. c. Needing addition of new treatments or major dose adjustments of current treatments (mild or moderate well-controlled comorbidities are allowed). 19. History of chronic neurological disorders such as multiple sclerosis,

	dementia, transient ischemic attacks, Parkinson's disease, degenerative neurological conditions, neuropathy, and epilepsy or a history of stroke or previous neurological disorder within 12 months with residual symptoms **Note:** Participants with a history of migraine or chronic headaches or nerve root compression that have been stable on treatment for the last 4 weeks are not excluded 20. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or make it unlikely that the participant could complete the protocol
Study Conduct:	The study will be initiated after permissions from the Drugs Controller General of India (DCGI) and Institutional Ethics Committee (IEC) of respective sites are obtained and registration of the study on Clinical Trial Registry of India (CTRI) is completed. The participants will be screened for eligibility after written informed consent is obtained. In female participants of childbearing age, urine pregnancy test (UPT) will be done on Day 1 before randomizing the study participant and again on Day 22 before vaccination. The eligible participants will be randomized as soon as possible but not beyond 7 days from screening. Approximately 3 ml blood sample will be collected for SARS-CoV-2 serology (IgG) before vaccination. In addition, nasopharyngeal / nasal and/or throat swab will be collected for RT-PCR test for detection of SARS-CoV-2 infection. A total of 1600 eligible participants will be randomized as mentioned above to receive study vaccine. The study vaccines will be injected intramuscularly in the deltoid as two doses of 0.5 mL each on Day 1 and Day 22 (+ 7 days). The participants will be observed closely for at least 30 minutes following vaccination. Participants will return to the clinical study site for follow up on Day 22 (+7 days), Day 36 (+7 days), Day 85 (+14 days) and Day 180 (+28 days). They will also be contacted telephonically on Day 120 (+14). In addition, initial

	200 participants from safety cohort (Phase 2 part of the study) will be contacted telephonically on Day 8 (+2). Approximately up to 10 ml blood sample will be collected at baseline (Day 1), Day 22, Day 36 and Day 180 post-vaccination in immunogenicity cohort participants. Additionally, up to 20 ml blood sample may be collected from subset of 28 participants for assessment of cell mediated immune (CMI) responses at baseline, Day 36 and Day 180. Additionally, in all study participants, approximately 3 ml blood will be collected for detection of anti-Nucleocapsid IgG antibodies on Day 36, Day 85 and Day 180. Physical examination (PE) and vital sign evaluations will be performed and medical history and prior/concomitant medications will be captured on Day 1 (Full PE), Day 22 (+7 days), Day 36 (+7 days), Day 85 (+14 days) and Day 180 (+28 days) (Targeted PE for post vaccination visits). Vital sign measurement after 30 minutes (+30 minutes) post-vaccination will also be done. **Adverse Events (AE):** **All participants:** 1. Unsolicited adverse events including MAAEs will be collected for 35 days after Dose 1 (14 days post second dose vaccination). 2. SAEs, related MAAEs and AESI including PIMMCs and AESIs relevant to COVID-19 including possible vaccine-enhanced disease will be collected throughout the study participation after vaccination. **Only for Reactogenicity and immunogenicity cohort:** Solicited local and systemic adverse events will be actively collected for 7 days after each vaccination using participant diary cards. The solicited local AEs to be collected include pain, tenderness, erythema, swelling and induration. The solicited systemic AEs to be collected include fever, headache, fatigue, malaise, arthralgia, myalgia, nausea and vomiting. All solicited AEs, even if they are medically attended will not be considered as MAAEs.

	Testing for COVID-19 during the study period: Participants will be tested for COVID-19 if they present with symptoms of suspected COVID-19 disease [Appendix II, Table 1] or history of contact with a confirmed COVID-19 positive case. Severe COVID-19 disease will be defined as per criteria described in Appendix II, Table 2. Detailed clinical parameters will be collected from medical records. These are likely to include, but are not limited to, oxygen saturation, need for oxygen therapy, respiratory rate and other vital signs, need for ventilatory support, X-ray and CT scan imaging and blood test results, amongst other clinically relevant parameters. **Occurrence of COVID-19 disease in between first and second dose:** If the participant is confirmed with COVID-19 after the first dose but before the second dose, then the participant will be vaccinated with the second dose only two weeks after clinical recovery from COVID-19 disease. This is applicable, even if it is outside the recommended window period for the second dose. These participants will be continued in the study until Day 180 visit.
Safety monitoring	Safety will be monitored during the study by on-site clinical staff and routinely by the Protocol Safety Review Team (PSRT), an internal group of physicians which includes the ICMR Medical Officers, SIIPL Medical Officers, a biostatistician and designated pharmacovigilance medical officer from the CRO. The PSRT may seek independent expert medical opinion as dictated by the occurrence of certain events. There will be periodic reviews of accruing safety data by the PSRT. In addition, there will be an independent Data Safety Monitoring Board (DSMB) who will review the safety data and provide oversight on the study.
Statistical considerations	The study is designed to have a 95% probability to detect at least one casually related SAE in participant administered COVOVAX, if the frequency of casually related SAE is 1/400. It is planned to randomize 460 participants in the immunogenicity cohort [345 to COVOVAX and 115 to the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) groups]. Assuming that the proportion of

	non-evaluable participants ≤ 20% (which leads to a sample size of 368 evaluable participants), the study will have at least 90% power to show non-inferiority of immune responses assuming a Coefficient of Variation of 1.35 [the $base_{10}$ log of the standard deviation (SD) from Day 35 was estimated from the Part 1 (Phase 1) of 2010nCoV-101 study for anti-spike (S) protein IgG EUs]. The study will have at least 80% power to show non-inferiority of immune responses with a sample size of 276 evaluable participants. Non-inferiority will be concluded if the lower limit of the two-sided 95% CI for the GMEU ratio for anti-S protein IgG antibodies against SARS-CoV-2 spike protein between COVOVAX and the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) is > 0.67. Additional assumptions include a one-sided significance level of 0.025 and '0' difference in anti-S protein IgG antibody titers against anti-spike(S) protein IgG between the two vaccine groups (i.e. a GMEU ratio between both vaccine groups of 1). Sample size calculations were performed using a Non-inferiority test for the ratio of two means in PASS 15.0.7 Version software. Detailed statistical analytical methods will be provided in statistical analysis plan (SAP) which will be prepared and approved before database lock. Data from the switched treatment safety population (Phase 2 part - safety cohort) will be summarized separately. The safety data collected from such participants till the time they receive first dose of COVOVAX will be analyzed as a part of Placebo group. Safety data 7 days post first dose from initial 200 participants from safety cohort in the Phase 2 part of the study will be summarized descriptively for DSMB review. Data will be analyzed separately for Phase 2 and Phase 3 parts. Two interim analyses are planned after completion of 14 days follow up after the second dose (till Day 36) of all study participants. The first interim analysis will include 14 days safety data after second dose (till Day 36). The second interim analysis will include the 14 days immunogenicity data after second dose (Day 36).

1. GENERAL INFORMATION

Sponsor	**SERUM INSTITUTE OF INDIA PVT. LTD.** 212/2, Off Soli Poonawalla Road, Hadapsar, Pune-411028 [redacted]
Co-Sponsor	**INDIAN COUNCIL OF MEDICAL RESEARCH** V. Ramalingaswami Bhawan, P.O. Box No. 4911 Ansari Nagar, New Delhi - 110029, India
[redacted]	



2. INTRODUCTION& BACKGROUND INFORMATION

2.1 INTRODUCTION

In December 2019, a cluster of a novel coronavirus, known as 2019-nCoV cases were identified in Wuhan, China.[1] The virus (subsequently named as SARS-CoV-2) is similar to the severe acute respiratory syndrome (SARS-CoV), and the Middle East respiratory syndrome (MERS-CoV) viruses.[2] Coronavirus disease 2019 (COVID-19) is the infectious disease caused by SARS-CoV-2.

Despite unprecedented containment measures adopted by the Chinese government, SARS-CoV-2 rapidly spread across the world. The WHO declared the COVID-19 outbreak a public health emergency of international concern on 30 January 2020. On March 11, 2020, the WHO declared COVID-19 a global pandemic.

As of 22 September 2020, there have been 31.17 million reported cases and 962,613 deaths worldwide.[3] Importantly, as of 22 September 2020, India reported total confirmed cases of about 5.5 million with 88,935 fatalities as per data of Ministry of Health, Government of India.[4]

Coronaviruses (CoVs) are spherical, enveloped, large positive-sense single-stranded RNA genomes. One-fourth of their genome is responsible for coding structural proteins, such as the spike (S) glycoprotein, envelope (E), membrane (M) and nucleocapsid (N) proteins. E, M, and N are mainly responsible for virion assembly whilst the S protein is involved in receptor binding, mediating virus entry into host cells during CoVs infection via different receptors.[5] SARS-CoV-2 belongs to the phylogenetic lineage B of the genus Betacoronavirus and it recognises the angiotensin-converting enzyme 2 (ACE2) as the entry receptor.[6] It is the seventh CoV known to cause human infections and the third known to cause severe disease after SARS-CoV and MERS-CoV.

The spike (S) protein is a type I, trimeric, transmembrane glycoprotein located at the surface of the viral envelope of CoVs, which can be divided into two functional subunits: the N-terminal S1 and the C-terminal S2. S1 and S2 are responsible for cellular receptor binding via the receptor binding domain (RBD) and fusion of virus and cell membranes respectively, thereby mediating the entry of SARS-CoV-2 into target cells.[5] The roles of S protein in receptor binding and membrane fusion make it an ideal target for vaccine and antiviral development, as it is the main target for neutralising antibodies.

Although individuals of any age can acquire SARS-CoV-2, certain individuals are at a higher

risk of infection with SARS-CoV-2. The high-risk group includes the health care workers (physicians and paramedical staff) working amid COVID-19 infected patients and all other people including household contacts of COVID-19 confirmed patients or people currently residing or working in COVID-19 hotspots/outbreak areas where there is a high risk of transmission of COVID-19 infection. The SARS-CoV-2 infections tend to be severe in population with co-morbidities or elderly population aged ≥ 60 years and therefore such subjects living or currently working in COVID-19 affected areas, are also considered high-risk population.

There is an urgent need to ensure the safety and health of existing health care workers and all other people living in SARS-CoV-2 infected areas where there is a high risk of disease transmission and find strategies to reduce the incidence, duration and intensity of SARS-CoV-2 infection among such population.

Currently, there is no specific antiviral treatment recommended for COVID-19, the current treatment strategy being only supportive. There are several vaccines in the various stages of clinical development and few vaccines have been provided emergency use authorization in several countries worldwide including in India.

2.2 SARS-COV-2 RECOMBINANT SPIKE PROTEIN NANOPARTICLE VACCINE (SARS-COV-2 rS) WITH MATRIX-M1™ ADJUVANT

Novavax, Inc. has developed a recombinant vaccine adjuvanted with the saponin-based Matrix-M1™ (previously referred to as Matrix-M) for the prevention of disease caused by the SARS-CoV-2 virus. SARS-CoV-2 recombinant spike (rS) protein nanoparticle vaccine (SARS-CoV-2 rS) is constructed from the full length wild-type SARS-CoV-2 S glycoprotein (GP) based upon the GenBank gene sequence MN908947, nucleotides 21563-25384. The S protein is a type 1 trimeric glycoprotein of 1,273 amino acids that is produced as an inactive S0 precursor. The S-gene was codon optimized for expression in Spodoptera frugiperda (Sf9) insect cells. The SARS-CoV-2 rS nanoparticle vaccine is intended for administration with Matrix-M1™ adjuvant, which is a saponin-based adjuvant that has been shown to enhance the immunogenicity of nanoparticle vaccines in nonclinical and clinical studies. The SARS-CoV-2 rS nanoparticle vaccine candidate features targeted mutations to improve resistance to proteolytic cleavage and enhance retention of the prefusion conformation. It binds to the human ACE2 receptor with high affinity and exhibits good thermostability. Further details on the study vaccine can be found in the IB (Novavax 2020).

The SARS-CoV-2 rS nanoparticle vaccine, developed by Novavax, is constructed from the full length wild-type SARS-CoV-2 S glycoprotein based upon the GenBank gene sequence MN908947, nucleotides 21563-25384. The S protein is a type 1 trimeric glycoprotein of 1,273 amino acids that is produced as an inactive S0 precursor. The S-gene was codon optimized for expression in Sf9 insect cells. The native S protein has been modified by mutation of the putative native furin cleavage site RRAR to QQAQ and insertion of 2 proline substitutions (positions K986P and V987P) in the HR1 domain. Coronavirus S proteins are metastable prefusion type I glycoproteins that undergo structural rearrangement to a post fusion form facilitating fusion of viral and host-cell membranes and infection. Mutation of the S protein furin site and 2 adjacent proline mutations in the C-terminal region of betacoronavirus S proteins is effective in stabilizing SARS-CoV-2 S in a prefusion conformation with high affinity to the human ACE2 receptor.[7] SARS-CoV-2 rS with these substitutions, as exemplified by the Novavax BV2373 construct, is resistant to proteolytic cleavage, binds to the ACE2 receptor with high affinity, and exhibits good thermostability.

The recombinant SARS-CoV-2 S genes are cloned into pBac™-1 deoxyribonucelic acid (DNA) baculovirus transfer vectors (Millipore Sigma, Burlington, Massachusetts) and co-transfected into Sf9 cells using the flashBAC™ GOLD system (Oxford Expression Technologies, Oxford, United Kingdom) using Roche – X-tremeGENE HP transfection reagent (Roche). The recombinant baculoviruses expressing the SARS-CoV-2 S protein are then identified and amplified in cell culture to produce a master virus seed.

2.3 MATRIX-M ADJUVANT

Adjuvants are compounds which, when combined with a specific vaccine antigen, serve to increase the immune response to the vaccine. In general, adjuvants work by engaging one or more component of the innate immune system, a system that provides a rapid response to infection or tissue damage based on recognition of molecular structures common to large groups of microbial pathogens.[8] Adjuvants may both quantitatively increase the antibody response and also qualitatively broaden its specificity. In addition, some adjuvants may modulate the cellular immune response.

Matrix-M is a saponin-based adjuvant, which can be co-administered with an antigen to induce a targeted and enhanced immune response. The proposed mode of action of Matrix-M does not include a depot effect, but rather is through a combination of activities including recruitment and activation of innate immune cells to the site of vaccine injection, rapid antigen delivery to antigen-presenting cells (APCs), and enhanced antigen presentation via both major histocompatibility complex (MHC) I and MHC II molecules in the draining lymph nodes.

Further details regarding the Matrix-M adjuvant are provided in the current version of the Matrix-M adjuvant safety supplement to the IB.

2.4 COVOVAX:

After technology transfer between Novavax and Serum Instiute of India Pvt Ltd., Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant vaccine is also manufacturedat SIIPL. It is called as COVOVAX [SII-SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant)].

Initially SIIPL had planned to get the Drug substance (DS) from Novavax from its USA or EU sites. However, during the course of development it was realized that the countries may impose a ban to export the DS to India, as they need to prioritize and fulfill their country's needs. Therefore, SIIPL has made arrangements with Novavax to manufacture DS at SIIPL and establish the facility for the same not only for India but also for global supply.

Test vaccine used in the Phase 2 part had DS manufactured by Novavax and fill finished at SIIPL.

Considering this background, the GMP batch of the Drug product has been manufactured using the DS manufactured at SIIPL with a similar process as that of Novavax using the cell line and the virus stock received from Novavax. Therefore, to cater the increasing vaccine requirement in India, **the Phase 3 part of this clinical trial will evaluate COVOVAX (both DS and DP manufactured at SIIPL)**.

2.4.1 Summary of Nonclinical Studies:

In support of the development of SARS-CoV-2 rS, Novavax has obtained nonclinical pharmacology data concerning several SARS-CoV-2 spike protein variants, toxicity data concerning SARS-CoV-2 rS with Matrix-M, and prior toxicity data concerning other viral glycoproteins manufactured in the baculovirus-Sf9 system and formulated with Matrix-M.

2.4.2 Nonclinical Data from Other Baculovirus-Sf9-Produced Nanoparticle Vaccines that Support SARS-CoV-2 rS Development

The immunogenicity and protective efficacy of 2002-2003 SARS-CoV S protein and chimeric influenza/SARS-CoV virus-like particle (VLP) vaccines produced in the baculovirus-Sf9 system and administered with and without aluminum hydroxide adjuvants was demonstrated in a mouse challenge study. The selected target was the S protein, which mediates coronavirus attachment to host cells and, in the case of SARS-CoV, binds to the same angiotensin converting enzyme 2 (ACE2) receptor as the SARS-CoV-2 responsible for the current COVID-19 outbreak. Robust neutralizing antibody titers were observed following vaccination, although both antigens required adsorption to aluminum hydroxide for optimal responses. Following SARS-CoV

challenge, there were no survivors among vehicle-treated mice, whereas 70% of mice in the lowest-dose SARS-CoV S group without aluminum, and 100% of mice from all other groups survived.[9]

Middle Eastern respiratory syndrome (MERS), arose in Saudi Arabia in 2012 and was found to be caused by another coronavirus, now termed MERS-CoV, that was resident in camels. The immunogenicity and protective efficacy of a MERS-CoV S nanoparticle vaccine with and without Matrix-M adjuvant was demonstrated in a mouse challenge study. Following vaccination, the MERS-CoV S nanoparticle was immunogenic across all active treatment groups; however, the presence of Matrix-M induced a 3 to > 10-fold enhancement of the binding and neutralizing antibody responses. In addition, Matrix-M essentially eliminated the antigen dose-response, suggesting the potential for major antigen sparing and consequent improved manufacturing efficiency and timeliness. Unlike SARS-CoV and SARS-CoV-2, which bind to the ACE2 receptor of human cells, the MERS-CoV host cell receptor is dipeptidyl peptidase IV (DPP4).[8] The MERS-CoV S protein does not bind to murine DPP4, and mice are not susceptible to MERS-CoV infection; therefore, mice were transduced with human DPP4 (hDPP4) prior to challenge. Following challenge with MERS-CoV, virus replication was significantly reduced in all immunized animals compared with placebo recipients, with virus replication almost completely blocked in animals receiving MERS-CoV S nanoparticles with Matrix-M.[10]

Protective efficacy of viral glycoproteins produced in the bacuilovirus-Sf9 system has also been shown against a highly virulent filovirus, Zaire ebolavirus (EBOV), with EBOV GP nanoparticle vaccine administered with Matrix-M adjuvant. Efficacy was demonstrated in a series of 5 nonhuman primate (NHP) active immunization and challenge studies. Apparent risk reduction was 45.7% and 82.4% among antigen-treated (0.6 to 4 μg and 5 μg, respectively) animals. Notably, of the 3 animals that died after receiving 5 μg of EBOV GP with Matrix-M adjuvant, 1 animal was deemed to have died due to causes other than EBOV disease and another had received an untried bivalent formulation. Potential risk reduction could theoretically exceed 93%.

The Matrix-M adjuvant was also shown to enhance antibody, cellular, and protective immune responses in Balb/c mice administered EBOV GP vaccine with or without Matrix-M or aluminum phosphate adjuvants.[11]

In addition, 3 Good Laboratory Practice (GLP)-compliant toxicology studies in New Zealand White (NZW) rabbits have been performed with 4 different antigens (influenza hemagglutinins ± respiratory syncytial virus [RSV] F, Zika virus envelope dimers [ZIKV EnvD], and EBOV GP), in which up to 100 μg Matrix-M alone or with antigen was

evaluated. These toxicological investigations indicated that baculovirus-Sf9-produced antigens (up to 240 μg total nanoparticle dose) with Matrix-M adjuvant (up to 100 μg) were well-tolerated in the animals tested with no evidence of toxicity suggestive of any unusual risk or target organ for toxicity. Non-adverse findings, including local injection site inflammation, enlargement of the lymph nodes draining the injection sites, and elevated serum markers of inflammation (including C-reactive protein), were transient and were considered consistent with immune system stimulation consequent to immunization.

2.4.3 Nonclinical Data from SARS-CoV-2 Spike Protein Constructs

Mouse immunogenicity studies were conducted to evaluate several SARS-CoV-2 spike protein variants and select the vaccine candidate. The BV2373 construct, a "3Q-2P" construct featuring a full-length S protein with amino acid substitutions in the S1/S2 cleavage domain furin cleavage site introduced to confer protease resistance and also 2 proline substitutions (K986P and V987P) introduced in the HR1 domain to produce a stable prefusion conformation, which is believed to maintain availability of the most neutralization-sensitive epitopes when used as a vaccine antigen,[7] was selected as the vaccine candidate. BV2373 (3Q-2P) was demonstrated to be immunogenic and elicited functional antibodies.

For the tested constructs, shallow dose responses with Matrix-M were observed, suggesting that the adjuvant may be significantly antigen-sparing in large animals and humans. When tested over a broad 1000-fold dose range in mice, BV2373 with Matrix-M adjuvant demonstrated a greater than 100-fold antigen-sparing effect. A plateau of anti-S immunoglobulin G (IgG) responses as well as human ACE2 (hACE2) binding inhibition was seen with adjuvanted 2-dose regimens at 1 μg of antigen and above in mice.

The candidate SARS-CoV-2 rS vaccine, based on the BV2373 construct, is also being evaluated in a dose titration study using baboons, as results from this animal model may be more predictive of responses in humans. Preliminary results demonstrated potentially valuable immune responses to BV2373 as assessed by anti-S IgG, hACE2-binding inhibiting antibodies, and neutralizing antibodies.

Matrix-M provided antigen-sparing, and supported induction of functional antibodies. Importantly, Matrix-M-adjuvanted BV2373 also appeared to induce strong Th1 type CD4+ T cell responses to SARS-CoV-2 spike protein which included polyfunctional effector phenotypes. IL-4 producing cells (a T helper 2 [Th2] cell marker) were not detected by enzyme-linked immunosorbent spot (ELISPOT), while data concerning Th2 responses from intracellular cytokine staining ICCS were unfortunately not informative due to technical issues in the assay. The available data in this small baboon study provided evidence that doses of 5 μg and 25 μg

with 50 μg Matrix-M are the correct doses to proceed with the Phase 1/2 trial, with Matrix-M appearing critical for maximum responses. The variability of response observed across doses with multiple response parameters (IgG, ACE2 receptor and neutralization) supported advancement of this dose ranging and dose schedule into the Phase 1/2 trial.

A GLP-compliant toxicity study in the NZW rabbit is being performed to evaluate 50 μg of the SARS-CoV-2 BV2373 construct with and without 50 μg Matrix-M adjuvant. The Interim Phase provides data informing "N+1" doses relative to the planned human Phase 1/2 trial; and the Main Phase addresses "N+1" exposures relative to a primary regimen plus a potential late booster dose. At the interim sacrifice, the well-being of the test animals appeared unaltered relative to controls, with no test article related effects on mortality, overall clinical status, Draize score of the injection sites, body weight, food consumption, body temperature, ocular examination findings, organ weights, and macroscopic observations at necropsy.

Some males in the BV2373 plus Matrix-M group had minimal erythema at the injection site after Dose 3, but this resolved by 72 hours, and there were no temperature elevations outside the normal range. As seen in other programs, doses of active vaccines, especially those with Matrix-M, induced a transient rise in acute-phase reactants such as the globulin fraction, fibrinogen, and C-reactive protein. These were interpreted as non-adverse events consistent with the inflammatory response and immune stimulation secondary to vaccination. Currently available data show no systematic alterations in gross pathology or organ weights through 3 days after the third dose; histopathology is pending.

2.4.4 Clinical Summary

Novavax has tested baculovirus-Sf9-produced nanoparticle vaccines in approximately 14,732 subjects comprising older adults, young adults, and a limited number of children 2 to 5 years of age; and also including 3,075 pregnant women, with acceptable safety. Matrix-M has been given to approximately 4,200 humans (of which, approximately 2,567 humans received nanoparticle vaccine) with acceptable short-term reactogenicity, and an unremarkable long-term safety profile.

Novavax, is also conducting a Phase 1/2 randomized, observer-blinded, placebo-controlled trial of SARS-CoV-2 recombinant spike protein nanoparticle (SARS-CoV-2 rS) (NVX-CoV2373) vaccine with and without Matrix-M™ adjuvant in healthey adults 18-59 years of age. Participants received NVX-CoV2373 with or without Matrix-M1 (n=106) or placebo (n=25) in part 1 of the study (Phase 1).[12]

Following Dose 1, tenderness and pain were the most frequent local symptoms and systemic events were individually less frequent with headache, fatigue and myalgia being reported most

commonly. As expected, following Dose 2, greater reactogenicity was reported, although the majority of symptoms were reported as ≤ Grade 1. The average duration of events was < 2 days. Unsolicited adverse events were collected through 28 days after Dose 2. There were no severe (Grade 3) unsolicited adverse events, and the vast majority of adverse events were mild and deemed not related to vaccination. No serious adverse events (SAEs) were reported and safety follow-up continues.

NVX-CoV2373 induced neutralization titers in 100% of participants; 5 µg adjuvanted dose group peak GMT: 3,906 (95% CI: 2,556; 5,970). All subjects developed anti-spike IgG antibodies after a single dose of vaccine, many of them also developing wild-type virus neutralizing antibody responses, and after Dose 2, 100% of participants developed wild-type virus neutralizing antibody responses. Both anti-spike IgG and viral neutralization responses compared favorably to responses from patients with clinically significant COVID-19 disease. Importantly, the IgG antibody response was highly correlated with neutralization titers, demonstrating that a significant proportion of antibodies were functional.

Matrix-M™ adjuvant induced robust polyfunctional CD4+ T cell responses. The adjuvant was dose-sparing, with the lower 5 µg dose of NVX-CoV2373 performing comparably with the 25 µg dose. Cellular immune responses were measured in a subset of participants, and NVX-CoV2373 induced antigen-specific polyfunctional CD4+ T cell responses with a strong bias toward the Th1 phenotype (IFN-g, IL-2, and TNF-a).

NVX-CoV2373/Matrix-M1 was well tolerated and elicited robust immune responses (IgG and neutralization) four-fold higher than the mean observed in COVID-19 convalescent serum from participants with clinical symptoms requiring medical care and induced CD4+ T-cell responses biased toward a Th1 phenotype.[12] These findings suggest that the vaccine may confer protection and favours evaluation in clinical efficacy studies.

Part 2 (Phase 2) is designed to evaluate the immunogenicity, safety and preliminary efficacy of SARS CoV-2 rS and Matrix-M1 adjuvant in up to 1,500 healthy adults ≥ 18 to ≤ 84 years of age with more co-morbidities than the participant population in Part 1 of the study [ClinicalTrials.gov Identifier: NCT04368988]. An interim 5-day reactogenicity analysis was conducted on 846 participants following the first dose of study vaccine to support initiation of the Phase 3 study in United Kingdom (UK). This analysis comprised 607 participants aged 18 to 59 years (the same age range of Part 1 of the study) and 239 participants aged 60 to 84 years, with data presented in masked groups to maintain the integrity of the study. Overall, local and systemic reactogenicity data from this analysis were consistent with the reactogenicity data in

Part 1 of the study, with no safety concerns between the younger and older age cohorts. Both local and systemic reactogenicity events occurred less frequently in older adults.

Phase 2a/b safety, efficacy and immunogenicity study in South Africa and Phase 3 efficacy study in UK are ongoing.

UK Phase 3 efficacy results[13]:

The study enrolled more than 15,000 participants between 18-84 years of age, including 27% over the age of 65. The primary endpoint of the UK Phase 3 clinical trial was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline.

Vaccine efficacy was 96.4% (95% CI: 73.8, 99.5) against the original virus strain and 86.3% (95% CI: 71.3, 93.5) against the B.1.1.7/501Y.V1 variant circulating in the U.K (post hoc). The primary efficacy endpoint demonstrated an overall vaccine efficacy of 89.7% (95% CI: 80.2, 94.6).[13]

South Africa Phase 2a/b interim results[14]:

In the South Africa Phase 2a/b clinical trial, 4387 received at least one injection of vaccine or placebo. 60% efficacy (95% CI: 19.9 – 80.1) for the prevention of mild, moderate and severe COVID-19 disease was observed in the 94% of the study population that was HIV-negative. Twenty-nine cases were observed in the placebo group and 15 in the vaccine group. One severe case occurred in the placebo group and all other cases were mild or moderate. The clinical trial also achieved its primary efficacy endpoint in the overall trial population, including HIV-positive and HIV-negative subjects (efficacy of 49.4%; 95% CI: 6.1 – 72.8).[14]

Tabular summary of clnical trials with Novavax-SARS-CoV-2 rS ± Matrix-M1™ adjuvant:

Study Number (Country and ClinicalTrials.gov Identifier)	Study Design	Primary Endpoints	Number of Subjects	Study Status
2019nCoV-101 – Part 1 (Australia, NCT04368988)	Phase 1, randomized, observer-blinded, placebo-controlled in healthy adults ≥ 18 to ≤ 59 years of age	Safety and Immunogenicity	131	Ongoing; Day 35 interim analysis complete
2019nCoV-101 – Part 2 (Australia and US, NCT04368988)	Phase 2, randomized, observer-blinded, placebo-controlled in healthy adult subjects ≥ 18 to < 85 years of age	Immunogenicity and Safety	~1500	Recruitment complete, Follow-up ongoing
2019nCoV-501 (South Africa, NCT04533399)	Phase 2a/2b, randomized, observer-blinded, placebo-controlled in healthy adult HIV-negative subjects and in medically stable adult HIV-positive subjects ≥ 18 to < 65 years of age	Efficacy, Immunogenicity and Safety	HIV Negative: 4160 HIV positive: 240	Recruitment complete, Follow-up ongoing
2019nCoV-302 (UK, NCT04583995)	Phase 3, randomized, observer-blinded, placebo-controlled in healthy adult subjects ≥ 18 to < 85 years of age	Efficacy, Immunogenicity and Safety	15000	Recruitment complete, Follow-up ongoing

2.5 RATIONALE FOR STUDY DESIGN

This is a Phase 2/3, observer-blind, randomised, controlled study in adults in India, to evaluate the safety of COVOVAX in comparison with Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) and Placebo; for comparison of the immunogenicity of COVOVAX with Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ adjuvant).

The proposed study will enroll adults aged ≥ 18 years. Deaths from SARS-CoV-2 infections are more common in adults aged 65 or older. SARS-CoV-2 infects children as well as adults and the elderly. However, SARS-CoV-2 infections in children are less severe and rarely result in death. It is the older age groups particularly with co-morbidities which are most at risk of death following natural infection, and who are likely to be prioritized along with at-risk essential workers for vaccination if deployed in a future public health campaign.

Immunogenicity and Reactogenicity cohort:

Clinical efficacy / immunogenicity trials of Novavax-SARS-CoV-2 rS are ongoing in South Africa and UK and an efficacy trial in USA is ongoing. Novavax-SARS-CoV-2 rS vaccine has demonstrated high efficacy in UK and South Africa trials. Therefore, Novavax-SARS-CoV-2 rS vaccine has been selected as an active control in order to bridge COVOVAX vaccine with Novavax-SARS-CoV-2 rS vaccine.

Safety cohort:

Phase 2 part: Two COVID-19 vaccines [COVISHIELD™ manufactured by Serum Institute of India Pvt Ltd (SII) and COVAXIN manufactured by Bharat Biotech Pvt Ltd] have received authorization for restricted use in emergency situation in India on 03 January 2021. The government has rolled out these vaccines on 16 January 2021 to priority group individuals such as health care workers and elderly with co-morbidities. When the Phase 2 part of the study was initiated, there was no COVID-19 vaccine available for the general population and it was not the standard of care. At that time, the ongoing COVID-19 vaccines trials globally including USA, UK and several other countries were also placebo controlled despite Pfizer, Moderna and AstraZeneca vaccines having received Emergency Use Authorizations in those countries. Therefore, placebo was used as a comparator in the Phase 2 part in the safety cohort for comparison of safety with COVOVAX. Moreover, the participants in the safety cohort in Phase 2 part will be unblinded on or after Day 85 visit i.e. about 2 months after administration of the second dose of study vaccine. The participants in the Placebo group will be offered COVOVAX (test vaccine that is being used in Phase 3 part i.e. both DS and DP manufactured by SIIPL). If they agree to receive COVOVAX, then COVOVAX will be administered as two

dose schedule (Each dose of 0.5 ml intramuscularly with minimum interval of 21 days between the doses). Even after unblinding, all the participants in the safety cohort will be continued in the study till Day 180 visit.

Phase 3 part: From 01 May 2021, COVID-19 vaccination has been started for the general population ≥ 18 years of age in India. Therefore, use of placebo as a control is not justifiable. Moreover, Novavax-SARS-CoV-2 rS with Matrix-M1™ adjuvant vaccine has already shown to be highly efficacious in prevention of COVID-19 disease in UK and South Africa clinical trials. Hence, considering the current pandemic situation, Novavax-SARS-CoV-2 rS with Matrix-M1™ adjuvant vaccine will be used as a control in the Phase 3 part in the safety cohort. Initially, SIIPL had received DS manufactured by Novavax which was fill finished (DP) at SIIPL and used as test vaccine (COVOVAX) in the Phase 2 part of the study. Subsequently SIIPL manufactured both DS and DP which will be used as test vaccine (COVOVAX) in the Phase 3 part of the study. Therefore, the data from Phase 2 and Phase 3 parts of the study will be analyzed separately.

3. OBJECTIVES AND ENDPOINTS

3.1 PRIMARY AND CO-PRIMARY OBJECTIVE(S) AND ESTIMAND(S)

Primary and co-primary Objective(s)	Estimand Description (including *Endpoint*)
To assess the safety of COVOVAX	**Estimand 1 (Primary)** Proportion of participants with at least one causally related SAE • Up to Visit 3 – Day 36 (+7) post first dose vaccination. • Up to Visit 4 – Day 85 (+14) post first dose vaccination. • Up to Visit 6 – Day 180 (+28) post first dose vaccination. A treatment policy strategy is used for assessing safety irrespective of use of immune-modifying medications/vaccinations or missed 2nd dose of vaccination. A whilst on randomized treatment strategy is used for placebo group participants who received additional COVOVAX vaccine at or after Day 85. **Endpoint** Occurrence of causally related SAEs • Up to Visit 3 – Day 36 (+7) post first dose vaccination. • Up to Visit 4 – Day 85 (+14) post first dose vaccination. • Up to Visit 6 – Day 180 (+28) post first dose vaccination.
To assess immunogenicity of COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) by IgG ELISA assay	**Estimand 2 (Co-Primary)** Ratio of geometric mean ELISA Units (GMEUs) of anti-Spike (S) protein IgG at 14 days post second dose vaccination (Visit 3 – Day 36 (+7) post first dose vaccination) between vaccines (COVOVAX/ Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)). Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines or missed 2nd dose of vaccine or death. **Endpoint** Ratio of GMEUs of anti-Spike (S) protein IgG at 14 days post second dose vaccination [Visit 3 – Day 36 (+7) post first dose vaccination].

3.2 SECONDARY OBJECTIVES AND ESTIMANDS

Secondary Objective(s)	Estimand Description (including *Endpoint*)
To assess the tolerability and reactogenicity profile of COVOVAX in comparison with Placebo (for Phase 2 part) AND COVOVAX with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part).	**Estimand 3** Proportion of participants with at least one SAE, related medically attended adverse events (MAAEs), and adverse events of special interest (AESI) which encompasses potential immune-mediated medical conditions (PIMMCs) and AESIs relevant to COVID-19; and proportion with at least one Unsolicited AE • Up to Visit 4 – Day 85 (+14) post first dose vaccination with SAEs, related MAAEs, and AESI. • Up to Visit 6 – Day 180 (+28) post first dose vaccination with SAEs, related MAAEs, and AESI. • Within Visit 3 – Day 36 (+7) post first dose vaccination with unsolicited AEs including MAAEs. A treatment policy strategy is used for assessing safety irrespective of use of immune modifying medications or other vaccinations and missed 2nd dose of vaccine. A whilst on randomized treatment strategy is used for placebo group participants who received additional COVOVAX vaccine at or after Day 85. **Endpoints** • Occurrence of SAEs, related MAAEs, and AESI which encompasses PIMMCs and AESIs relevant to COVID-19 up to Visit 4 – Day 85 (+14) and Visit 6 – Day 180 (+28) post first dose vaccination. • Occurrence of unsolicited AEs including MAAEs up to Visit 3 – Day 36 (+7) post first dose vaccination. **Estimand 4** Proportion of participants with at least one solicited local and/or systemic adverse event (AE) • Within 7 days following each vaccination. A treatment policy strategy is used for assessing safety irrespective of use of modifying medications to assess missed 2nd dose of vaccine. While on treatment strategy is used to utilize all available data until event. **Endpoint** • Occurrence of solicited local and systemic adverse events (AEs) for 7 days following each vaccination (Reactogenicity cohort).
To assess immunogenicity of COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) by IgG ELISA and neutralizing antibody assays.	**Estimand 5** • GMEUs of anti-S IgG antibodies at Baseline, Visit 2 – Day 22 (+7), Visit 3 – Day 36 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination. • GMTs of NAb at Baseline and Visit 3 – Day 36 (+7) post first dose vaccination. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.

Secondary Objective(s)	Estimand Description (including *Endpoint*)
	Endpoints • GMEUs of anti-S IgG antibodies at Baseline, Visit 2 – Day 22 (+7), Visit 3 – Day 36 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination. • GMTs of virus NAb against SARS-CoV-2 spike protein at Baseline and Visit 3 – Day 36 (+7) post first dose vaccination. **Estimand 6** Proportion with seroconversion for anti-spike (S) protein IgG at Visit 2 – Day 22 (+7), Visit 3 – Day 36 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination and proportion of participants with seroconversion for virus neutralizing antibodies (NAb) at Visit 3 – Day 36 (+7) post first dose vaccination. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death. **Endpoints** • Seroconversion for virus neutralizing antibodies NAb at Visit 3 – Day 36 (+7) post first dose vaccination. Seroconversion for anti-spike (S) protein IgG at Visit 2 – Day 22 (+7), Visit 3 – Day 36 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination. Please note seroconversion is defined as four-fold increase in the titer from Baseline.

3.3 EXPLORATORY OBJECTIVES AND ESTIMANDS

Exploratory Objective(s)	Estimand Description (including *Endpoint*)
To assess immunogenicity of the COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant).	**Estimand 7** GMTs of virus neutralising antibodies (NAb) at Visit 2 – Day 22 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination and mean of change from baseline in cell-mediated immune responses 35 and 179 days post first dose vaccination. Hypothetical strategy is used to understand antibody levels and cell-mediated immunity achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death. **Endpoints** • GMTs of virus neutralising antibodies (NAb) at Visit 2 – Day 22 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination. • Mean of change from Baseline (Day 1) in the cell-mediated immune responses (for example, as measured by enzyme-linked immune absorbent spot (ELISpot) ± intracellular cytokine staining) Day 36 and Day 180. **Estimand 8** Proportion with seroconversion for NAb at Visit 2 – Day 22 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death. **Endpoints** Proportion with seroconversion for NAb at Visit 2 – Day 22 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination.

Exploratory Objective(s)	Estimand Description (including *Endpoint*)
• To assess the incidence SARS-CoV-2 infection between COVOVAX and Placebo (for Phase 2 part) AND between COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part). • To assess the incidence of severe COVID-19 disease between COVOVAX and Placebo (for Phase 2 part) AND between COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part).	**Estimand 9** Proportion of participants with incidence of virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19, laboratory confirmed (RT-PCR positive and /or Anti-Nucleocapsid IgG) asymptomatic cases of COVID-19, and laboratory confirmed (RT-PCR positive and /or Anti-Nucleocapsid IgG) SARS-CoV-2 cases (symptomatic as well as asymptomatic) which occur 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28); proportion of participants with severe virologically confirmed COVID-19 infection, Intensive care unit (ICU) admissions associated with virologically confirmed COVID-19 infection and all cause deaths in virologically confirmed COVID-19 infection. A treatment policy strategy is used for assessing safety irrespective of use of immune-modifying medications/vaccinations or missed 2nd dose of vaccination. Infections and death (meeting criteria) are included in the endpoint (composite strategy). A whilst on randomized treatment strategy is used for placebo group participants who received additional COVOVAX vaccine at or after Day 85. **Endpoint** • Virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19 which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28). • Laboratory confirmed (RT-PCR and /or Anti-Nucleocapsid IgG) asymptomatic cases of COVID-19 which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28). • Laboratory confirmed (RT-PCR positive and /or Anti-Nucleocapsid IgG) SARS-CoV-2 cases (symptomatic as well as asymptomatic) which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28). • Severe virologically confirmed COVID-19 infection which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28). • Intensive care unit (ICU) admissions associated with virologically confirmed COVID-19 infection which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28). • All cause deaths in virologically confirmed COVID-19 infection which occur 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28).

4. STUDY DESIGN

This is a Phase 2/3, observer-blind, randomised, controlled study in adults in India, to evaluate the safety of COVOVAX in comparison with Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) and Placebo; and for comparison of the immunogenicity of COVOVAX with Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant).

A total of 1600 eligible participants of ≥ 18 years of age will be enrolled the study. Of these 460 participants will be part of immunogenicity cohort. The remaining 1140 participants will be part of safety cohort.

All eligible participants (n=1600) will receive two doses of 0.5 ml of either COVOVAX or the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) or Placebo on Day 1 and Day 22 as per randomization. Post first dose vaccination site visits are planned on Day 22, Day 36, Day 85 and Day 180. All participants will also be contacted telephonically on Day 120 for safety follow up.

The study will be conducted in two parts as below:

Phase 2 part: Initial 200 participants have been enrolled in the Safety cohort with 3:1 allocation to COVOVAX (n=150) or Placebo (n=50). There was a telephonic contact at 7 days after first dose for safety assessment. The independent Data Safety Monitoring Board (DSMB) reviewed this safety data and recommended to continue the recruitment in the Phase 3 part of the study. This interim safety data and DSMB recommendation was submitted to DCGI. DCGI issued permission to continue the study for recruitment in the Phase 3 part.
On or after Day 85 visit, unblinding will be done for all the participants and those in the Placebo group will be offered COVOVAX (test vaccine that is being used in Phase 3 part i.e. both DS and DP manufactured by SIIPL). If they agree to receive COVOVAX, then COVOVAX will be administered as two dose schedule (Each dose of 0.5 ml intramuscularly with minimum interval of 21 days between the doses). Even after unblinding all the participants will be continued in the study till Day 180 visit.

Phase 3 part: Enrolment of remaining 1400 participants (940 from the Safety cohort and 460 from the Immunogenicity and Reactogenicity cohort) will be done.

Treatment allocation for the Phase 3 part:

Safety cohort (n=940)	COVOVAX	705
	Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant)	235
Reactogenicity and Immunogenicity cohort (n=460)	COVOVAX	345
	Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant)	115

Immunogenicity and Reactogenicity cohort: In the 460 participants [345 in COVOVAX group and 115 in the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)

group] who agree to give blood for immunogenicity testing, approximately 10 ml blood sample will be collected at Baseline (Day 1), Day 22, Day 36, Day 85 and Day 180. Additionally, up to 20 ml blood sample may be collected from subset of 28 participants for assessment of cell mediated immune (CMI) responses at baseline, Day 36 and Day 180. Of these 460 participants, 120 participants of ≥ 60 years of age will be enrolled. These participants will be enrolled as shown in Table below:

Treatment allocation			
Age group	**COVOVAX**	**Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant)**	**Total**
18-59 years	255	85	340
≥ 60 years*	90	30	120
Total	345	115	460

**Since the majority of population ≥ 60 years of age may have already received COVID-19 vaccination, there may be difficulty in recruiting these numbers. If this is not achieved, any shortfall in these numbers will be recruited in 18-59 years age group.*

In the same cohort, data of solicited local and systemic adverse events through 7 days following each vaccination will be collected using participant diary cards.

Safety Cohort: 940 participants in this cohort will receive two doses of 0.5 ml of either COVOVAX (n=705) or Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (n=235) as per randomization. Post first dose vaccination site visits are planned on Day 22, Day 36, Day 85 and Day 180. All participants will also be contacted telephonically on Day 120 for safety follow up.

Table 1a: Schedule of study events for Safety Cohort

Visit Number	1	2	3	4	5 (TC)	6
Visit time and window	**Day 1**	**Day 22 (+7)**	**Day 36[h] (+7)**	**Day 85 (+14)**	**Day 120 (+14)**	**Day 180 (+28)**
Informed Consent	X					
Demographic Data	X					
Medical History	X					
General Physical Examination & vital signs	X	X[b]	X[b]	X[b]		X[b]
Urine pregnancy test[c]	X	X[a]				
Inclusion/Exclusion Criteria	X	X[d]				
Randomization	X					
Blood Collection for serological evidence of COVID-19 infection[e]	X[a]		X	X		X
Nasopharyngeal /Nose and/or throat swab for RT-PCR[f]	X[a]					
Study Vaccination	X	X				
30-Minute Post-Vaccination Assessment	X	X				
Recording of unsolicited AEs including MAAEs	*Through 35 days post first vaccination*					
Reporting of SAEs, related MAAEs, AESI	*Throughout the study period post first vaccination*					
Recording of concomitant medications and vaccinations[g]	*Throughout the study period*					

TC – Telephonic contact for safety follow up.

a. Procedure to be performed prior to vaccination
b. A targeted physical examination (only at post vaccination visits) will be performed if there has been any AE reported since the previous visit that has not already been recorded and closed within unscheduled visits
c. Only among female participants of child bearing potential.
d. Inclusion and exclusion criteria will be reassessed before Dose 2 with respect to any acute illness. If the participant presents with any acute illness with or without fever on Day 22 then second vaccination will be delayed till the event is resolved.
e. Approximately up to 3 ml blood will be drawn on Day 1, Day 36, Day 85 and Day 180 to detect anti-Nucleocapsid IgG antibodies.
f. If the participant presents with qualifying symptoms of suspected COVID-19 disease [Appendix II, Table 1] OR history of contact with a confirmed COVID-19 positive case then a swab from nasopharynx / nose and/or throat will be collected for RT-PCR testing for SARS-CoV-2 infection.
g. Beyond Day 36, only the concomitant medications indicated for SAEs / related MAAEs and AESI, if any will be recorded
h. On or after Day 85 visit, unblinding will be done for the participants in the safety cohort in Phase 2 part and those in the Placebo group will be offered COVOVAX. If they agree to receive COVOVAX, then COVOVAX will be administered as two dose schedule (Each dose of 0.5 ml intramuscularly with minimum interval of 21 days between the doses). Even after unblinding, all the participants in the safety cohort will be continued in the study till Day 180 visit.

Only for Phase 2 study part (n=200, safety cohort): there will be a telephonic contact at 7 days after first dose [Day 8 (+2)] for safety assessment.

Table 1b: Schedule of study events for Immunogenicity and Reactogenicity Cohort

Visit Number	**1**	**2**	**3**	**4**	**5 (TC)**	**6**
Visit time and window	**Day 1**	**Day 22 (+7)**	**Day 36 (+7)**	**Day 85 (+14)**	**Day 120 (+14)**	**Day 180 (+28)**
Informed Consent	X					
Demographic Data	X					
Medical History	X					
General Physical Examination & vital signs	X	X[b]	X[b]	X[b]		X[b]
Urine pregnancy test[c]	X	X[a]				
Exclusion/Inclusion Criteria	X	X[d]				
Randomization	X					
Blood Collection for serological eviednce of COVID-19 infection[e]	X[a]		X	X		X
Blood Collection for immunogenicity assessment [f]	X[a]	X[a]	X			X
Nasopharyngeal /Nose and/or throat swab for RT-PCR[g]	X[a]					
Study Vaccination	X	X				
30-Minute Post-Vaccination Assessment	X	X				
Issue of diary card	X	X				
Review and collection of diary card		X	X			
Recording of solicited AEs	*7 days post vaccination*	*7 days post vaccination*				
Recording of unsolicited AEs including MAAEs	*Through 35 days post first vaccination*					
Reporting of SAEs, related MAAEs, AESI	*Throughout the study period post first vaccination*					
Recording of concomitant medications and vaccinations[h]	*Throughout the study period*					

TC – Telephonic contact for safety follow up.

a. Procedure to be performed prior to vaccination
b. A targeted physical examination (only at post vaccination visits) will be performed if there has been any AE reported since the previous visit that has not already been recorded and closed within unscheduled visits
c. Only among female participants of child bearing potential.
d. Inclusion and exclusion criteria will be reassessed before Dose 2 with respect to any acute illness. If the participant presents with any acute illness with or without fever on Day 22 then second vaccination will be delayed till the event is resolved.
e. Approximately up to 3 mL of blood will be drawn on day 1, Day 36, Day 85 and Day 180 to detect anti-Nucleocapsid IgG antibodies.
f. Approx. 10 ml blood to be drawn prior to vaccination on Day 1as baseline sample and also at Day 22, Day 36 and Day 180 for anti-S IgG and neutralizing antibody assessment. In a subset of 28 participants, additional 20 ml sample will be collected on Day 1, Day 36 and Day 180 for assessment of CMI response.
g. If the participant presents with qualifying symptoms of suspected COVID-19 disease [Appendix II, Table 1] OR history of contact with a confirmed COVID-19 positive case then a swab from nasopharynx / nose and/or throat will be collected for RT-PCR testing for SARS-CoV-2 infection.
h. Beyond Day 36, only the concomitant medications indicated for SAEs / related MAAEs and AESI, if any will be recorded

5. STUDY POPULATION

5.1 INCLUSION CRITERIA

Eligible participants must meet all of the below criteria at the time of enrolment:

1. Adults aged ≥ 18 years of either sex
2. Written informed consent by participants
3. The participant is resident of the study area and is willing to comply with study protocol requirements, including availability for all scheduled visits of the study
4. Healthy, as determined by medical history and physical examination
5. Sexually active female participants of childbearing potential* must have practiced adequate contraception** for 28 days prior to study vaccine administration and agree to continue adequate contraception until completion of their Day 36 visit.

   * Females can be considered not of childbearing potential only if they have undergone bilateral tubal ligation or occlusion, or hysterectomy, or bilateral ovariectomy, or are post- menopausal (defined as continuous amenorrhea for 12 months).

   ** Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label as follows:

   - Combined estrogen and progesterone oral contraceptives
   - Injectable progestogen
   - Implants of etenogestrel or levonorgestrel
   - Contraceptive vaginal ring
   - Percutaneous contraceptive patches
   - Intrauterine device or intrauterine system
   - Male partner (sole partner for participant) sterilized
   - Male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository), and/or progesterone alone oral contraceptive
6. Female participants of childbearing potential must have a negative urine pregnancy test within 24 hours prior to study vaccine administration

5.2 EXCLUSION CRITERIA

Participants meeting any of the below criteria at the time of enrolment will be ineligible to participate in the trial:

1. Acute illness including COVID-19 with or without fever at the time of study vaccine administration
2. History of laboratory confirmed (by PCR or serology to SARS-CoV-2) COVID-19 disease
3. History of severe allergic reactions after previous vaccinations or hypersensitivity to any component of study vaccines
4. Any confirmed or suspected condition with impaired/altered function of immune system (e.g. immunodeficient or autoimmune conditions)

   Note: Stable endocrine disorders that have a confirmed autoimmune etiology (e.g., thyroid, pancreatic) are allowed.
5. Have any bleeding disorder which is considered as a contraindication to intramuscular injection or blood draw
6. Suspected or known current alcohol or drug dependence
7. Chronic administration (defined as more than 14 continuous days) of immunosuppressant or other immune-modifying drugs within three months prior to the study vaccination or planned use throughout the study period. (For corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg per day. Inhaled, intranasal and topical steroids are allowed, use of Hydroxychloroquine prophylaxis is allowed)
8. Administration of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 3 months or planned use throughout the study period
9. Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban etc.)

   Note: The use of ≤ 325 mg of aspirin per day with or without any other antiplatelet drugs like clopidogrel, prasugrel, ticagrelor is permitted
10. Administration of any vaccine within 28 days prior to enrolment in the study or planned administration of any vaccine for until 28 days after second study vaccination
11. Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data
12. Prior receipt of a COVID-19 vaccine or planning to receive a COVID-19 vaccine during the course of the study

13. Current or planned participation in prophylactic drug trials for the duration of the study
14. Use of any investigational or non-registered drug or vaccine within 30 days prior to the administration of study vaccines or planned during the study
15. Pregnant or breast-feeding
16. Individuals who are part of study team or close family members of individuals conducting this study
17. Participants who are having any current workup of undiagnosed illness within the last 8 weeks that is either participant-reported or has been clinician-assessed, which could lead to a new condition or diagnosis
18. Acute or chronic, clinically significant pulmonary, cardiovascular, endocrine, metabolic, gastrointestinal, neurological, hepatic, renal functional abnormality or any other systemic disorder, that are assessed by the investigator (based on medical history or physical examination) as being clinically unstable within the prior 4 weeks as evidenced by:
    a. Hospitalisation for the condition, including day surgical interventions.
    b. New significant organ function deterioration.
    c. Needing addition of new treatments or major dose adjustments of current treatments (mild or moderate well-controlled comorbidities are allowed)
19. History of chronic neurological disorders such as multiple sclerosis, dementia, transient ischemic attacks, Parkinson's disease, degenerative neurological conditions, neuropathy, and epilepsy or a history of stroke or previous neurological disorder within 12 months with residual symptoms

    Note: Participants with a history of migraine or chronic headaches or nerve root compression that have been stable on treatment for the last 4 weeks are not excluded
20. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or make it unlikely that the participant could complete the protocol.

6. TREATMENT OF STUDY PARTICIPANTS

6.1 DESCRIPTION OF STUDY VACCINES

The term 'study vaccine' refers to those vaccines provided by the Sponsor, which will be evaluated as part of the study objectives. The study vaccines specific to this study are described below.

Study vaccines for Phase 2 and Phase 3 part

Study vaccines for Phase 2	**Test vaccine**	COVOVAX – DS manufactured by Novavax and DP (fill finish) by SIIPL
	Control	Placebo
Study vaccines for Phase 3	**Test vaccine**	COVOVAX – DS and DP manufactured by SIIPL
	Control	Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ Adjuvant - DS and DP manufactured by Novavax

6.1.1 Test vaccine:

COVOVAX [SII-SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] is available as a ready to use liquid formulation in a single dose (0.5 mL) vial containing 5 μg antigen and 50 μg Matrix-M1 adjuvant. The other ingredients are 25 mM phosphate buffer (pH 7.2), 300 mM sodium chloride, and 0.01% (v/v) polysorbate 80.

- **Manufacturer:** Serum Institute of India Pvt. Ltd. (SIIPL)
- **Formulation:** Ready to use liquid formulation in a single dose vial.
- **Route of administration:** Intramuscular
- **Site of injection:** Deltoid muscle
- **Dose:** 0.5 ml containing 5 μg antigen and 50 μg Matrix-M adjuvant
- **Dose schedule:** Two doses 3 weeks apart (First dose on Day 1and Second dose on Day 22)

6.1.2 Comparator product (Placebo) for Phase 2 part:

Placebo is available as a ready to use solution of 0.9% Sodium chloride (NaCl) for injection in glass ampoules.

- **Manufacturer**: Serum Institute of India Pvt. Ltd.
- **Formulation:** Ready to use solution in glass ampoules.
- **Route of administration:** Intramuscular
- **Site of injection:** Deltoid muscle
- **Dose:** 0.5 ml containing 0.9% NaCl
- **Dose schedule:** Two doses 3 weeks apart (First dose on Day 1 and Second dose on Day 22)

6.1.3 Active comparator vaccine (Control vaccine) for Phase 3 part:

Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ Adjuvant is available as a ready to use liquid formulation in a 10-dose vial with each dose of 0.5 mL containing 5 μg antigen and 50 μg Matrix-M adjuvant. The other ingredients are 25 mM phosphate buffer (pH 7.2), 300 mM sodium chloride, and 0.01% (v/v) polysorbate 80.

- **Manufacturer:** Novavax, 21 First field Road, Gaithersburg, MD20878, USA
- **Formulation:** Ready to use liquid formulation in a 10-dose vial.
- **Route of administration:** Intramuscular
- **Site of injection:** Deltoid muscle
- **Dose:** 0.5 ml containing 5 μg antigen and 50 μg Matrix-M adjuvant
- **Dose schedule:** Two doses 3 weeks apart (First dose on Day 1and Second dose on Day 22)

6.2 PRECAUTIONS TO BE OBSERVED IN ADMINISTRATING STUDY VACCINES

Prior to vaccination, participants must be determined to be eligible for study vaccination and it must be clinically appropriate in the judgment of the investigator to vaccinate.

Study vaccines should not be administered to individuals with known hypersensitivity to any component of the vaccines.

Standard immunization practices are to be observed and care should be taken to administer the injection intramuscularly. Before administering vaccine, the vaccination site is to be disinfected with a skin disinfectant (e.g., 70% alcohol). Allow the skin to dry. DO NOT inject intravascularly.

As with all vaccines, appropriate medical treatment (like adrenaline 1:1000, anti-histamine (diphenhydramine), corticosteroids (hydrocortisone) and resuscitation equipment etc.) must

be available at the site, and staff and supervision must be readily available in case of rare anaphylactic or any severe allergic reactions following administration of the study vaccine.

Prompt use of resuscitation measure can be lifesaving and must be implemented at the first suspicion of anaphylaxis.

6.3 PREPARATION AND ADMINISTRATION OF THE STUDY VACCINE

Study vaccines are available as a ready to use vial / ampoules and does not need any reconstitution. A vial /ampoule will be removed from cold storage and inspected to confirm the absence of particulate materials. Using needle and syringe 0.5 ml volume from vial / ampoule will be withdrawn and injected intramuscularly.

Study vaccine should be visually inspected before administration and in the event of any foreign particulate matter and/or any unusual appearance of the study vaccine, vial / ampoule will be set aside and replacement vial /ampoule / kit should be used.

The study vaccine will be administered as per randomization schedule via intramuscular injection on Day 1 and Day 22. Preferred site of injection is deltoid muscle. The study vaccines are supplied as single dose vials for COVOVAX, multidose vials for Control vaccine and ampoules for Placebo. The used vial / ampoule will be kept securely at site for accountability by study monitor.

The investigator or designee will be responsible for oversight of the administration of vaccine to participants enrolled in the study according to the procedures presented in this study protocol. All vaccines will be prepared and administered only by designated personnel who are qualified to perform that function.

Study vaccine to be administered to the participants must be stored in a safe and locked place with no access by unauthorized personnel.

6.4 VACCINE SUPPLY, LABELLING, STORAGE, ACCOUNTABILITY AND DISPOSAL

The sponsor will ensure the following:

- Appropriate supply of the study vaccines;
- Appropriate labeling of all study vaccines that complies with regulatory requirements.

The investigator must ensure the following:

- Availability of appropriately trained site staff to manage vaccine supply, accountability, preparation and administration.

- Acknowledge receipt of the study vaccines by site staff, including confirmation that the vaccines:
  - were received in good condition;
  - remained within the appropriate temperature range during shipment from the sponsor to the investigator's designated storage location;
  - have been confirmed by the sponsor as authorized for use
- Proper storage of the study vaccines, including:
  - storage in a secure, locked, temperature-controlled location;
  - proper storage according to the instructions specified on the labels;
  - appropriate record keeping and inventory of the study vaccines, including regular documentation of adequate storage temperature
- Appropriate use of the study vaccines, including:
  - use only in accordance with the approved protocol;
  - proper handling, including confirmation that the vaccine has not expired prior to administration;
  - appropriate documentation of administration of vaccines to study participants including:
    - Date, dosage, batch number, screening number assigned to participants, and time of vaccine administration. This information will be maintained in an accountability log that will be reviewed by the site monitor;
    - Proper reconciliation of all study vaccines received from the sponsor. Reconciliation is defined as maintaining records of which and how many vaccines were received, which vaccines (and volume thereof) were administered to participants, and which vaccines were destroyed at the site.
- Vaccine will be either destroyed at site after sponsor approval or can be returned back to sponsor. Site will provide adequate documentation of destruction in the former case.

The study vaccines will be stored at +2^{o}C to +8^{o}C in a secure refrigerator. The storage temperature of the vaccines will be monitored daily with temperature monitoring devices and will be recorded.

Vaccines that have been stored differently from the manufacturer's instructions must not be used unless the sponsor provides written authorization for use. Any temperature deviation, i.e. temperature outside the range, must be reported to the sponsor as soon as detected. Following

the exposure to such a temperature deviation, vaccines will not be used until written approval has been given by the sponsor. Expired vaccines must not be administered.

In the event that the use cannot be authorized, the sponsor will make every effort to replace the vaccine supply. Monitoring of vaccine accountability will be performed by the study monitor during site visits and at the completion of the trial.

7. STUDY PROCEDURES

7.1 GENERAL CONSIDERATIONS

The study will be initiated only after approvals from each site's Institutional ethics committee (IEC) and the DCGI have been obtained.

The schedules of evaluations and procedures that must be performed at specific time points are described in the following sections and in Tables 1a and 1b: Schedule of Events.

At each visit participants need to be counselled thoroughly to follow all the standard measures like wearing mask, social distancing, regular hand washing, using of hand sanitizer etc. as per the health authority guidelines to prevent getting infected with COVID-19.

7.2 STUDY VISITS

Visit #1 – Screening, Randomization and First Vaccination

Potential participants will be informed about the scope of the study and the possibility of their inclusion in the study. If they are willing to participate, informed consent will be obtained. A signed (or thumb print with witness signature) and dated informed consent must be obtained by the principal investigator (PI) or the designee before initiating any study specific procedures. The informed consent document used for the purpose must be approved by respective site IEC.

The process of obtaining informed consent should be documented in the source documents in addition to maintaining the original signed and dated informed consent at the site. A copy of the consent form will be given to the participants.

The participants will be screened for eligibility by the site staff under the direction of the PI after the informed consent process has been completed. All participants screened for the study will be assigned a screening number.

All participants who have consented will be included into the screening cohort and will be evaluated for eligibility.

The following procedures will be completed for each participant to confirm eligibility for the study:

- Demography (Age, sex, height and weight)

- Medical History (significant past and concurrent conditions, family history, history of allergies and vaccinations)
- Complete physical Examination [general, head, eyes, ears, nose, oropharynx, neck, lymph nodes, abdomen, skin (especially injection sites), respiratory, cardiovascular system, musculoskeletal and central nervous system] including vital signs measurements (temperature, resting blood pressure, pulse and respiratory rate)
- Relevant prior and Concomitant medications
- In case of female participants of child bearing potential, urine pregnancy test (UPT) will be performed prior to randomization.

The participants who are ineligible for the study or not randomized will be documented as screen failures on the Screening Log and eCRF. The reason for screen failure must be documented.

A complete review of inclusion/exclusion criteria will be conducted. Participants who satisfy all inclusion criteria and none of the exclusion criteria will be enrolled.

Randomization:

The eligible participants will be randomized on the same day. However, randomization can be performed until 7 days from screening in cases of any unavoidable circumstances, after reassessing eligibility. The eligible participants will be randomized via an Interactive Web Response System (IWRS).

If for any reason, after signing the informed consent form, the participant (who has passed screening) fails to be randomized, the reason for not being randomized should be recorded in source documents.

Blinding:

The study is designed as an observer-blind study. The study participants and the study personnel responsible for the evaluation of any study endpoints (e.g. safety and reactogenicity) will be unaware which study vaccine is administered. At each site, only designated study personnel will be involved in getting randomization code by accessing IWRS, vaccine preparation and administration. The unblinded personnel involved in study vaccine preparation and administration will not participate in any of the study end-point evaluations. All other site personnel will remain blinded to the treatment allocation.

The sponsor personnel involved in the study will also remain blinded. The CRO will designate an unblinded monitor(s) and a statistician who may be able to access the subject level unblinded data as per the need. Other CRO personnel working on the trial will remain blinded.

For the safety cohort, blind may be broken on or after Day 85 visit upon participant's request.

The laboratories involved in the immunological testing will be blinded to the treatment allocation.

Prior to Vaccination:

All Participants: Approximately 3 ml blood sample will be collected for SARS-CoV-2 serology (IgG) before vaccination. A swab from nasopharynx /nose and/or throat will be collected for RT-PCR testing to detect SARS-CoV-2 infection.

Immunogenicity cohort: Approximately 10 ml blood will be collected from participants in immunogenicity cohort for anti-S IgG and neutralizing antibody assessment prior to vaccination on Day 1. Additionally, up to 20 ml blood sample may be collected from subset of 28 participants for assessment of cell mediated immune (CMI) responses. This will be the baseline sample.

Study Vaccination (First dose): The participant will receive first dose of 0.5 ml of either COVOVAX or Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) or Placebo as per the randomization schedule.

Post - Vaccination Activities:

The participants will be observed closely for at least 30 minutes following vaccination, with appropriate medical treatment readily available in case of a rare anaphylactic reaction following the administration of vaccine. After 30 minutes (+30 minutes) post vaccination, any solicited local and systemic AEs, any unsolicited AEs and Vitals (temperature, resting blood pressure, pulse and respiratory rate) will be recorded.

The participants in immunogenicity and reactogenicity cohort will receive a digital thermometer, measuring scale and a diary. These participants will be trained by the site personnel for recording and documenting any solicited reactions and AEs they may experience and concomitant medications they may use within 7 days following each vaccination in the diary. The participants will be informed to visit the site on Day 22 and carry this completed diary at the time of visit.

All participants in the safety cohort will also be provided with a thermometer.

The investigator or a delegate should ensure that all information is recorded in the source documents and accurately transcribed in the eCRF as soon as possible after the participant's visit has been completed.

The participant will be reminded to contact the site if there is any health problem / illness or if they have any questions and to return to the clinic on Day 22.

Initial 200 participants from safety cohort (Phase 2 part of the study) will be contacted telephonically 7 days post first vaccination on Day 8 (+2).

Visit #2 (Day 22 [+7]): Blood collection and Second Vaccination:

Study participants will return for follow-up evaluations to the clinical study site 21 days following the first vaccination. At this visit, investigator or delegate will perform the following procedures and evaluations in the following order:

1. Review and retrieval of diary card records till day 7 (reactogenicity cohort)
2. Assessment of any ongoing solicited AEs (note that all ongoing solicited AEs must be followed up by site staff until resolution) (reactogenicity cohort)
3. Medical interview of participant to assess any unsolicited AEs/SAEs/MAAEs/AESI since previous study visit
4. Collection of concomitant medications and vaccinations history
5. Targeted physical examination including assessment of vital signs
6. Only for immunogenicity cohort: Collection of blood sample (approximately 10 mL) for anti-S IgG and neutralizing antibody assessment prior to second vaccination
7. Inclusion and exclusion criteria will be reassessed before Dose 2 with respect to any acute illness. If the participant presents with any acute illness with or without fever on Day 22 then second vaccination will be delayed till the event is resolved
8. In case of female participants of child bearing potential, UPT will be performed prior to second vaccination. If UPT comes positive then the second dose of vaccine will not be administered

Study Vaccination (Second dose)

The participant will receive second dose of 0.5 ml of either COVOVAX or Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) or Placebo as per the randomization schedule.

Post-Vaccination Activities

The participants will be observed closely for at least 30 minutes following vaccination, with appropriate medical treatment readily available in case of a rare anaphylactic reaction following the administration of vaccine. After 30 minutes (+30 minutes) post vaccination any solicited local and systemic AEs, any unsolicited AEs and Vitals (temperature, resting blood pressure, pulse and respiratory rate) will be recorded.

The participants in reactogenicity cohort will be issued a new diary card to record solicited adverse events for 7 days following second vaccination. The participants will be informed to visit the site on Day 36 and carry this completed diary at the time of visit.

The investigator or a delegate should ensure that all information is recorded in the source documents and accurately transcribed in the eCRF as soon as possible after the participant's visit has been completed.

The participant will be reminded to contact the site if there is any health problem / illness or if they have any questions and to return to the clinic on Day 36.

Occurrence of COVID-19 disease in between first and second dose: If the participant is confirmed with COVID-19 after the first dose but before the second dose, then the participant will be vaccinated with the second dose only two weeks after clinical recovery from COVID-19 disease. This is applicable, even if it is outside the recommended window period for the second dose. These participants will be continued in the study until Day 180 visit.

Visit # 3 (Day 36 [+7]): Blood collection

Study participants will return for follow-up evaluations to the study site 14 days following second vaccination. At this visit, investigator or delegate will perform the following procedures and evaluations in the following order:

1. Medical interview of participant to determine if any unsolicited AEs/SAEs/MAAEs/AESI occurred and if any concomitant medications or vaccines were taken/ received since the last study visit.)
2. Review and retrieval of diary card records till day 7 (reactogenicity cohort)
3. Assessment of any ongoing solicited AEs (note that all ongoing solicited AEs must be followed up by site staff until resolution) (reactogenicity cohort)
4. Check any ongoing AEs and concomitant medications since the last study visit and record the resolution date (the end date), if available, in the source documents and eCRF.
5. Targeted physical examination including assessment of vital signs.

6. For all participants: Approximately, 3 ml blood to be drawn to detect anti-Nucleocapsid IgG antibodies.
7. Only for immunogenicity cohort: Collection of blood sample (approximately 10 mL) for anti-S IgG and neutralizing antibody assessment. Additionally, up to 20 ml blood sample may be collected from subset of 28 participants for assessment of cell mediated immune (CMI) responses.

The investigator or a delegate should ensure that all information is recorded in the source documents and accurately transcribed in the eCRF as soon as possible after the participant's visit has been completed.

The participant will be reminded to contact the site if there is any health problem / illness or if they have any questions and to return to the clinic on Day 180

Visit #4 (Day 85 [+14]): Blood collection:

Study participants will return for follow-up evaluations to the study site 2 months following second vaccination. At this visit, investigator or delegate will perform the following procedures and evaluations in the following order:

1. Medical interview of participant to determine if any SAEs/related MAAEs/AESI occurred and if any concomitant medications or vaccines were taken/ received since the last study visit.)
2. Check any ongoing AEs and concomitant medications since the last study visit and record the resolution date (the end date), if available, in the source documents and eCRF (if applicable).
3. Targeted physical examination including assessment of vital signs.
4. For all participants: Approximately, 3 ml blood to be drawn to detect anti-Nucleocapsid IgG antibodies.
5. Only for Phase 2 part: On or after Day 85 visit, unblinding will be done and those participants in the Placebo group will be offered COVOVAX (test vaccine that is being used in Phase 3 part i.e. both DS and DP manufactured by SIIPL). If they agree to receive COVOVAX, then COVOVAX will be administered as two dose schedule (Each dose of 0.5 ml intramuscularly with minimum interval of 21 days between the doses). Even after unblinding, all the participants in the safety cohort will be continued in the study till Day 180 visit.

The investigator or a delegate should ensure that all information is recorded in the source documents and accurately transcribed in the eCRF as soon as possible after the participant's visit has been completed.

The participant will be reminded to contact the site if there is any health problem / illness or if they have any questions and to return to the clinic on Day 180.

Visit #5 Telephonic contact Day 120 [+14]):

The study participants will be contacted by telephone on Day 120 to assess any SAEs /related MAAEs/AESI that may have occurred since last visit / contact. The participants will be reminded to contact the site if there is any health problem / illness or if they have any questions. They will also be reminded of the end of study visit at Day 180. SAEs, if any will be recorded and evaluated and participants will be advised for unscheduled visit to the site, if need be. Source records will be completed and all information will be recorded in the eCRF.

Visit#6 (Day 180 [+28]): End of study Visit

Study participants will return for follow-up evaluations to the clinical study site 179 days (approximately 6 months) following first vaccination. At this visit, investigator or delegate will perform the following procedures and evaluations in the following order:

1. Medical interview of participant if any SAEs/ related MAAEs/AESI occurred and if any concomitant medications or vaccines were taken/ received for treating the SAE since the last study visit.
2. Check any ongoing AEs and concomitant medications since the last study visit and record the resolution date (the end date), if available, in the source documents and eCRF (if applicable).
3. Targeted physical examination including assessment of vital signs.
4. For all participants: Approximately, 3 ml blood to be drawn to detect anti-Nucleocapsid IgG antibodies.
5. Only for immunogenicity cohort: Collection of blood sample (approximately 10 mL) for anti-S IgG and neutralizing antibody assessment. Additionally, up to 20 ml blood sample may be collected from subset of 28 participants for assessment of cell mediated immune (CMI) responses.

The investigator or a delegate should ensure that all information is recorded in the source documents and accurately transcribed in the eCRF as soon as possible after the participant's visit has been completed.

In case there are no ongoing SAEs, after this visit, the participation in the study will be completed. Source records will be completed and all information will be recorded in the eCRF (including "end of study" page).

Unscheduled Visits

Unscheduled visits may be performed at participant's requests or directly by the study site when the investigator or a delegate considers it necessary for diagnosis and/or management of a finding or an AE. All unscheduled visits will be recorded in source and eCRF.

7.3 TESTING FOR COVID-19 DURING THE STUDY PERIOD:

If the participant presents with qualifying symptoms of suspected COVID-19 disease [Appendix II, Table 1] OR history of contact with a confirmed COVID-19 positive case then a swab from nasopharynx / nose and/or throat will be collected for RT-PCR testing for SARS-CoV-2 infection.

At the COVID-19 testing visit, a swab from nasopharynx /nose and/or throat, vital signs and other clinical data will be taken. Symptomatic cases will be managed as per national guidelines.

7.4 PARTICIPANT DISCONTINUATION

Participant discontinuation from study procedures prior to completion of the last study visit may occur for any of the following reasons:

- Dropout (defined as discontinuation initiated by a participant): Participation in the study is strictly voluntary. Participants have the right to withdraw their consent from study participation at any time and for any reason, without penalty. The participant may also initiate discontinuation due to an adverse event.
- Investigator-initiated: The study investigator may, at their discretion, discontinue a participant from the study if they consider it to be in the participant's best interest to do so (e.g., for safety concerns), or if the participant does not comply with the study requirements.
- Lost to follow-up: For participants who fail to attend scheduled visits, study staff are to make at least three attempts to contact the participant or participant's parent/guardian prior to considering the participant as lost to follow-up. These attempts should be recorded in the source documents.
- Sponsor-initiated: For example, if the sponsor is obliged to end the study for administrative or any other reasons.

- Ineligibility (either arising during the study or retrospectively, having been overlooked at screening).

Participants who discontinue prior to administration of the vaccine will be replaced, whereas those withdrawn after administration of the vaccine will not be replaced.

The reason for and date of participant discontinuation will be documented in the source documents and relevant electronic Case Report Form (eCRF). Before entering any category as the reason for the participant's discontinuation from the study, the investigator should make every effort to investigate whether an AE may have been related to the participant's discontinuation from the study. If an AE has been associated with the discontinuation, this must be described on the discontinuation eCRF page, even if it is not the primary reason for the participant's withdrawal. For participants considered lost to follow-up, the discontinuation date for the participant to be captured on the discontinuation eCRF page is the date of the participant's last completed study visit.

In the event of participant discontinuation from the study, reasonable efforts should be made to conduct the following procedures (unless participant consent to do so has been withdrawn):

- Review the solicited (and unsolicited) AE if still in use prior to discontinuation.
- Update any AE/SAEs that remained ongoing at the time of the participant's last visit prior to discontinuation.
- If within the protocol defined reporting period, collect any new AE/SAEs and concomitant medications since the participant's last visit and the time of discontinuation.
- If any new AE/SAEs reported since the participant's last visit and the time of discontinuation, perform a physical examination.
- Update participant contact information.

The sponsor or the investigator (following consultation with the sponsor) has the right to discontinue this study at any time. The study may be discontinued at one site or across multiple sites. If the clinical study is prematurely terminated at any of the site, the investigator of the respective site is to promptly inform the study participants and respective IEC and should assure appropriate therapy and follow up for the participants. All procedures and requirements pertaining to the archiving of study documents should be followed. All other study materials (study medication/vaccines, etc.) must be returned to the sponsor.

7.5 MANAGEMENT OF PREGNANCY DURING STUDY

If a female participant becomes pregnant following administration of vaccine, she will be encouraged to complete remaining visits and study procedures unless medically contraindicated, and if possible and agreed to by the participant, she will continue to be followed for pregnancy outcome. The pregnancy and its outcome will be documented, even if birth occurs after the scheduled end of the study for the participant.

7.6 PRIOR AND CONCOMITANT THERAPY

7.6.1 Prior Medications and Vaccines

Any medications (including vaccines) that were administered to the participant within 30 days prior to the study vaccination will be considered as prior medications for this study. These will be recorded in the eCRF.

7.6.2 Concomitant Medications and Vaccines

At each study visit, the investigator/designee will ask the participants about any prescription or over-the-counter medication(s) taken since the last visit. Any medications taken at any time during the study period must be recorded on source documents and the eCRF with trade and/or generic name, indication, dose, start and end dates.

Any treatments and/or medications specifically contraindicated, e.g., any investigational or non-registered product, any immunosuppressant and immune-modifying drug including systemic steroids, any immunoglobulin and blood product should be checked at each study visit subsequent to the study vaccination. If any become applicable during the study, it will not require withdrawal of the participant from the study but may determine a participant's evaluability in the per-protocol analysis.

Any vaccine not foreseen in the study protocol in the period starting at Visit 1 (Day 1) and ending at end of study visit must be recorded in the eCRF.

8. ASSESSMENTS OF IMMUNOGENICITY AND DISEASE INCIDENCE

Immunogenicity:

Immunogenicity will be assessed by anti-spike (S) protein IgG antibodies to SARS-CoV-2-Spike antigen by ELISA and virus/pseudovirus neutralising antibody assay.

Seroconversion is defined as four-fold increase in antibody titres from baseline.

Immunogenicity testing will be performed in compliance with GCP and GCLP requirements at the following laboratories:

- Anti-S IgG antibodies at the Novavax, USA
- Neutralizing antibodies by microneutralization (MNT) assay at 360biolabs, Australia
- Cell mediated immune (CMI) response assays at NARI-ICMR, Pune, India
- Anti-N IgG testing (Qualitative assay) will be performed at NARI-ICMR, Pune, India

Any other laboratories as appropriate may be used, if required.

Incidence of COVID-19:

If the participant presents with qualifying symptoms of suspected COVID-19 disease [Appendix II, Table 1] OR history of contact with a confirmed COVID-19 positive case then a swab from nose and/or throat will be collected for RT-PCR testing for SARS-CoV-2 infection. These samples will be processed for SARS CoV-2 RT-PCR testing. This process will be detailed in the laboratory manual.

All RT-PCR positive SARS CoV-2 cases (symptomatic as well as asymptomatic) from 14 days after each vaccination will be considered for analysis.

Severe COVID-19 disease will be defined as per criteria described in Appendix II, Table 2. Detailed clinical parameters will be collected from medical records. These are likely to include, but are not limited to, oxygen saturation, need for oxygen therapy, respiratory rate and other vital signs, need for ventilatory support, X-ray and CT scan imaging and blood test results, amongst other clinically relevant parameters.

9. METHODS FOR PROCESSING, LABEL AND STORAGE OF BLOOD SAMPLES

For all eligible participants:

- At screening, approximately 3 ml blood sample will be collected for SARS-CoV-2 serology (IgG).

- On Day 36, Day 85 and Day 180: Approximately, 3 ml blood to be drawn to detect anti-Nucleocapsid IgG antibodies.

For participants in immunogenicity cohort: Approximately 10 mL of blood will be drawn On Day 1, Day 22, Day 36 and Day 180 for anti-S IgG and neutralizing antibody assessments. Additionally, up to 20 ml blood sample may be collected from subset of 28 participants for assessment of cell mediated immune (CMI) responses on Day 1, Day 36 and Day 180.

The blood will be processed and sera / CMI samples will be aliquoted according to the Laboratory Manual. All aliquots for anti-S IgG and neutralizing antibodies and anti-Nucleocapsid IgG will be stored at a temperature of -20°C or below. CMI samples will be stored at -70°C or below or in Liquid nitrogen as applicable as per laboratory manual. Each aliquot (Cryotube / cryovial) will be labeled with the labels provided by Sponsor/designee. All samples will be sent to the Sponsor or Sponsor designated laboratory.

Complete instructions for labeling and storage of samples will be provided in the Laboratory Manual.

10. ASSESSMENT OF SAFETY

10.1 SAFETY MONITORING

The Investigators at each study site will be responsible for continuous close safety monitoring of all study participants, and for alerting the protocol team if concerns arise. An internal team - the Protocol Safety Review (PSRT) and an independent Data Safety Monitoring Board (DSMB), will be set up for safety monitoring of the trial participants.

10.2 PROTOCOL SAFETY REVIEW TEAM (PSRT) AND DATA SAFETY MONITORING BOARD (DSMB)

Safety will be monitored during the study by on-site clinical staff and routinely by the PSRT, an internal group of physicians which includes the ICMR Medical Officers, SIIPL Medical Officers, a biostatistician and designated pharmacovigilance medical officer from the CRO. The PSRT may seek independent expert medical opinion as dictated by the occurrence of certain events. There will be periodic reviews of accruing safety data by the PSRT.

In addition, there will be an independent DSMB who will review the safety data and provide oversight on the study. DSMB will review the 7 days safety data post first dose of first 200 participants from the safety cohort from Phase 2 part of the study. Additional safety data reviews may be performed by DSMB as and when necessary at periodic intervals.

10.3 ADVERSE EVENT (AE)

An AE is any untoward medical occurrence in a participant after administration of the vaccine and that does not necessarily have a causal relationship with the vaccine. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the vaccine, whether or not related to the vaccine. This definition includes exacerbations of pre-existing conditions. Stable pre-existing conditions which do not change in nature or severity during the study are not considered AEs; however, these should be reported as part of the medical history at screening.

Adverse events that may be related to the study vaccine are listed in the Investigator's Brochure for each product.

Solicited AEs are pre-specified local and systemic AEs that occur relatively more frequently or are known to be associated with immunization, which are monitored actively as potential indicators of vaccine reactogenicity. Investigators will not be required to assess causality of solicited AEs if the onset is during the solicitation period.

The following specific solicited adverse events will be monitored for this study:

Local reactions at injection site:

- Pain
- Tenderness
- Erythema
- Swelling
- Induration

Systemic reactions:

- Fever
- Headache
- Fatigue
- Malaise
- Arthralgia
- Myalgia
- Nausea
- Vomiting

Unsolicited AEs are any AEs reported spontaneously by the participant, observed by the study staff during study visits or those identified during review of medical records or source documents. Solicited AEs with an onset after the seven-day solicitation period will be considered unsolicited AEs.

MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, or other visits to or from medical personnel for any reason. Scheduled study visits will not be considered medically attended visits. All MAAEs are to be reported from the time of first study vaccination until Day 36. MAAEs related to study vaccination are to be reported from the time of first study vaccination until completion of the participant's last study-related procedure, which may include contact for safety follow-up.

10.4 SERIOUS ADVERSE EVENT (SAE)

An SAE is any AE that results in any of the following outcomes:

- Death

- Is life-threatening (i.e., the participant was, in the opinion of the investigator, at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)
- Requires inpatient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- Congenital anomaly or birth defect
- Important medical event that may not result in one of the above outcomes but may jeopardize the health of the study participant or may require medical or surgical intervention to prevent one of the outcomes listed above

10.5 REPORTING PERIOD AND PARAMETER

Reactogenicity cohort:

Solicited AEs will be collected through 7 days following each vaccination using participant diary card. Solicited AEs with onset during the seven-day solicitation period that continue beyond the seven-day period will be reported as solicited AEs. Solicited AEs with onset after the seven-day solicitation period will be reported as unsolicited AEs.

All solicited AEs, even if they are medically attended will not be considered as MAAEs.

All study participants:

Unsolicited AEs and MAAEs will be collected through 35 days (Day 36) following administration of first dose of study vaccine. SAEs, related MAAEs and AESI including PIMMCs and AESIs relevant to COVID-19 including possible vaccine-enhanced disease will be collected following administration of the first dose of study vaccine until completion of the Visit 6 (Day 180) procedures.

Any untoward medical occurrence in a participant prior to administration of the vaccine but after signing the informed consent form, which is assessed by the investigator as being related to a study procedure, must also be documented and reported to the Sponsor.

10.6 ADVERSE EVENTS OF SPECIAL INTEREST (AESI)

Subjects will be assessed for diagnosis of an AESI at all study visits. AESIs include PIMMCs, AEs specific to COVID-19, or other potential AEs that may be determined at any time by regulatory authorities as additional information concerning COVID-19 is obtained. Given the

concern for cytokine storm, an AESI of cytokine release syndrome will be included as an AE specific to COVID-19. Listings of AESI are presented in Appendix I.

10.7 SEVERITY OF ADVERSE EVENTS

The grading scales cited below will be used to interpret the severity of each AE as such:

Grade 1 = Mild

Grade 2 = Moderate

Grade 3 = Severe (a severe AE is not necessarily an SAE, unless it meets one of the criteria that define an SAE; likewise, all SAEs are not necessarily by definition severe)

Grade 4 = Potentially Life-threatening (life-threatening AEs are to be reported as SAEs)

Grade 5 = Death

The severity of all AEs, listed specifically as an event in the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, corrected version 2.1, July 2017, of the US National Institute of Health, will be assessed based on this Table, which is provided as Appendix III to this protocol and is currently also available at: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf

The following grading scale should be used to grade the severity of all unsolicited AEs that are not listed as a specific event in the DAIDS Table cited:

Grade 1= Causes no or minimal interference with usual social & functional activities

Grade 2 = Causes greater than minimal interference with usual social & functional activities

Grade 3 = Causes inability to perform usual social & functional activities

Grade 4 = Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability

Grade 5 = Death

10.8 CAUSALITY OF ADVERSE EVENTS

The investigator will determine the causal relationship between the vaccine and the AE for all unsolicited AEs. The causality assessment is made based on the available information at the time of reporting and can subsequently be changed according to follow-up information. Causality determination is based on clinical assessment and should take into consideration the following factors:

- Is there a temporal relationship between the event and administration of the vaccine?
- Is there a plausible biological mechanism for the vaccine to cause the AE?

- Is there a possible alternative etiology for the AE, such as a concurrent illness or a concomitant medication?
- Are there previous reports of similar AEs associated with the vaccine or other vaccines in the same class?

For this study, the investigator must classify the causality of the AE according to the categories defined below:

Related: There is a reasonable possibility that the vaccine caused the event. 'Reasonable possibility' means that there is evidence to suggest a causal relationship between the vaccine and the AE.

Not Related: There is not a reasonable possibility that the administration of the vaccine caused the event.

All solicited AEs within 7 days of each vaccination in the reactogenicity cohort will be considered as related AEs. In addition, related SAEs will be evaluated by the investigator for "expectedness" also. An unexpected AE is one that is not listed in the current Summary of Product Characteristics or the IB or it is an event that is by nature more specific or more severe than a listed event.

10.9 FOLLOW-UP OF ADVERSE EVENTS

All AEs should be followed by the investigator or their designee until the event is resolved or determined to be irreversible, chronic, or stable by the investigator or participant is lost to follow up (including death). The investigator must ensure that any participants with AEs ongoing at study completion are advised or referred appropriately for continuation of care.

The outcome of an AE will be assessed as at the time of last observation per the following categories:

- Recovered/resolved without sequelae
- Recovered/resolved with sequelae
- Ongoing
- Death
- Unknown

10.10 GENERAL GUIDANCE ON REPORTING ADVERSE EVENTS

To improve the quality and precision of AE data, the investigator should observe the following guidelines:

- AEs must be graded, assessed for severity and causality, and reviewed by a site investigator.
- Whenever possible, use recognized medical terms when reporting AEs and avoid the use of colloquialisms or abbreviations.
- If known, report the diagnosis (i.e., syndrome or disease) rather than component symptoms, signs or laboratory values (e.g., report congestive heart failure rather than dyspnoea, rales, and cyanosis); however, symptoms or signs that are considered unrelated to an observed syndrome or disease should be reported as individual AEs (e.g., if congestive heart failure and severe headache are observed at the same time, each event should be recorded as an individual AE).
- AEs occurring secondary to other events (e.g., sequelae) should be identified by the primary cause. A 'primary' AE, if clearly identifiable, generally represents the most accurate clinical term to report. For example: orthostatic hypotension → fainting and fall to floor → head trauma → neck pain; the primary AE is orthostatic hypotension, which is what should be reported. If a primary SAE is reported, events occurring secondary to the primary event should be described in the narrative description of the case.
- Death is an outcome of an event. The event that resulted in the death should be reported as the SAE.
- For hospitalizations for surgical or diagnostic procedures, the illness leading to the surgical or diagnostic procedure should be recorded as the SAE, not the procedure itself. The procedure should be captured in the case narrative as part of the action taken in response to the illness.
- Elective surgical or diagnostic procedures with or without hospitalizations (e.g., circumcision or elective abortion of a pregnancy) will not be recorded as an AE. The procedure should be captured in the case narrative as part of medical history.
- A pregnancy in a participant is not in and of itself an AE.

10.11 REPORTING OF SAE

Any SAE occurring in a study participant during the study (after vaccine administration) must be reported. Information about all SAEs will be collected and recorded in SAE form. To ensure

participant safety, each SAE must be reported by the Investigator to the Sponsor within 24 hours of learning of its occurrence, even if it is not felt to be treatment-related.

The SAE form will always be completed as thoroughly as possible with all available details of the event. Even if the investigator does not have the entire recommended minimum information regarding a SAE, the SAE should still be submitted to sponsor, DCGI & respective IEC within 24 hours. Once additional relevant information is received, the SAE form should be updated. Reporting procedures will be followed as per the New Drugs and Clinical Trials Rules, 2019.

The investigator will always provide an assessment of causality at the time of the initial report.

Instructions for reporting of SAEs

The recommended minimum information required for the initial SAE report is:

- Identifiable study participant
- A suspect medicinal product
- Identifiable reporting source
- An event or outcome that can be identified as SAE
- Preliminary causality assessment
- Severity

All SAEs are also to be documented on the Adverse Events eCRF. Any medication or other therapeutic measures used to treat the AE will be recorded on the appropriate eCRF pages in addition to the grading and outcome of the AE.

Contact Persons and Numbers

The details of the Sponsor's contact person for safety reporting or questions are listed below and will also be kept on-site in the Investigator File.

[redacted]

[redacted]

[redacted]

[redacted]

Follow-up of SAEs

After receipt of the initial report, sponsor/designee may contact the investigator if it is necessary to obtain further information for assessment of the event.

All SAEs must be documented and followed up until the event has resolved, subsided, stabilized, disappeared or is otherwise explained. All follow-up activities have to be reported, if necessary on one or more consecutive SAE report forms in a timely manner.

10.12 TREATMENT OF AE AND SAES

Treatment of any AE and SAE is at the sole discretion of the investigator and according to current Good Medical Practice. The applied measures should be recorded in eCRF.

Cost of the medical care for vaccine related AEs will be borne by the sponsor.

11. STATISTICAL CONSIDERATIONS

11.1 OVERVIEW AND GENERAL CONSIDERATIONS

This is a Phase 2/3, observer-blind, randomised, controlled study in individuals aged ≥ 18 years in India, to evaluate the safety of COVOVAX in comparison with Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) and Placebo; and for comparison of the

immunogenicity of COVOVAX with the Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant).

A detailed statistical analysis plan will be created and finalized prior to database lock. All statistical analyses will be performed using SAS® software Version 9.4 or later.

Medical History and AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) (version 23.0 or later). The frequency count and percentage of participants will be summarized by system organ class (SOC) and preferred term (PT). Study participant-wise data listing will be provided.

The non-inferiority test will be performed using a one-sided significance level of 2.5%. Any other statistical tests will be performed using a two-sided significance level of 5%. For consistency two-sided 95% confidence intervals (CIs) will be provided throughout. The main purpose of the safety analysis is to estimate the incidence rate of different events in each vaccine group and their difference between vaccine groups. Whilst the intention is not to show a difference between vaccine groups, p-values corresponding to CIs will also be calculated and shown for illustrative purposes. No statistical tests will be performed at any interim analyses of safety data.

11.2 RANDOMIZATION

The randomization scheme for treatment assignment (vaccine groups) will be generated and maintained by independent personnel at PPD. PPD Biostatistics will generate the randomization schedule using SAS software Version 9.4 or later (SAS Institute Inc, Cary, North Carolina) for Interactive Response Technology (IRT), which will link sequential participant randomization numbers to treatment codes.

The eligible participants will be enrolled and randomized in the study online through IRT. Each participant enrolled into the study will be assigned a randomization number to assign vaccine group after identification and eligibility data have been entered into the IRT system.

A total of 1600 eligible participants of ≥ 18 years of age will be enrolled in the study. 200 participants have been enrolled in safety cohort in Phase 2 part and were randomly assigned in a 3:1 ratio to receive either COVOVAX or Placebo. Of the remaining 1400 participants in the Phase 3 part, 460 participants will be enrolled in immunogenicity cohort and will be randomly assigned in a 3:1 ratio to receive either COVOVAX or Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant), respectively. The remaining 940 participants from safety cohort in Phase 3 part will be randomly assigned in a 3:1 ratio to receive either COVOVAX

(n=705) or Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (n=235), respectively.

All eligible participants (n=1600) will receive 0.5 ml of either COVOVAX or the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) or Placebo on Day 1 and Day 22 as per randomization.

11.3 SAMPLE SIZE AND POWER

The study is designed to have a 95% probability to detect at least one causally related serious adverse event among 1200 participants administered COVOVAX, if the frequency of causally related serious adverse events is 1/400.

It is planned to randomize 460 participants in the immunogenicity cohort [345 to COVOVAX and 115 to the Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) groups]. Assuming that the proportion of non-evaluable participants ≤ 20% (which leads to a sample size of 368 evaluable participants), the study will have at least 90% power to show non-inferiority of immune responses assuming a Coefficient of Variation of 1.35 [the base10 log of the standard deviation (SD) from Day 35 was estimated from the Part 1 (Phase 1) of 2010nCov-101 study for anti-spike (S) protein IgG EUs]. The study will have at least 80% power to show non-inferiority of immune responses with a sample size of 276 evaluable participants. Non-inferiority will be concluded if the lower limit of the two-sided 95% CI for the GMEU ratio for anti-S protein IgG antibodies against SARS-CoV-2 spike protein between COVOVAX and the Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) is > 0.67. Additional assumptions include a one-sided significance level of 0.025 and '0' difference in anti-S protein IgG antibody titers against anti-spike(S) protein IgG between the two vaccine groups (i.e. a GMEU ratio between both vaccine groups of 1). Sample size calculations were performed using a Non-inferiority test for the ratio of two means in PASS 15.0.7 Version software.

The following table shows the evaluable sample size to demonstrate non-inferiority of immune response:

Power (%)	Evaluable sample size (SS)			% Non-evaluable participants (Dropout rate)
	Total number of participants	COVOVAX	Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)	
90	368	276	92	20%

11.4 ANALYSIS POPULATIONS

11.4.1 Enrolled Population

All participants who provide written informed consent, regardless of the participants screening, randomization and treatment status in the study.

11.4.2 Randomized Population

All participants in the enrolled population who are randomized (i.e. assigned treatment).

11.4.3 Full Analysis Population

All participants in the Enrolled population who received first dose of study vaccine and provided an evaluable serum sample post vaccination for at least one assessment. Participants in the Full Analysis population will be analyzed 'as randomized', i.e., according to the vaccine a participant was designated to receive, which may be different from the vaccine the participants actually received.

11.4.4 Safety Population

All participants who receive at least one dose of study vaccine [COVOVAX or Control Vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) or Placebo]. All safety analyses will be performed using this population. Participants in the safety population will be analyzed as 'treated' (i.e. actual vaccine received).

11.4.5 Switched Treatment Safety Population (Safety cohort)

All participants originally randomized to Placebo group who were unblinded on or after Day 85 in order to receive COVOVAX Vaccine will be analysed as 'treated' with the additional vaccine (i.e. actual additional vaccine received).

11.4.6 Immunogenicity Population

Immunogenicity Analysis population will be a subset of Full Analysis population. Immunogenicity Analysis population consist of all participants who received first dose of study vaccine and provided an evaluable serum sample post vaccination for at least one assessment, excluding any data from time points following a SARS-CoV-2 infection or major protocol deviation (defined as having missed 2nd dose of Vaccination or use of an immunosuppressant, immune-modulating medication or vaccines which interfere with assessing immunogenicity). All immunogenicity analyses will be performed using this population. Participants in the immunogenicity population will be analyzed as 'treated' (i.e. actual vaccine received). The

review and determination for exclusion from the Immunogenicity Populations will be carried out in a blinded fashion by a study clinician prior to unblinding.

11.5 ANALYSIS PLAN

11.5.1 Intercurrent events (IcEv)

Label	Intercurrent Event Type
IcEv1 (Death)	Death due to any cause; this is an IcEv because it leads to the endpoint (e.g. antibody titer) not existing at later timepoints.
IcEv2 (Immune modifiers)	Use of Immunosuppressant and Immune modifying medications or vaccines which interfere with assessing immunogenicity.
IcEv3 (COVID-19/SARS-CoV-2 infection)	Incidence of COVID-19/SARS-CoV-2 infection after vaccination.
IcEv4 (Missed 2nd dose of vaccine)	Does not receive the second scheduled vaccine at Day 22
IcEv5 (non-randomized receipt of COVOVAX vaccine)	After unblinding on or after Day 85, participant in placebo group receives COVOVAX.

11.5.2 Estimand Specifications;

Attributes for the primary safety estimand with strategies for IcEvs are presented in the Table 11.5.2.1.

Table 11.5.2.1 Primary Objective(s) and Estimand(s) with Rationale for Strategies to Address Intercurrent Events

Objective	To assess the safety of COVOVAX
Estimand Label	Estimand 1
Estimand Description	Proportion of participants with at least one causally related SAE • Up to Visit 3 – Day 36 (+7) post first dose vaccination. • Up to Visit 4 – Day 85 (+14) post first dose vaccination. • Up to Visit 6 – Day 180 (+28) post first dose vaccination. A treatment policy strategy is used for assessing safety irrespective of use of immune-modifying medications/vaccinations or missed 2nd dose of vaccination.
Target Population	Vaccinated individuals aged 18 years and older
Endpoint	Occurrence of causally related SAEs • Up to Visit 3 – Day 36 (+7) post first dose vaccination. • Up to Visit 4 – Day 85 (+14) post first dose vaccination. • Up to Visit 6 – Day 180 (+28) post first dose vaccination.
Treatment Condition(s)	Test: COVOVAX Vaccine - and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) and COVOVAX and Placebo.
Population-Level Summary	Proportion of participants with causally related SAEs • Up to Visit 3 – Day 36 (+7) post first dose vaccination. • Up to Visit 4 – Day 85 (+14) post first dose vaccination. • Up to Visit 6 – Day 180 (+28) post first dose vaccination.
Intercurrent Event Strategy	
IcEv1 (Death)	Treatment Policy: Not Applicable
IcEv2 (Immune modifiers)	Treatment policy – i.e. included, irrespective use of Immune modifiers.
IcEv3 (COVID-19/SARS-CoV-2 infection)	Not Applicable
IcEv4 (Missed 2nd Dose of Vaccine)	Treatment policy – assessed irrespective of whether 2nd dose of vaccination received
IcEv5 (non-randomized receipt of COVOVAX vaccine)	Whilst on randomized treatment – data after additional receipt of non-randomized COVOVAX vaccine will not be included
Rationale for Strategies	A treatment policy strategy is used for assessing safety irrespective of use of immune-modifying medications (we cannot exclude the safety events even subject receive the immune modifier) or missed 2nd dose of vaccination. A whilst on randomized treatment strategy is used for placebo group participants who received additional COVOVAX vaccine at or after Day 85 (as any causally related SAEs after receipt of the additional COVOVAX vaccine should not be attributed to the original placebo group).

Refer to Section 11.5.1 specific numbered intercurrent event definitions.

Table 11.5.2.2 Co-Primary Immunogenicity Objectives and Estimands with Rationale for Strategies to Address Intercurrent Events

Objective	To assess immunogenicity of COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) by IgG ELISA assay.
Estimand Label	Estimand 2
Estimand Description	Ratio of geometric mean ELISA Units (GMEUs) of anti-spike (S) protein IgG at 14 days post second dose vaccination (Visit 3 – Day 36 (+7) post first dose vaccination) between vaccines [COVOVAX/ Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)]. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines or missed 2nd dose of vaccine or death.
Target Population	Vaccinated individuals aged 18 years and older.
Endpoint	Ratio of GMEUs of anti-spike (S) protein IgG at 14 days post second dose vaccination [Visit 3 – Day 36 (+7) post first dose vaccination].
Treatment Condition(s)	COVOVAX and the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)
Population-Level Summary	Ratio of GMEUs between vaccinations (test/reference)
Intercurrent Event Strategy	
IcEv1 (Death)	Hypothetical strategy
IcEv2 (Immune modifiers)	Hypothetical strategy
IcEv3 (COVID-19/SARS-CoV-2 infection)	Hypothetical strategy
IcEv4 (Missed 2nd Dose of Vaccine)	Hypothetical strategy as interested in antibody levels had the 2nd dose of vaccination been received per schedule.
IcEv5 (non-randomized receipt of COVOVAX vaccine)	Not Applicable
Rationale for Strategies	The hypothetical strategy is used to estimate effect attributable to the difference in vaccines without any use of immune-modifying medications or other vaccinations and without influence from subsequent infection, missed 2nd dose of vaccine and death.

Refer to Section 11.5.1 specific numbered intercurrent event definitions.

Table 11.5.2.3 Secondary Safety Objective(s) and Estimand(s) with Rationale for Strategies to Address Intercurrent Events

Objective	To assess the tolerability and reactogenicity profile of the COVOVAX in comparison with Placebo (for Phase 2 part) AND COVOVAX with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part).	
Estimand Label	Estimand 3	Estimand 4
Estimand Description	Proportion of participants with at least one SAE, related MAAEs, and AESI which encompasses PIMMCs and AESIs relevant to COVID-19; and proportion with at least one Unsolicited AEs including MAAEs • Up to Visit Visit 4 – Day 85 (+14) and 6 – Day 180 (+28) post first dose vaccination with SAEs, related MAAEs, AESI which encompasses PIMMCs and AESIs relevant to COVID-19. • Within Visit 3 – Day 36 (+7) following each vaccination with Unsolicited AEs including MAAEs. A treatment policy strategy is used for assessing safety irrespective of use of immune modifying medications or other vaccinations and missed 2nd dose of vaccine.	Proportion of participants with at least one solicited local and/or systemic adverse event (AE) • Within 7 days following each vaccination. A treatment policy strategy is used for assessing safety irrespective of use of modifying medications to assess missed 2nd vaccine dose. While on treatment strategy is used to utilize all available data until event.
Target Population	Vaccinated individuals aged 18 years and older	Vaccinated individuals aged 18 years and older.
Endpoint	• Occurrence of SAEs, MAAEs, and AESI which encompasses PIMMCs and AESIs relevant to COVID-19 up to Visit 4 – Day 85 (+14) and Visit 6 – Day 180 (+28) post first dose vaccination. • Occurrence Unsolicited AEs for Visit 3 – Day 36 (+7) post first dose vaccination.	• Occurrence of solicited local and systemic adverse events (AEs) for 7 days following each vaccination (Reactogenicity cohort).
Treatment Condition(s)	COVOVAX, Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) and Placebo.	COVOVAX, Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) and Placebo.
Population-Level Summary	Proportion	Proportion
Intercurrent Event Strategy		
IcEv1 (Death)	Treatment strategy	While on treatment strategy (data until death is utilized)
IcEv2 (Immune modifiers)	Treatment policy	Treatment policy
IcEv3 (COVID-19/SARS-CoV-2 infection)	Treatment strategy	Treatment Policy

Objective	To assess the tolerability and reactogenicity profile of the COVOVAX in comparison with Placebo (for Phase 2 part) AND COVOVAX with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part).	
Estimand Label	Estimand 3	Estimand 4
IcEv4 (Missed 2nd Dose of Vaccine)	Treatment policy – If subject missed second dose of vaccine then AEs data post second vaccination will not be used in the analysis	Treatment policy – If subject missed second dose of vaccine then AEs data post second vaccination will not be used in the analysis
IcEv5 (non-randomized receipt of COVOVAX vaccine)	Whilst on randomized treatment – data after additional receipt of non-randomized COVOVAX vaccine will not be included	Not Applicable
Rationale for Strategies	A treatment policy strategy is used for assessing safety irrespective of use of Immune modifiers (we cannot exclude the safety events even subject receive the immune modifier). A whilst on randomized treatment strategy is used for placebo group participants who received additional COVOVAX vaccine at or after Day 85 (as any SAEs, MAAEs, and AESI which encompasses PIMMCs and AESIs relevant to COVID-19 after receipt of the additional COVOVAX vaccine should not be attributed to the original placebo group).	A treatment policy strategy is used for assessing safety irrespective of use of Immune modifiers (we cannot exclude the safety events even subject receive the immune modifier). While on treatment policy is used to utilize the data until death

Refer to Section 11.5.1 specific numbered intercurrent event definitions.

Table 11.5.2.4 Secondary Immunogenicity Objectives and Estimands with Rationale for Strategies to Address Intercurrent Events

Objective	To assess immunogenicity of the COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) by IgG ELISA and neutralizing antibody assays.	
Estimand Label	Estimand 5	Estimand 6
Estimand Description	GMEUs of anti-S IgG antibodies at Baseline, Visit 2 – Day 22 (+7), Visit 3 – Day 36 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination and GMTs of NAb at Baseline and Visit 3 – Day 36 (+7) post first dose vaccination. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.	Proportion with seroconversion for anti-spike (S) protein IgG at Visit 2 – Day 22 (+7), Visit 3 – Day 36 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination and proportion of participants with seroconversion for virus neutralizing antibodies (NAb) at Visit 3 – Day 36 (+7) post first dose vaccination. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.
Target Population	Vaccinated individuals aged 18 years and older.	Vaccinated individuals aged 18 years and older.
Endpoint	• GMEUs of anti-spike (S) protein IgG antibodies at Baseline, Visit 2 – Day 22 (+7), Visit 3 – Day 36 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination. • GMTs of virus NAb against SARS-CoV-2 spike protein at Baseline and Visit 3 – Day 36 (+7) post first dose vaccination.	• Seroconversion for virus neutralizing antibodies NAb at Visit 3 – Day 36 (+7) post first dose vaccination. • Seroconversion for anti-spike (S) protein IgG at Visit 2 – Day 22 (+7), Visit 3 – Day 36 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination.
Treatment Condition(s)	COVOVAX and the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)	COVOVAX and the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)
Population-Level Summary	GMEU ratio between vaccinations (COVOVAX/ Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant))	Proportion of participants with seroconversion in COVOVAX and the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)
Intercurrent Event Strategy		
IcEv1 (Death)	Hypothetical	Hypothetical
IcEv2 (Immune modifiers)	Hypothetical	Hypothetical
IcEv3 (COVID-19/SARS-CoV-2 infection)	Hypothetical.	Hypothetical
IcEv4 (Missed 2nd Dose of Vaccine)	Hypothetical.	Hypothetical
IcEv5 (non-randomized receipt of COVOVAX vaccine)	Not Applicable	Not Applicable

Objective	To assess immunogenicity of the COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) by IgG ELISA and neutralizing antibody assays.	
Estimand Label	Estimand 5	Estimand 6
Rationale for Strategies	Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection and immune-modifying medications.	Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection and immune-modifying medications.

Refer to Section 11.5.1 specific numbered intercurrent event definitions.

Table 11.5.2.5 Exploratory Immunogenicity Objectives and Estimands with Rationale for Strategies to Address Intercurrent Events

Objective	To assess immunogenicity of the COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant).	
Estimand Label	Estimand 7	Estimand 8
Estimand Description	GMTs of virus neutralizing antibodies (NAb) at Visit 2 – Day 22 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination and mean of change from Baseline in cell-mediated immune responses 35 and 179 days post first dose vaccination. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.	Proportion with seroconversion for NAb at Visit 2 – Day 22 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.
Target Population	Vaccinated individuals aged 18 years and older.	Vaccinated Individuals aged 18 years and older.
Endpoint	• GMTs of virus neutralizing antibodies (NAb) at Visit 2 – Day 22 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination. • Mean of change from Baseline (Day 1) in the cell-mediated immune responses (for example, as measured by enzyme-linked immune absorbent spot (ELISpot) ± intracellular cytokine staining) on Day 36 (14 days post second dose vaccination) and Day 180 .	• Proportion with seroconversion for NAb at Visit 2 – Day 22 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination.
Treatment Condition(s)	COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)	COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)
Population-Level Summary	GMT ratio between vaccinations (COVOVAX/ Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)	Proportion of participants with seroconversion for NAb in COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)
Intercurrent Event Strategy		
IcEv1 (Death)	Hypothetical	Hypothetical
IcEv2 (Immune modifiers)	Hypothetical	Hypothetical
IcEv3 (COVID-19/SARS-CoV-2 infection)	Hypothetical.	Hypothetical
IcEv4 (Missed 2nd Dose of Vaccine)	Hypothetical.	Hypothetical
IcEv5 (non-randomized receipt of COVOVAX vaccine)	Not Applicable	Not Applicable

Objective	To assess immunogenicity of the COVOVAX in comparison with the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant).	
Estimand Label	Estimand 7	Estimand 8
Rationale for Strategies	Hypothetical strategy is used to understand antibody levels and cell-mediated immunity achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.	Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.

Refer to Section 11.5.1 specific numbered intercurrent event definitions.

Table 11.5.2.5 Exploratory Objective(s) of Incidence of SARS-CoV-2 infection, severe COVID-19 and Estimand(s) with Rationale for Strategies to Address Intercurrent Events

Objective	• To assess the incidence SARS-CoV-2 infection between COVOVAX and Placebo (for Phase 2 part) AND between COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part). • To assess the incidence of severe COVID-19 disease between COVOVAX and Placebo (for Phase 2 part) AND between COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part).
Estimand Label	Estimand 9
Estimand Description	Proportion of participants with incidence of virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19, laboratory confirmed (RT-PCR positive and /or Anti-Nucleocapsid IgG) asymptomatic cases of COVID-19, and laboratory confirmed (RT-PCR positive and /or Anti-Nucleocapsid IgG) SARS-CoV-2 cases (symptomatic as well as asymptomatic) which occur 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28); proportion of participants with severe virologically confirmed COVID-19 infection, Intensive care unit (ICU) admissions associated with virologically confirmed COVID-19 infection and all cause deaths in virologically confirmed COVID-19 infection. A treatment policy strategy is used for assessing safety irrespective of use of immune-modifying medications/vaccinations or missed 2nd dose of vaccination Infections and death (meeting criteria) are included in the endpoint (composite strategy).
Target Population	Vaccinated participants who do not have an active or prior infection at vaccination
Endpoint	• Virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19 which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28). • Laboratory confirmed (RT-PCR and /or Anti-Nucleocapsid IgG) asymptomatic cases of COVID-19 which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28). • Laboratory confirmed (RT-PCR positive and /or Anti-Nucleocapsid IgG) SARS-CoV-2 cases (symptomatic as well as asymptomatic) which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28). • Severe virologically confirmed COVID-19 infection which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28). • Intensive care unit (ICU) admissions associated with virologically confirmed COVID-19 infection which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28). • All cause deaths in virologically confirmed COVID-19 infection which occur from 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28).
Treatment Condition(s)	COVOVAX, and the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) and Placebo.
Population-Level Summary	Proportions of COVID -19 incidence [defined in the endpoint in COVOVAX, Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) and Placebo]

Objective	• To assess the incidence SARS-CoV-2 infection between COVOVAX and Placebo (for Phase 2 part) AND between COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part). • To assess the incidence of severe COVID-19 disease between COVOVAX and Placebo (for Phase 2 part) AND between COVOVAX and Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) (Phase 3 part).
Estimand Label	Estimand 9

Intercurrent Event Strategy	
IcEv1 (Death)	Composite (meeting criteria of COVID 19)
IcEv2 (Immune modifiers)	Treatment policy
IcEv3 (COVID-19/SARS-CoV-2 infection)	Composite
IcEv4 (Missed 2nd Dose of Vaccine)	Treatment policy
IcEv5 (non-randomized receipt of COVOVAX vaccine)	Whilst on randomized treatment – data after additional receipt of non-randomized COVOVAX vaccine will not be included
Rationale for Strategies	A treatment policy strategy is used for assessing safety irrespective of use of immune-modifying medications/vaccinations or missed 2nd dose of vaccination. Infections and death (meeting criteria) are included in the endpoint (composite strategy). A whilst on randomized treatment strategy is used for placebo group participants who received additional COVOVAX vaccine at or after Day 85 (as any infections and death (meeting criteria) after receipt of the additional COVOVAX vaccine should not be attributed to the original placebo group).

Refer to Section 11.5.1 specific numbered intercurrent event definitions.

11.5.3 Table of statistical method and sensitivity analysis -

		Main Estimation			Sensitivity Analysis
Estimand Label	**Estimand Description**	**Analysis Set**	**Imputation/ Data/ Censoring Rules**	**Analysis Model/Method**	
Estimand 1 (Primary)	Proportion of participants with at least one causally related SAE • Up to Visit 3 – Day 36 (+7) post first dose vaccination. • Up to Visit 4 – Day 85 (+14) post first dose vaccination. • Up to Visit 6 – Day 180 (+28) post first dose vaccination. A treatment policy strategy is used for assessing safety irrespective of use of immune-modifying medications/vaccinations or missed 2nd dose of vaccination. A whilst on randomized treatment strategy is used for placebo group participants who received additional COVOVAX vaccine at or after Day 85 (as any causally related SAEs after receipt of the additional COVOVAX vaccine should not be attributed to the original placebo group)	Safety Analysis Population	Infections and death.	Frequencies and estimate of the proportion of participants with at least one causally related SAE throughout the study duration following the study vaccination will be computed by vaccine group using two sided 95% Clopper-Pearson confidence intervals.	

Estimand 2 (Co-Primary)	Ratio of geometric mean ELISA Units (GMEUs) of anti-Spike (S) protein IgG at 14 days post second dose vaccination (Visit 3 – Day 36 (+7) post first dose vaccination) between vaccines (COVOVAX/ Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)). Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines or missed 2nd dose of vaccine or death.	Immunogenicity Analysis Population	Values below the limit of quantification (LOQ) or limit of detection (LOD) will be replaced by LOQ/2 and LOD/2, respectively. Multiple imputation of missing values (and those removed from IA population) assumed to MAR.	ANCOVA will be fitted to the log transformed anti-Spike (S) protein IgGs with terms for vaccine group, log baseline titer, age group (18-59 years and ≥ 60) and sex. Individual mean and 95% CI values by treatment from this model will be used to generate the geometric mean ELISA Units with 95% CI at each time point and geometric mean ratio (GMR) with 95% CI at 14 post second dose vaccination by back transforming to the original scale. Hypothesis testing H0: $GMEU_{SII}/GMEU_{NOV} \leq 0.67$ (Inferior) H1: $GMEU_{SII}/GMEU_{NOV} > 0.67$ (Non-Inferior) Where – SII- COVOVAX and NOV-Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant). The lower limit of the 95% CI for the GMR will be compared with a non-inferiority margin of 0.67 and COVOVAX vaccine will be declared non-inferior to and the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) if > 0.67.	

Estimand 3	Proportion of participants with at least one SAE, related MAAEs, and AESI which encompasses PIMMCs and AESIs relevant to COVID-19; and proportion with at least one Unsolicited AE • Up to Visit 4 – Day 85 (+14) post first dose vaccination with SAEs, related MAAEs, AESIs which encompasses PIMMCs and AESIs relevant to COVID-19. • Up to Visit 6 – Day 180 (+28) post first dose vaccination with SAEs, related MAAEs, AESIs which encompasses PIMMCs and AESIs relevant to COVID-19. • Within Visit 3 – Day 36 (+7) post first dose vaccination with unsolicited AEs including MAAEs. A treatment policy strategy is used for assessing safety irrespective of use of immune modifying medications or other vaccinations and missed 2nd dose of vaccine. A whilst on randomized treatment strategy is used for placebo group participants who received additional COVOVAX vaccine at or after Day 85 (as any SAEs, MAAEs, and AESI which encompasses PIMMCs and AESIs relevant to COVID-19 after receipt of the additional COVOVAX vaccine should not be attributed to the original placebo group).	Safety Analysis Population	None	Frequencies and estimate of the proportion of participants with at least one SAE, related MAAEs, and AESI which encompasses PIMMCs and AESIs relevant to COVID-19 throughout the study duration following the study vaccination and proportion of participants with at least one unsolicited AE including MAAEs for 35 days following the first vaccination will be computed by vaccine group using two sided 95% Clopper-Pearson confidence intervals. The difference between the vaccines (COVOVAX - Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)) and for Phase 2 (COVOVAX - Placebo] in the proportion of the participants with at least one SAE, related MAAEs and AESIs which encompasses PIMMCs and AESIs relevant to COVID-19 throughout the study duration following the study vaccination and proportion of participants with at least one unsolicited AE for 35 days following the first vaccination will be provided along with their two-sided 95% CIs obtained by the Miettinen and Nurminen method.	

Estimand 4	Proportion of participants at least one solicited local and/or systemic adverse event (AE) • Within 7 days following each vaccination. A treatment policy strategy is used for assessing safety irrespective of use of modifying medications to assess missed 2nd vaccine dose. While on treatment strategy is used to utilize all available data until event.	Safety Analysis Population (Reactogenicity cohort)	None	Frequencies and estimate of the proportion of participants with at least one solicited local and systemic adverse event (AE) for 7 days following each vaccination will be computed by vaccine group using two sided 95% Clopper-Pearson confidence intervals. The difference between the vaccines (COVOVAX - Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)) in the proportion of the participants with at least one solicited local and systemic adverse event (AE) for 7 days following each vaccination will be provided along with their two-sided 95% CIs obtained by the Miettinen and Nurminen method.	
Estimand 5	GMEUs of anti-S IgG antibodies at Baseline, Visit 2 – Day 22 (+7), Visit 3 – Day 36 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination; GMTs of NAb at Baseline and Visit 3 – Day 36 (+7) post first dose vaccination. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.	Immunogenicity Analysis Population	Values below the limit of quantification (LOQ) or limit of detection (LOD) will be replaced by LOQ/2 and LOD/2, respectively.	MMRM will be fitted to the log transformed titer values of NAb and anti-S IgG antibodies with terms for vaccine group, visit, log baseline titer, age group (18-59 years and ≥ 60) and sex with interactions for treatment by visit. The repeated timepoints on subject will be modelled (Details of the covariance structure will be provided in the SAP). Individual mean and 95% CI values by treatment from this model will be used to generate the geometric mean ELISA Units with 95% CI at each time point and GMRs with 95% CIs at each time point by back transforming to the original scale.	

Estimand 6	Proportion with seroconversion for anti-spike (S) protein IgG at Visit 2 – Day 22 (+7), Visit 3 – Day 36 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination and proportion of participants with seroconversion for virus neutralizing antibodies (NAb) at Visit 3 – Day 36 (+7) post first dose vaccination. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.	Immunogenicity Analysis Population	Rules for determination of seroconversion status for participants with missing values (and those removed from IA population) will be described in the SAP.	Summary of the number of participants with missing measurement, proportion of participant with seroconversion and associated confidence intervals will be summarized by vaccine group at Visit 3 – Day 36 (+7) post first dose vaccination. The proportion participant with seroconversion for NAb at each post baseline visit will be analyzed using a logistic regression model with the treatment group as factor, baseline titer value and age group (18-59 years and ≥ 60) as covariates. The odds ratio estimate (with 95% CI) for the comparison between COVOVAX and the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) will be converted to a difference in proportion (with 95% CI). If the seroconversion rates in both treatment groups do not allow a logistic regression analysis, the difference in proportions between the two treatment groups (with 95% confidence interval) will be calculated using exact binomial method.	Supplementary: Similar repeat analysis based on Full Analysis population will be provided.

Estimand 7	GMTs of virus neutralizing antibodies (NAb) at Visit 2 – Day 22 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination and mean of change from baseline in cell-mediated immune responses 35 and 179 days post first dose vaccination. Hypothetical strategy is used to understand antibody levels and cell-mediated immunity achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.	Immunogenicity Analysis Population	MMRM will be fitted to the log transformed titer values of NAb with terms for vaccine group, visit, log baseline titer, age group (18-59 years and ≥ 60) and sex with interactions for treatment by visit. The repeated timepoints on subject will be modelled (Details of the covariance structure will be provided in the SAP). Individual mean and 95% CI values by treatment from this model will be used to generate the geometric mean titers with 95% CI at each time point and GMRs with 95% CIs at each time point by back transforming to the original scale. ANCOVA will be fitted to change from Baseline in cell-medicated immune responses with terms for vaccine group, Baseline cell-medicated immune response value, age group (18-59 years and ≥ 60) and sex. Mean difference between treatment groups and associated 95% CI will be presented.	

Estimand 8	Proportion with seroconversion for NAb at Visit 2 – Day 22 (+7) and Visit 6 – Day 180 (+28) post first dose vaccination. Hypothetical strategy is used to understand antibody levels achieved through vaccination, without subsequent COVID-19/SARS-CoV-2 infection or use of any immune-modifying medications or other vaccines missed 2nd dose of vaccine and death.	Immunogenicity Analysis Population	Rules for determination of seroconversion status for participants with missing values (and those removed from IA population) will be described in the SAP.	Summary of the number of participants with missing measurement, proportion of participant with seroconversion and associated confidence intervals will be summarized by vaccine group and visit for NAb. The proportion participant with seroconversion for NAb at each post Baseline visit will be analyzed using a logistic regression model with the treatment group as factor, baseline titer and age group (18-59 years and ≥ 60) as covariates. The odds ratio estimate (with 95% CI) for the comparison between COVOVAX and the Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant) will be converted to a difference in proportion (with 95% CI). If the seroconversion rates in both treatment groups do not allow a logistic regression analysis, the difference in proportions between the two treatment groups (with 95% confidence interval) will be calculated using the normal approximation to the binomial distribution.	
Estimand 9	Proportion of participants with incidence of virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19, laboratory confirmed (RT-PCR positive and /or Anti-Nucleocapsid IgG) asymptomatic cases of COVID-19, and laboratory confirmed (RT-PCR positive and /or Anti-Nucleocapsid IgG) SARS-CoV-2 cases (symptomatic as well as asymptomatic) which occur 14 days after each vaccination up to Visit 4 – Day 85 (+14) and until the end of the study Visit 6 - Day 180 (+28); proportion of participants	Safety Analysis Population		Frequencies and estimate of the proportion of participants with incidence of virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19, laboratory confirmed (RT-PCR positive and/or Anti-Nucleocapsid IgG) asymptomatic cases of COVID-19 and laboratory confirmed (RT-PCR positive and /or Anti-Nucleocapsid IgG) SARS-CoV-2 cases (symptomatic as well as asymptomatic) which occur 14 days after each vaccination until the end of the study Visit 6 - Day 180 (+28); proportion of participants with severe virologically confirmed COVID-19 infection, Intensive care unit (ICU) admissions associated with virologically confirmed COVID-19 infection	

with severe virologically confirmed COVID-19 infection, Intensive care unit (ICU) admissions associated with virologically confirmed COVID-19 infection and all cause deaths in virologically confirmed COVID-19 infection.

A treatment policy strategy is used for assessing safety irrespective of use of immune-modifying medications/vaccinations or missed 2nd dose of vaccination. Infections and death (meeting criteria) are included in the endpoint (composite strategy). A whilst on randomized treatment strategy is used for placebo group participants who received additional COVOVAX vaccine at or after Day 85 (as any infections and death (meeting criteria) after receipt of the additional COVOVAX vaccine should not be attributed to the original placebo group).

and all cause deaths in virologically confirmed COVID-19 infection will be computed by vaccine group using two sided 95% Clopper-Pearson confidence intervals.

The Risk Ratio between the vaccines (COVOVAX - Control vaccine (Novavax-SARS-CoV-2 rS with Matrix-M1™ Adjuvant)) and for Phase 2 (COVOVAX - Placebo) will be provided along with their two-sided 95% CIs.

The details about analysis regarding cell mediated immune responses will be defined in the SAP.

Safety data 7 days post first dose from initial 200 participants from safety cohort in the Phase 2 part of the study will be summarized descriptively for DSMB review.

Data from the switched treatment safety population (safety cohort) will be summarized separately. The safety data collected from such participants till the time they receive first dose of COVOVAX will be analyzed as a part of Placebo group.

Two interim analyses are planned as below:

1. Safety data of 14 days following the second vaccination (Day 36) of all study participants.
2. Immunogenicity data by anti-spike (S) protein IgG ELISA at 14 days post second vaccination (Day 36) of participants in immunogenicity cohort.

11.5.4 Analysis of Demographic and Baseline Characteristics

Demographic (age, gender, height, weight) and baseline characteristics (medical history, Pre-existing conditions, and Prior medications) will be presented descriptively by vaccine group.

The quantitative variables will be summarized as mean, standard deviation, median, minimum and maximum and categorical variables will be summarized as frequency and percentage. Distributions of participants by gender, and age group (18-59 years and ≥ 60) will be summarized as frequency and percentages by overall and by vaccine group.

Baseline characteristics such as medical history, pre-existing conditions will be tabulated by vaccine group using MedDRA dictionary classification and prior and concomitant medications will be tabulated by vaccine group using WHODD drug classification.

11.5.5 Statistical Methods for Primary and Co-Primary Objective

Statistical Method for the Primary endpoint

A summary of the statistical methods for primary objective (Estimand 1) is presented in the section 11.5.3 of the protocol.

Summaries of the number of participants (%) with at least one causally related SAE throughout the study duration will be presented separately for Phase 2 and Phase 3.

The number of events leading to a participant not proceeding with the second vaccination will also be summarized.

Statistical Method for the Co-Primary endpoint

A summary of the statistical methods for the Co- primary objective (Estimand 2) is presented in the section 11.5.3 of the protocol.

To assess the Co-primary objectives, the following non-inferiority hypotheses will be tested on the GMEU for of antibodies measured by anti-spike (S) protein IgG on Visit 3 - Day 36 (+7) post second vaccination.

Hypothesis testing:

H0: GMEUSII/GMEUNOV ≤ 0.67 (Inferior)

H1: GMEUSII/GMEUNOV > 0.67 (Non-Inferior)

Where – SII- COVOVAX and NOV- the Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant)

The lower limit of the 95% CI will be compared with non-inferiority margin of 0.67 and COVOVAX will be declared non-inferior to and the Control vaccine (Novavax- SARS-CoV-2 rS with Matrix-M1™ Adjuvant) if > 0.67.

11.5.6 Statistical Methods for Secondary and Exploratory Objectives

Immunogenicity analysis of virus neutralizing antibodies (NAb), anti-spike (S) Protein IgG antibodies, seroconversion of NAb and cell-mediated immune responses;

A summary of the statistical methods and sensitivity analysis for the immunogenicity objective (Estimand 5, 6, 7 and 8) is presented in the section 11.5.3 of the protocol.

Seroconversion is defined as at least four-fold increase in antibody titers from baseline.

Summary of the number of participants with missing measurement, proportion of participant with seroconversion and associated confidence intervals will be summarized by vaccine group. In addition to the proposed analysis in section 11.5.3, the GMEUs and GMFRs from baseline will be summarized with descriptive statistics including a boxplot (on log scale) versus time.

Analysis of Incidence of COVID-19:

A summary of the statistical methods for the analysis secondary objective of COVID (Estimand 9) is presented in the section 11.5.3 of the protocol.

In addition to the proposed analysis summary of frequencies and percentage of participants with confirmed (RT-PCR positive) symptomatic cases of COVID-19, virologically confirmed (RT-PCR positive) cases of SARS-CoV-2, Severe COVID-19 infection, Intensive care unit (ICU) admissions associated with COVID-19, and All Deaths associated with COVID-19 which occur 14 days after each vaccination until the end of the study Visit 6 – Day 180 (+28) will be presented for both vaccine group and overall.

11.5.6.1 Safety Objectives

11.5.6.1.1 Analysis of Solicited and Unsolicited Adverse Events

A summary of the statistical methods for the analysis relating secondary objective of safety, tolerability and reactogenicity profile (Estimand 3 and 4) is presented in Section 11.5.3 of the protocol, separately for Phase 2 and Phase 3.

In addition to above proposed analysis, the following summaries will be provided.

All solicited AEs will be summarized according to defined severity grading scales. Frequencies and percentages of participants experiencing each AE will be presented for each symptom severity. Summary tables showing the occurrence of any local or systemic AE overall will also be presented.

Solicited adverse events reported until 7 days post-vaccination from first and second dose will be summarized by maximal severity and by vaccine group. Separate analysis will be performed for solicited AEs reported 30 minutes after vaccination. All the solicited reaction occurring up to 7 days after each vaccination will be summarized according to severity grading.

All unsolicited AEs including MAAEs occurring during the study, assessed either as related or not related to vaccine by the investigator, will be recorded. The original verbatim terms used by investigators to identify AEs in the eCRFs will be mapped to PTs using MedDRA. The AEs will then be grouped by MedDRA PTs into frequency tables according to SOC. All reported AEs, as well as AEs assessed by the investigator as related to vaccine, will be summarized according to SOC, PT within SOC, and severity.

Safety and tolerability of study vaccines will be evaluated using the following endpoints:

- Number and severity of solicited local and systemic adverse events (AEs) and relatedness of all solicited systemic adverse events during the first 7 days after each vaccination.
- Number, severity and relatedness of all unsolicited AEs through 35 days after first vaccination.
- Number, severity and relatedness of all SAEs including MAAEs through the entire study period up to Visit 6 i.e. Day 180 visit.
- Number, severity and relatedness of all MAAEs, AESIs which encompasses PIMMCs and AESIs relevant to COVID-19 through the entire study period up to Visit 6 i.e. Day 180 visit.

Generally, safety evaluations will be descriptive in nature, and observed differences will be evaluated for medical relevance. Tabular summaries of safety data will be provided for each vaccine group.

Occurrence of local and systemic reactogenicity within 7 days after each vaccination, as well as AEs through 35 days after first vaccination and SAEs during the entire study period, will be reported for all vaccine groups. Proportions of severe (Grade >= 3) reactions and classes of AEs of interest (at least one AE) will be compared.

Data listings of all adverse events will be provided by participant.

Additional details of the safety analysis such as (vital, physical examination. Etc.), disposition demographic will be provided in the statistical analysis plan.

11.5.7 Handling of Dropouts and Missing Data

Details for the imputation of missing values are outlined in Section 11.5.3; further details will be documented in the SAP.

12. QUALITY CONTROL AND QUALITY ASSURANCE

12.1 PRE-STUDY DOCUMENTATION

Prior to enrolment of participants at the study site, specific regulatory documents must be available, such as regulatory (DCGI) and Institutional Ethics Committee (IECs) approvals; curriculum vitae for investigator and study staff; standard operating procedures (SOPs) and other essential documents. Sponsor/designee will inform the investigator which documents need to be provided according to the applicable regulatory requirements.

12.2 MONITORING

Sponsor monitoring responsibilities will be provided through qualified and appropriately trained individuals designated by CRO to carefully monitor all aspects of the study. A site initiation visit will be conducted prior to the beginning of the study and monitoring will be conducted during and at closeout of the study by the study monitor.

During the course of the study, the monitors will visit the clinical sites at intervals in order to verify that:

- The data are authentic, accurate and complete
- The safety and rights of participants are being protected
- The study is conducted in accordance with the approved protocol (and any subsequent amendment), GCP and all applicable regulatory requirements

Monitors will periodically contact the site and perform site visits. The extent, nature and frequency of site visits will be decided before the start of the study and will be based on considerations as study objectives, study design and complexity, and enrolment rate. During these contacts, the monitor will:

- Check and assess the progress of the study
- Review study data collected
- Perform source data verification, identify any issues and address their resolution

Monitoring will be conducted according to ICH-GCP. The individuals responsible for monitoring the study will have access to all records necessary to ensure the integrity/validity of the recorded data and will periodically review the progress of the study.

The investigator must agree to allow the monitor direct access to all relevant documents and to allocate his/her time and the time of his/her staff to the monitor to discuss findings and any relevant issues.

The monitor must contact the site prior to the start of the study to discuss the protocol and data collection procedures with the site personnel.

The investigator should allow representatives of the Ethics Committee, Regulatory Authority and the sponsor to visit the study site.

12.3 DATA MANAGEMENT AND PROCESSING

Site PI is responsible for ensuring timely completeness and accuracy of data reported. Data collection is the responsibility of clinical trial staff at the study site under supervision of site PI. The CRO is responsible for clinical data management activities, including quality review, analysis and reporting of study data according to SOPs.

Data Collection

Data will be entered electronically by site study staff using Internet in eCRF. The data system will include password protection. Instructions for use of the system will be included in eCRF manual.

Clinical data will be entered directly from source documents. All source documents should be completed in neat and legible manner to ensure accurate interpretation of data. All information required by the study protocol must be entered into eCRF. An explanation must be provided for any missing data. Source documentation supporting the eCRF data should document the dates and details of study procedures, AEs and participant status. PI/site staff will maintain

information in eCRFs and all source documents that support the data collected from each participant.

Study monitor will check for completeness and accuracy of eCRF during the monitoring visits.

Data Management Procedures

Site staff should complete eCRFs as soon as possible after the information is collected. Completed eCRFs must be submitted for each screened participant who signs the study specific ICF.

Internal data quality checks such as automatic range checks, checks to identify data that appear inconsistent, incomplete or inaccurate will be programmed into eCRF that will help in real time review of data, as and when, clinical data is entered into the system by site staff.

Clinical Data Management team at CRO will review the data for quality and will provide several quality assurance reports to ensure that study data is clean and complete. Quality assurance reports will include, but are not limited to, the following: missing forms, automated and manual data queries. Data queries will be distributed to the sites at scheduled time period for site staff to review and update the database.

Coding

All medical verbatim terms will be coded by Clinical Data Management and reviewed by a medical doctor according to most recent versions of MedDRA (Adverse events and medical history) and the WHO Drug Dictionary enhanced version (concomitant medication).

Database Lock Procedures

Database will be locked upon completion of the following activities:

- All participants have completed the follow up visits
- All the participant data has been entered in the database
- All data anomalies have been resolved
- Study monitoring has been completed
- All listings of the database have been reviewed and discussed for assessment of consistency and medical plausibility.

Procedures for Analysis

Data will be analyzed as per the **pre-specified Statistical Analysis Plan (SAP)** after the database lock**.** An audit trail will be kept of any subsequent changes to the data.

12.4 STUDY AND SITE CLOSURE

Upon completion of the study, the monitor and the investigator will conduct the following activities:

- Data clarification and/or resolution
- Accounting, reconciliation and return to sponsor or destruction at sites of used and unused vaccines
- Review of site study records for completeness
- Return of all study data to Sponsors or designee.

Sponsors reserve the right to temporarily suspend or prematurely discontinue this study at either a single site or at all sites at any time for any other reason.

If the study is stopped or suspended prematurely, Sponsor will inform the investigator(s) as well as the regulatory authorities about the decision and the reasons for termination or suspension. If such action is taken, all effort must be made to ensure the safety of the participants enrolled in the study. The investigator(s) will inform the responsible IECs and provide the reason for the suspension or termination.

In case of premature study or study site closure, the monitor will conduct all activities as indicated above.

12.5 AUDITS AND INSPECTIONS

For the purpose of compliance with ICH-GCP and regulatory guidelines, it may be possible that the sponsor/designee or a national regulatory authority may conduct a site audit/inspection. This may occur at any time from start to after conclusion of the study.

The investigator agrees to allow the auditor direct access to all relevant documents and to allocate his/her time and the time of his/her staff to the auditor to discuss findings and any relevant issues.

If a regulatory authority requests an inspection, the investigator must inform the sponsor or its designee immediately about this request. The investigator(s) and the study coordinator(s) must make the relevant records available for inspection and must be available to respond to reasonable requests and audit queries made by authorized representatives of regulatory agencies. The sponsor will provide any needed assistance in responding to regulatory audits or correspondence.

13. REGULATORY AND ETHICAL REQUIREMENTS

13.1 ETHICS COMMITTEE REVIEW AND COMMUNICATION

It is the investigator's responsibility to ensure that this protocol is reviewed and approved by the IECs responsible for the study sites. The IECs must also review and approve the Informed Consent Form and any other written information to be provided to the participant. Written IEC approval shall be obtained prior to study start.

No deviations from, or changes to, the protocol shall be initiated without prior written IEC approvals of an appropriate amendment, except when necessary to eliminate immediate hazards to the participants or when the change(s) involves only logistical or administrative aspects of the study (e.g., change of monitor(s), telephone number(s)). The investigator shall provide to the sponsors a statement from the IEC confirming the IEC is organized and operates according to GCP and applicable laws and regulations.

13.2 PROTOCOL AMENDMENTS

Any significant change in the study protocol shall be addressed in a written protocol amendment, which will be signed by the investigator(s) and the sponsors. It is the investigator's responsibility to submit protocol amendments to the IECs and to obtain written approval where required.

In some cases, protocol amendments may also be submitted to DCGI.

A protocol amendment may be implemented after it has been approved by IECs. In the case of a protocol change intended to eliminate an apparent immediate hazard to participants, the change may be implemented immediately. In this case, the change must be later documented in an amendment and reported to the IECs as soon as possible. Amendments affecting only logistical or administrative aspects of the study may not require formal IEC approval. Logistical and administrative amendments (e.g., concerning a change of telephone number) shall be submitted to the IECs for information purposes. However, the investigator must provide the sponsors with written verification that such logistical or administrative amendments are submitted to the relevant IECs.

13.3 PARTICIPANT INFORMATION AND INFORMED CONSENT

Prior to including any participant in the clinical study, his/her free and expressed informed consent must be obtained in writing. Consent must be given with free will of choice, and without inducement.

The investigator or his/her designee shall provide to each potential participant sufficient knowledge and understanding of the nature of the proposed research, the anticipated risks and

potential benefits, and the requirements of the research to be able to make an informed decision. The investigator shall give the participants ample time and opportunity to inquire about details of the study and ask any questions.

The process for obtaining the informed consent of the participant shall be in accordance with the recommendations in the New Drugs and Clinical Trials Rules, 2019.

The written informed consent must be signed and dated by both investigator/designee and participant prior to any study related procedure. In case of illiterate individuals, the study will be explained to them by the investigator or his/her designee and the Informed consent form (ICF) read for them in the presence of an impartial witness. The witness shall personally sign and date the consent form while a fingerprint will be requested from illiterate individuals. The process of informed consent should be described in source template.

Original ICF must be kept on file by the investigator for possible inspection by IECs member, regulatory authorities and the sponsors (or their designees). Participant must receive a copy of the signed ICF, and any subsequent updates or amendments.

The study monitor shall check the documentation of the individual ICF during each monitoring visit.

13.4 PARTICIPANT CONFIDENTIALITY

The investigator(s) must ensure that participant confidentiality is maintained. Personal identifiers will not be included in any study reports. Participants will be identified by the screening number and by participant initials. If a participant's name appears on any other document (e.g., pathologist report), it will be obliterated before the copy of the document is supplied to the sponsor/designee. Study findings stored on a computer will subject to local data protection laws. Participant will be informed that representatives of the sponsor, IEC, or regulatory authorities may inspect their medical records to verify the information collected, and that all personal information made available for inspection will be handled in the strictest confidence.

13.5 ETHICAL CONDUCT OF THE STUDY

This study will be conducted in compliance with:

1. The approved clinical trial protocol,
2. ICH-GCP guidelines.
3. Current revision of the Declaration of Helsinki (Revised Fortaleza, 2013).
4. ICH Harmonized Tripartite Guideline for Good Clinical Practice (E6) 1996.

5. 'Guidelines for Clinical Trials on Pharmaceutical Products in India – GCP Guidelines' issued by Central Drugs Standard Control Organization (CDSCO), Ministry of Health, Government of India in 2005.
6. New Drugs and Clinical Trials Rules, 2019 and any amendment thereof
7. 'Ethical Guidelines for Biomedical Research on Human Subjects' issued by Indian Council of Medical Research, 2017.

14. DATA HANDLING AND RECORD KEEPING

In accordance with applicable regulatory requirements, following closure of the study, the investigator/site/institution will maintain a copy of all essential documents in a secure and designated location at the study site. Essential documents shall be retained for at least 5 years after the completion or discontinuation of the study. Sponsor will notify the investigator/institution when the study-related records are no longer required. The investigator agrees to adhere to the document retention procedures by signing the protocol. Essential documents include:

1. Signed protocol and all amendments;
2. Ethics committee approval for the study protocol and all amendments;
3. All source documents;
4. eCRF records;
5. Study Participant Informed Consent and
6. Any other pertinent study document.

The document should not be destroyed without the written permission from SIIPL. It is responsibility of SIIPL to inform the study Investigator when these documents no longer need to be retained.

15. INSURANCE AND COMPENSATION OF STUDY PARTICIPANTS

All the study participants in this study are insured by Sponsor against any injury caused by any AE causally related to the study investigational product.

The cost of medical care needed for treatment of vaccine related AEs (including SAEs) occurring among trial participants will be borne by sponsor and as required by the Rules and Regulations passed by DCGI. In case DCGI directs to pay compensation for any AE, sponsor will pay the same and the details of compensation provided would be intimated to the office of the DCGI.

Pending respective site's IEC approval, participants will be compensated for their time in this study, and reimbursed for travel to study visits. The study ICF will state the plan for reimbursement. Study participants will not be charged for study vaccinations, research clinic visits, research-related examinations, or research-related laboratory tests.

PI and delegated study staff as well as IEC members will be insured by Sponsor for this study as per regulatory and ethical requirements.

16. PUBLICATION POLICY & CONFIDENTIALITY

SIIPL and ICMR hold the exclusive rights to publish the study results jointly. Due credit will be given to the investigators in case the results of the study are published.

All proprietary or confidential information communicated to the investigator by or for SIIPL or communicated to the investigator during the course of and/or as a result of the clinical study is the exclusive property of SIIPL, and the investigator shall ensure that the same shall be kept strictly confidential by him/her and any other person connected with the clinical study and shall not be disclosed, either orally or in written form, by him/her or such person to any third party without the prior written consent of SIIPL.

The investigator shall communicate the results of the clinical study promptly to SIIPL.

All rights and interests worldwide in any inventions, know-how, or other intellectual or industrial property rights which arise during the course of and/or as a result of the clinical study which is the subject of this protocol or which otherwise arise from the information or materials supplied under this protocol, shall be assigned to, vest in and remain the property of SIIPL.

17. REFERENCES

1. Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine 382, 727-733, doi:10.1056/NEJMoa2001017 (2020).
2. Lu, R. Et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England) 395, 565-574, doi:10.1016/S0140-6736(20)30251-8 (2020).
3. https://covid19.who.int/. Accessed 22 Sep 2020
4. COVID-19 Updates by Ministry of Health and Family Welfare, Government of India. Available at https://www.mohfw.gov.in/. Accessed 22 Sep 2020
5. Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annual review of virology 3, 237-261, doi:10.1146/annurev-virology-110615-042301 (2016).
6. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, doi:10.1038/s41586-020-2012-7 (2020).
7. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260-1263.
8. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010 Oct 29;33(4):492-503.
9. Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine. 2011 Sep 2;29(38):6606-13.
10. Coleman CM, Venkataraman T, Liu YV, Glenn GM, Smith GE, Flyer DC, Frieman MB. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 2017 Mar 14;35(12):1586-1589.
11. Bengtsson KL, Song H, Stertman L, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine. 2016 Apr 7;34(16):1927-35.
12. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 Sep 2. doi: 10.1056/NEJMoa2026920. Epub ahead of print. PMID: 32877576.
13. https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and-0
14. Shinde V, Bhikha S, Hoosain Z et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 May 5. doi: 10.1056/NEJMoa2103055. Epub ahead of print. PMID: 33951374.

APPENDICES

I. Listings of AESI including PIMMCs and AESI related to COVID-19

II. COVID-19 disease symptoms and severity definition

III. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, corrected version 2.1, July 2017

IV. Declaration of Helsinki

V. Sponsor's Signature Page

VI. Investigator's statement of compliance

[redacted]

Appendix I

Listings of AESI including PIMMCs and AESI related to COVID-19

APPENDIX I: LISTINGS OF ADVERSE EVENTSOF SPECIALINTEREST

Because it has been hypothesized that immunizations with or without adjuvant may be associated with autoimmunity, sponsors need to instruct investigators to be especially vigilant regarding the Potential Immune-Mediated Medical Conditions(PIMMC) listed in the table below. Note that this is not specific to SARS-CoV-2 rS vaccine or Matrix-M1 adjuvant; and there is no current evidence to suggest that the study products in this study are, or are not, associated with these illnesses. The list is not intended to be exhaustive, nor does it exclude the possibility that other diagnoses may be AESI.

TABLE 1 POTENTIAL IMMUNE-MEDIATED MEDICAL CONDITIONS (PIMMC)

Categories	Diagnoses (as MedDRA Preferred Terms)
Neuroinflammatory Disorders:	Acute disseminated encephalomyelitis (including site specific variants: e.g., non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), cranial nerve disorders including paralyses/paresis (e.g., Bell's palsy), generalized convulsion, Guillain-Barre syndrome (including Miller Fisher syndrome and other variants), immune-mediated peripheral neuropathies and plexopathies (including chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and polyneuropathies associated with monoclonal gammopathy), myasthenia gravis, multiple sclerosis, narcolepsy, optic neuritis, transverse myelitis, uveitis
Musculoskeletal and Connective Tissue Disorders:	Antisynthetase syndrome, dermatomyositis, juvenile chronic arthritis (including Still's disease), mixed connective tissue disorder, polymyalgia rheumatic, polymyositis, psoriatic arthropathy, relapsing polychondritis, rheumatoid arthritis, scleroderma (including diffuse systemic form and CREST syndrome), spondyloarthritis (including ankylosing spondylitis, reactive arthritis [Reiter's Syndrome] and undifferentiated spondyloarthritis), systemic lupus erythematosus, systemic sclerosis, Sjogren's syndrome
Vasculidities:	Large vessels vasculitis (including giant cell arteritis such as Takayasu's arteritis and temporal arteritis), medium sized and/or small vessels vasculitis (including polyarteritis nodosa, Kawasaki's disease, microscopic polyangiitis, Wegener's granulomatosis, Churg–Strauss syndrome [allergic granulomatous angiitis], Buerger's disease [thromboangiitis obliterans], necrotizing vasculitis and anti-neutrophil cytoplasmic antibody [ANCA] positive vasculitis [type unspecified], Henoch-Schonlein purpura, Behcet's syndrome, leukocytoclastic vasculitis)
Gastrointestinal Disorders:	Crohn's disease, celiac disease, ulcerative colitis, ulcerative proctitis
Hepatic Disorders:	Autoimmune hepatitis, autoimmune cholangitis, primary sclerosing cholangitis, primary biliary cirrhosis
Renal Disorders:	Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapidly progressive, membranous glomerulonephritis, membranoproliferative glomerulonephritis, and mesangioproliferative glomerulonephritis
Cardiac Disorders:	Autoimmune myocarditis/cardiomyopathy

Categories	Diagnoses (as MedDRA Preferred Terms)
Skin Disorders:	Alopecia areata, psoriasis, vitiligo, Raynaud's phenomenon, erythema nodosum, autoimmune bullous skin diseases (including pemphigus, pemphigoid and dermatitis herpetiformis), cutaneous lupus erythematosus, morphoea, lichen planus, Stevens-Johnson syndrome, Sweet's syndrome
Hematologic Disorders:	Autoimmune hemolytic anemia, autoimmune thrombocytopenia, antiphospholipid syndrome, thrombocytopenia
Metabolic Disorders:	Autoimmune thyroiditis, Grave's or Basedow's disease, Hashimoto thyroiditis[a], diabetes mellitus type 1, Addison's disease
Other Disorders:	Goodpasture syndrome, idiopathic pulmonary fibrosis, pernicious anemia, sarcoidosis

[a] For Hashimoto thyroiditis: new onset only.

AESIs relevant to COVID-19 are listed in the table below. The list is not intended to be exhaustive, nor does it exclude the possibility that other diagnoses may be AESI. It is anticipated that additional AESI may be associated with COVID-19. Investigators should stay updated regarding such public health notifications.

TABLE 2. ADVERSE EVENTS OF SPECIAL INTEREST RELEVANT TOCOVID-19

Body System	Diagnoses[a]
Immunologic	Enhanced disease following immunization, cytokine release syndrome related to COVID-19[b], Multisystem inflammatory syndrome in children (MIS-C)
Respiratory	Acute respiratory distress syndrome (ARDS)
Cardiac	Acute cardiac injury including: • Microangiopathy • Heart failure and cardiogenicshock • Stresscardiomyopathy • Coronary arterydisease • Arrhythmia • Myocarditis,pericarditis
Hematologic	Coagulation disorder • Deep veinthrombosis • Pulmonaryembolus • Cerebrovascularstroke • Limbischemia • Hemorrhagicdisease • Thromboticcomplications
Renal	Acute kidney injury
Gastrointestinal	Liver injury
Neurologic	Guillain-Barré Syndrome, anosmia, ageusia, meningoencephalitis
Dermatologic	Chilblain-like lesions, single organ cutaneous vasulitis, erythema multiforme

Abbreviations: COVID-19 = coronavirus disease 2019; DAIDS = Division of AIDS.

[a] COVID-19 manifestations associated with more severe presentation and decompensation withconsiderationof enhanced disease potential (SPEAC2020).

[b] Cytokine release syndrome related to COVID-19 infection is a disorder characterized bynausea,headache, tachycardia, hypotension, rash, and/or shortness of breath (DAIDS2017).

Appendix II

COVID-19 disease symptoms and severity definition

APPENDIX II.COVID-19 disease symptoms and severe COVID-19 disease definition

Table 1. Qualifying Symptoms of Suspected COVID-19 Disease

- Fever or chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue
- Muscle or body aches
- Headache
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea

Table 2. Definition of Severe COVID-19 Disease

≥ 1 of:

- Tachypnea: ≥ 30 breaths per minute at rest
- Resting heart rate ≥ 125 beats per minute
- SpO2: ≤ 93% on room air or PAO2/FiO2 < 300
- High flow oxygen therapy or NIV/NIPPV (e.g., CPAP or BiPAP)
- Mechanical ventilation or ECMO
- One or more major organ system dysfunction or failure (e.g., cardiac/circulatory, pulmonary, renal, hepatic, and/or neurological, to be defined by diagnostic testing/clinical syndrome/interventions), including any of the following:
    - ARDS
    - Acute renal failure
    - Acute hepatic failure
    - Acute right or left heart failure
    - Septic or cardiogenic shock (with shock defined as SBP < 90 mm Hg OR DBP < 60 mm Hg

- Acute stroke (ischemic or hemorrhagic)
- Acute thrombotic event: AMI, DVT, PE
- Requirement for: vasopressors, systemic corticosteroids, or hemodialysis.

- Admission to an ICU
- Death

Abbreviations: AMI = acute myocardial infarction; ARDS = acute respiratory distress syndrome; BiPAP = bi-level positiveairway pressure; CPAP = continuous positive air pressure; DBP = diastolic bloodpressure;
DVT = deep vein thrombosis; ECMO = extracorporeal membrane oxygenation; FiO2 = fraction of inspiredoxygen; ICU = intensive care unit; NIV = non-invasive ventilation;NIPPV = non-invasive positive pressure ventilation; PAO2 = partial pressure of oxygen in the alveolus;PE = pulmonary embolism; SBP = systolic blood pressure; SpO2 = oxygen saturation.

Appendix III

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, corrected version 2.1, July 2017

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events

Corrected Version 2.1
July 2017

Division of AIDS
National Institute of Allergy and Infectious Diseases
National Institutes of Health
US Department of Health and Human Services

Table of Contents

Glossary and Acronyms

AE	Adverse event; Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure regardless of whether it is considered related to the medical treatment or procedure.
ALT (SGPT)	Alanine aminotransferase (*serum glutamic pyruvic transaminase)*
ANC	Absolute neutrophil count
AST (SGOT)	Aspartate aminotransferase (*serum glutamic-oxaloacetic transaminase)*
AV	Atrioventricular
Basic Self-care Functions	Adult Activities such as bathing, dressing, toileting, transfer or movement, continence, and feeding. Young Children Activities that are age and culturally appropriate, such as feeding one's self with culturally appropriate eating implements.
BMI z-score	Body mass index z- score; A body reference norm. Specifically, the number of standard deviations a participant's BMI differs from the average BMI for their age, sex, and ethnicity.
BMD t-score	Bone mineral density t-score; The number of standard deviations above or below the mean bone mineral density of a healthy 30 year old adult of the same sex and ethnicity as the participant.
BMD z-score	Bone mineral density z-score; The number of standard deviations a participant's BMD differs from the average BMD for their age, sex, and ethnicity.
BPAP	Bilevel positive airway pressure; A mode used during noninvasive positive pressure ventilation.
Chemical Pregnancy	A pregnancy in which a positive pregnancy test is followed by a negative pregnancy test without evidence of a clinical pregnancy loss.
CNS	Central nervous system
CPAP	Continuous positive airway pressure
DAERS	DAIDS Adverse Experience Reporting System; An internet-based system developed for clinical research sites to report Expedited Adverse Events (EAEs) to DAIDS. It facilitates timely EAE report submission and serves as a centralized location for accessing and processing EAE information for reporting purposes.
Disability	A substantial disruption of a person's ability to conduct normal life functions.
ECG	Electrocardiogram
eGFR	Estimated glomerular filtration rate
Hospitalization	Does not include the following hospital admissions: under 24 hours, unrelated to an adverse event (e.g., for labor and delivery, cosmetic surgery, social or administrative for temporary placement [for lack of a place to sleep]), protocol-specified, and for diagnosis or therapy of a condition that existed before the receipt of a study agent and which has not increased in severity or frequency.
INR	International normalized ratio

Glossary and Acronyms

Intervention	Medical, surgical, or other procedures recommended or provided by a healthcare professional for the treatment of an adverse event.
IV	Intravenous
IVIG	Intravenous immune globulin
LDL	Low density lipoprotein
LLN	Lower limit of normal
Life-threatening AE	Any adverse event that places the participant, in the view of the investigator, at immediate risk of death from the reaction when it occurred (i.e., it does not include a reaction that would have caused death if it had occurred in a more severe form).
NA	Not applicable
Participant ID	The identification number assigned to a study participant which is used to track study-related documentation, including any reported AEs.
PR Interval	The interval between the beginning of the P wave and the beginning of the QRS complex of an electrocardiogram that represents the time between the beginning of the contraction of the atria and the beginning of the contraction of the ventricles.
PT	Prothrombin time
PTT	Partial thromboplastin time
QTc Interval	The measure of time between the onset of ventricular depolarization and completion of ventricular repolarization corrected for ventricular rate.
RBC	Red blood cell
SI	Standard international unit
ULN	Upper limit of normal
Usual Social & Functional Activities	Activities which adults and children perform on a routine basis and those which are part of regular activities of daily living, for example: <u>Adults</u> Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, or pursuing a hobby. <u>Young Children</u> Activities that are age and culturally appropriate, such as social interactions, play activities, or learning tasks.
WBC	White blood cell
WHO	World Health Organization
WNL	Within normal limits

Introduction

The Division of AIDS (DAIDS) oversees more than 300 clinical trials domestically and internationally, which evaluate the safety and efficacy of therapeutic products, vaccines, and other preventive modalities. Adverse event (AE) data collected during these clinical trials form the basis for subsequent safety and efficacy analyses of pharmaceutical products and medical devices. Incorrect and inconsistent AE severity grading can lead to inaccurate data analyses and interpretation, which in turn can impact the safety and well-being of clinical trial participants and future patients using pharmaceutical products.

Over the years, DAIDS scientific knowledge and experience have expanded, necessitating revisions of the DAIDS grading table which serves as a guide for assessing the severity of AEs (including clinical and laboratory abnormalities) in participants enrolled in DAIDS-sponsored and -supported clinical trials. The *Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 (July 2017)* updates and replaces version 2.1 (March 2017).

DAIDS is grateful to the DAIDS Grading Table Working Group, numerous government and non-government affiliated medical subject matter experts and reviewers who were instrumental in the revision of the DAIDS grading table.

Instructions for Use

General Considerations

The *Division of AIDS* (*DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1* consists of parameters, or AEs, with severity grading guidance that are to be used in DAIDS clinical trials for safety data reporting to maintain accuracy and consistency in the evaluation of AEs. The term "severe" is not the same as the term "serious" in classifying AEs. The severity of a specific event describes its intensity, and it is the intensity which is graded. Seriousness, which is not graded, relates to an outcome of an AE and is a regulatory definition.

Clinical sites are encouraged to report parameters in the DAIDS grading table as they are written to maintain data consistency across clinical trials. However, since some parameters can be reported with more specificity, clinical sites are encouraged to report parameters that convey additional clinical information. For example, diarrhea could be reported as neonatal diarrhea; seizures, as febrile seizures; and pain, as jaw pain.

The DAIDS grading table provides an AE severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines:

- Grade 1 indicates a mild event
- Grade 2 indicates a moderate event
- Grade 3 indicates a severe event
- Grade 4 indicates a potentially life-threatening event
- Grade 5 indicates death (*Note*: This grade is not specifically listed on each page of the grading table).

Other points to consider include:

- Use age and sex values as applicable.
- Unless noted, laboratory values are for term neonates. Preterm neonates should be assessed using local laboratory normal ranges.
- Where applicable, Standard International (SI) units are included in italics.

Selecting and Reporting a Primary AE Term

When selecting a primary AE term to report, sites should select the term that best describes what occurred to the participant. For example, a participant may present with itching, urticaria, flushing, angioedema of the face, and dyspnea. If the underlying diagnosis is determined to be an acute allergic reaction, sites should report "Acute Allergic Reaction" as the primary AE term.

Primary AE terms should be reported using the DAIDS Adverse Experience Reporting System (DAERS) only if they meet expedited reporting criteria. However, all primary AE terms should be reported using protocol-specific case report forms (CRFs). Because the reported information is stored in different databases (i.e., safety and clinical), sites should report primary AE terms using the same terminology for data consistency.

Instructions for Use

When reporting using DAERS, other clinically significant events associated with a primary AE term that more fully describe the nature, severity, or complications of the primary AE term should be entered in the "Other Events" section. However, the severity grade for these events must be lower than or equal to the severity grade of the primary AE term. In the example above, dyspnea and angioedema of the face may be entered in the "Other Events" section, because they are more descriptive and provide additional information on the severity of the acute allergic reaction. However, their severity grades must be lower than or equal to the severity grade of the primary AE term of "Acute Allergic Reaction".

Differences exist in the reporting and recording of information (e.g., signs and symptoms, clinically significant events) in DAERS and CRFs. Therefore, sites should refer to their protocols and CRF requirements for further instructions.

Grading Adult and Pediatric AEs
When a single parameter is not appropriate for grading an AE in both adult and pediatric populations, separate parameters with specified age ranges are provided. If no distinction between adult and pediatric populations has been made, the listed parameter should be used for grading an AE in both populations.

Reporting Pregnancy Outcomes
In the *Pregnancy, Puerperium, and Perinatal* section, all parameters are pregnancy outcomes and should be reported using the mother's participant ID. If an infant is not enrolled in the same study as the mother, any identified birth defects should be reported using the mother's participant ID. However, if an infant is enrolled in the same study as the mother or in another study, any identified birth defects should be reported using the infant's participant ID. Sites should refer to the applicable network standards for reporting abnormal pregnancy outcomes on the CRFs.

Determining Severity Grade for Parameters between Grades
If the severity of an AE could fall in either one of two grades (i.e., the severity of an AE could be either grade 2 or grade 3), sites should select the higher of the two grades.

Laboratory Values
General. An asymptomatic, abnormal laboratory finding without an accompanying AE should not be reported to DAIDS in an expedited timeframe unless it meets protocol-specific reporting requirements. Sites should refer to the applicable network standards for reporting abnormal laboratory findings on the clinical case report forms.

Values below Grade 1. Any laboratory value that is between the ULN and grade 1 (for high values) or the LLN and grade 1 (for low values) should not be graded or reported as an AE. Sites should consult the *Manual for Expedited Reporting of Adverse Events to DAIDS, Version 2.0* and their protocol when making an assessment of the need to report an AE.

Overlap of Local Laboratory Normal Values with Grading Table Ranges. When local laboratory normal values fall within grading table laboratory ranges, the severity grading is based on the ranges in the grading table unless there is a protocol-specific grading criterion for the laboratory

value. For example, "Magnesium, Low" has a grade 1 range of 1.2 to < 1.4 mEq/L, while a particular laboratory's normal range for magnesium may be 1.3 to 2.8 mEq/L. If a study participant's magnesium laboratory value is 1.3 mEq/L, the laboratory value should be graded as grade 1.

Appendix Usage
Appendix A takes priority over the main grading table in all assessments of total bilirubin for term and preterm neonates.

Using Addenda 1-3: Grading Tables Used in Microbicide Studies
In protocols involving topical application of products to the female and male genital tracts or rectum, strong consideration should be given to using Addenda 1-3 (see below) as the primary grading tables for these areas. Although these grading tables are used specifically in microbicide studies, they may be used in other protocols as adjuncts to the main grading table (i.e., the *Division of AIDS (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0*). It should be clearly stated in a protocol which addendum is being used as the primary grading table (and thus takes precedence over the main grading table) and which addendum is being used in a complementary fashion.

- Addendum 1 – Female Genital Grading Table for Use in Microbicide Studies- *http://rsc.tech-res.com/clinical-research-sites/safety-reporting/daids-grading-tables*
- Addendum 2 – Male Genital Grading Table for Use in Microbicide Studies – *http://rsc.tech-res.com/clinical-research-sites/safety-reporting/daids-grading-tables*
- Addendum 3 – Rectal Grading Table for Use in Microbicide Studies – *http://rsc.tech-res.com/clinical-research-sites/safety-reporting/daids-grading-tables*

Estimating Severity Grade for Parameters Not Identified in the Grading Table
The functional table below should be used to grade the severity of an AE that is not specifically identified in the grading table. In addition, all deaths related to an AE are to be classified as grade 5.

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Clinical adverse event **NOT** identified elsewhere in the grading table	Mild symptoms causing no or minimal interference with usual social & functional activities with intervention not indicated	Moderate symptoms causing greater than minimal interference with usual social & functional activities with intervention indicated	Severe symptoms causing inability to perform usual social & functional activities with intervention or hospitalization indicated	Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death

Major Clinical Conditions
Cardiovascular

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Arrhythmia (by ECG or physical examination) *Specify type, if applicable*	No symptoms AND No intervention indicated	No symptoms AND Non-urgent intervention indicated	Non-life-threatening symptoms AND Non-urgent intervention indicated	Life-threatening arrhythmia OR Urgent intervention indicated
Blood Pressure Abnormalities[1]				
Hypertension *(with the lowest reading taken after repeat testing during a visit)* *≥ 18 years of age*	140 to < 160 mmHg systolic OR 90 to < 100 mmHg diastolic	≥ 160 to < 180 mmHg systolic OR ≥ 100 to < 110 mmHg diastolic	≥ 180 mmHg systolic OR ≥ 110 mmHg diastolic	Life-threatening consequences in a participant not previously diagnosed with hypertension (e.g., malignant hypertension) OR Hospitalization indicated
< 18 years of age	> 120/80 mmHg	≥ 95th to < 99th percentile + 5 mmHg adjusted for age, height, and gender (systolic and/or diastolic)	≥ 99th percentile + 5 mmHg adjusted for age, height, and gender (systolic and/or diastolic)	Life-threatening consequences in a participant not previously diagnosed with hypertension (e.g., malignant hypertension) OR Hospitalization indicated
Hypotension	No symptoms	Symptoms corrected with oral fluid replacement	Symptoms AND IV fluids indicated	Shock requiring use of vasopressors or mechanical assistance to maintain blood pressure
Cardiac Ischemia or Infarction *Report only one*	NA	NA	New symptoms with ischemia (stable angina) OR New testing consistent with ischemia	Unstable angina OR Acute myocardial infarction
Heart Failure	No symptoms AND Laboratory or cardiac imaging abnormalities	Symptoms with mild to moderate activity or exertion	Symptoms at rest or with minimal activity or exertion (e.g., hypoxemia) OR Intervention indicated (e.g., oxygen)	Life-threatening consequences OR Urgent intervention indicated (e.g., vasoactive medications, ventricular assist device, heart transplant)

[1] Blood pressure norms for children < 18 years of age can be found in: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. *Pediatrics* 2011;128;S213; originally published online November 14, 2011; DOI: 10.1542/peds.2009-2107C.

Cardiovascular

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Hemorrhage (with significant acute blood loss)	NA	Symptoms AND No transfusion indicated	Symptoms AND Transfusion of ≤ 2 units packed RBCs indicated	Life-threatening hypotension OR Transfusion of > 2 units packed RBCs (for children, packed RBCs > 10 cc/kg) indicated
Prolonged PR Interval or AV Block *Report only one* *> 16 years of age*	PR interval 0.21 to < 0.25 seconds	PR interval ≥ 0.25 seconds OR Type I 2nd degree AV block	Type II 2nd degree AV block OR Ventricular pause ≥ 3.0 seconds	Complete AV block
≤ 16 years of age	1st degree AV block (PR interval > normal for age and rate)	Type I 2nd degree AV block	Type II 2nd degree AV block OR Ventricular pause ≥ 3.0 seconds	Complete AV block
Prolonged QTc Interval[2]	0.45 to 0.47 seconds	> 0.47 to 0.50 seconds	> 0.50 seconds OR ≥ 0.06 seconds above baseline	Life-threatening consequences (e.g., Torsade de pointes, other associated serious ventricular dysrhythmia)
Thrombosis or Embolism *Report only one*	NA	Symptoms AND No intervention indicated	Symptoms AND Intervention indicated	Life-threatening embolic event (e.g., pulmonary embolism, thrombus)

[2] As per Bazett's formula.

Dermatologic

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Alopecia (scalp only)	Detectable by study participant, caregiver, or physician AND Causing no or minimal interference with usual social & functional activities	Obvious on visual inspection AND Causing greater than minimal interference with usual social & functional activities	NA	NA
Bruising	Localized to one area	Localized to more than one area	Generalized	NA
Cellulitis	NA	Non-parenteral treatment indicated (e.g., oral antibiotics, antifungals, antivirals)	IV treatment indicated (e.g., IV antibiotics, antifungals, antivirals)	Life-threatening consequences (e.g., sepsis, tissue necrosis)
Hyperpigmentation	Slight or localized causing no or minimal interference with usual social & functional activities	Marked or generalized causing greater than minimal interference with usual social & functional activities	NA	NA
Hypopigmentation	Slight or localized causing no or minimal interference with usual social & functional activities	Marked or generalized causing greater than minimal interference with usual social & functional activities	NA	NA
Petechiae	Localized to one area	Localized to more than one area	Generalized	NA
Pruritus[3] (without skin lesions)	Itching causing no or minimal interference with usual social & functional activities	Itching causing greater than minimal interference with usual social & functional activities	Itching causing inability to perform usual social & functional activities	NA
Rash *Specify type, if applicable*	Localized rash	Diffuse rash OR Target lesions	Diffuse rash AND Vesicles or limited number of bullae or superficial ulcerations of mucous membrane limited to one site	Extensive or generalized bullous lesions OR Ulceration of mucous membrane involving two or more distinct mucosal sites OR Stevens-Johnson syndrome OR Toxic epidermal necrolysis

[3] For pruritus associated with injections or infusions, see the *Site Reactions to Injections and Infusions* section (page 23).

Endocrine and Metabolic

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Diabetes Mellitus	Controlled without medication	Controlled with medication OR Modification of current medication regimen	Uncontrolled despite treatment modification OR Hospitalization for immediate glucose control indicated	Life-threatening consequences (e.g., ketoacidosis, hyperosmolar non-ketotic coma, end organ failure)
Gynecomastia	Detectable by study participant, caregiver, or physician AND Causing no or minimal interference with usual social & functional activities	Obvious on visual inspection AND Causing pain with greater than minimal interference with usual social & functional activities	Disfiguring changes AND Symptoms requiring intervention or causing inability to perform usual social & functional activities	NA
Hyperthyroidism	No symptoms AND Abnormal laboratory value	Symptoms causing greater than minimal interference with usual social & functional activities OR Thyroid suppression therapy indicated	Symptoms causing inability to perform usual social & functional activities OR Uncontrolled despite treatment modification	Life-threatening consequences (e.g., thyroid storm)
Hypothyroidism	No symptoms AND Abnormal laboratory value	Symptoms causing greater than minimal interference with usual social & functional activities OR Thyroid replacement therapy indicated	Symptoms causing inability to perform usual social & functional activities OR Uncontrolled despite treatment modification	Life-threatening consequences (e.g., myxedema coma)
Lipoatrophy[4]	Detectable by study participant, caregiver, or physician AND Causing no or minimal interference with usual social & functional activities	Obvious on visual inspection AND Causing greater than minimal interference with usual social & functional activities	Disfiguring changes	NA

[4] Definition: A disorder characterized by fat loss in the face, extremities, and buttocks.

Endocrine and Metabolic

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Lipohypertrophy[5]	Detectable by study participant, caregiver, or physician AND Causing no or minimal interference with usual social & functional activities	Obvious on visual inspection AND Causing greater than minimal interference with usual social & functional activities	Disfiguring changes	NA

[5] Definition: A disorder characterized by abnormal fat accumulation on the back of the neck, breasts, and abdomen.

Gastrointestinal

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Anorexia	Loss of appetite without decreased oral intake	Loss of appetite associated with decreased oral intake without significant weight loss	Loss of appetite associated with significant weight loss	Life-threatening consequences OR Aggressive intervention indicated (e.g., tube feeding, total parenteral nutrition)
Ascites	No symptoms	Symptoms AND Intervention indicated (e.g., diuretics, therapeutic paracentesis)	Symptoms recur or persist despite intervention	Life-threatening consequences
Bloating or Distension *Report only one*	Symptoms causing no or minimal interference with usual social & functional activities	Symptoms causing greater than minimal interference with usual social & functional activities	Symptoms causing inability to perform usual social & functional activities	NA
Cholecystitis	NA	Symptoms AND Medical intervention indicated	Radiologic, endoscopic, or operative intervention indicated	Life-threatening consequences (e.g., sepsis, perforation)
Constipation	NA	Persistent constipation requiring regular use of dietary modifications, laxatives, or enemas	Obstipation with manual evacuation indicated	Life-threatening consequences (e.g., obstruction)
Diarrhea *≥ 1 year of age*	Transient or intermittent episodes of unformed stools OR Increase of ≤ 3 stools over baseline per 24-hour period	Persistent episodes of unformed to watery stools OR Increase of 4 to 6 stools over baseline per 24-hour period	Increase of ≥ 7 stools per 24-hour period OR IV fluid replacement indicated	Life-threatening consequences (e.g., hypotensive shock)
< 1 year of age	Liquid stools (more unformed than usual) but usual number of stools	Liquid stools with increased number of stools OR Mild dehydration	Liquid stools with moderate dehydration	Life-threatening consequences (e.g., liquid stools resulting in severe dehydration, hypotensive shock)
Dysphagia or Odynophagia *Report only one and specify location*	Symptoms but able to eat usual diet	Symptoms causing altered dietary intake with no intervention indicated	Symptoms causing severely altered dietary intake with intervention indicated	Life-threatening reduction in oral intake
Gastrointestinal Bleeding	Not requiring intervention other than iron supplement	Endoscopic intervention indicated	Transfusion indicated	Life-threatening consequences (e.g., hypotensive shock)

Gastrointestinal

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Mucositis or Stomatitis *Report only one and specify location*	Mucosal erythema	Patchy pseudomembranes or ulcerations	Confluent pseudomembranes or ulcerations OR Mucosal bleeding with minor trauma	Life-threatening consequences (e.g., aspiration, choking) OR Tissue necrosis OR Diffuse spontaneous mucosal bleeding
Nausea	Transient (< 24 hours) or intermittent AND No or minimal interference with oral intake	Persistent nausea resulting in decreased oral intake for 24 to 48 hours	Persistent nausea resulting in minimal oral intake for > 48 hours OR Rehydration indicated (e.g., IV fluids)	Life-threatening consequences (e.g., hypotensive shock)
Pancreatitis	NA	Symptoms with hospitalization not indicated	Symptoms with hospitalization indicated	Life-threatening consequences (e.g., circulatory failure, hemorrhage, sepsis)
Perforation (colon or rectum)	NA	NA	Intervention indicated	Life-threatening consequences
Proctitis	Rectal discomfort with no intervention indicated	Symptoms causing greater than minimal interference with usual social & functional activities OR Medical intervention indicated	Symptoms causing inability to perform usual social & functional activities OR Operative intervention indicated	Life-threatening consequences (e.g., perforation)
Rectal Discharge	Visible discharge	Discharge requiring the use of pads	NA	NA
Vomiting	Transient or intermittent AND No or minimal interference with oral intake	Frequent episodes with no or mild dehydration	Persistent vomiting resulting in orthostatic hypotension OR Aggressive rehydration indicated (e.g., IV fluids)	Life-threatening consequences (e.g., hypotensive shock)

Musculoskeletal

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Arthralgia	Joint pain causing no or minimal interference with usual social & functional activities	Joint pain causing greater than minimal interference with usual social & functional activities	Joint pain causing inability to perform usual social & functional activities	Disabling joint pain causing inability to perform basic self-care functions
Arthritis	Stiffness or joint swelling causing no or minimal interference with usual social & functional activities	Stiffness or joint swelling causing greater than minimal interference with usual social & functional activities	Stiffness or joint swelling causing inability to perform usual social & functional activities	Disabling joint stiffness or swelling causing inability to perform basic self-care functions
Myalgia (generalized)	Muscle pain causing no or minimal interference with usual social & functional activities	Muscle pain causing greater than minimal interference with usual social & functional activities	Muscle pain causing inability to perform usual social & functional activities	Disabling muscle pain causing inability to perform basic self-care functions
Osteonecrosis	NA	No symptoms but with radiographic findings AND No operative intervention indicated	Bone pain with radiographic findings OR Operative intervention indicated	Disabling bone pain with radiographic findings causing inability to perform basic self-care functions
Osteopenia[6] *≥ 30 years of age*	BMD t-score -2.5 to -1	NA	NA	NA
< 30 years of age	BMD z-score -2 to -1	NA	NA	NA
Osteoporosis[6] *≥ 30 years of age*	NA	BMD t-score < -2.5	Pathologic fracture (e.g., compression fracture causing loss of vertebral height)	Pathologic fracture causing life-threatening consequences
< 30 years of age	NA	BMD z-score < -2	Pathologic fracture (e.g., compression fracture causing loss of vertebral height)	Pathologic fracture causing life-threatening consequences

[6] BMD t and z scores can be found in: Kanis JA on behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. 2007: Printed by the University of Sheffield.

Neurologic

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Acute CNS Ischemia	NA	NA	Transient ischemic attack	Cerebral vascular accident (e.g., stroke with neurological deficit)
Altered Mental Status (for Dementia, see *Cognitive, Behavioral, or Attentional Disturbance* below)	Changes causing no or minimal interference with usual social & functional activities	Mild lethargy or somnolence causing greater than minimal interference with usual social & functional activities	Confusion, memory impairment, lethargy, or somnolence causing inability to perform usual social & functional activities	Delirium OR Obtundation OR Coma
Ataxia	Symptoms causing no or minimal interference with usual social & functional activities OR No symptoms with ataxia detected on examination	Symptoms causing greater than minimal interference with usual social & functional activities	Symptoms causing inability to perform usual social & functional activities	Disabling symptoms causing inability to perform basic self-care functions
Cognitive, Behavioral, or Attentional Disturbance (includes dementia and attention deficit disorder) *Specify type, if applicable*	Disability causing no or minimal interference with usual social & functional activities OR Specialized resources not indicated	Disability causing greater than minimal interference with usual social & functional activities OR Specialized resources on part-time basis indicated	Disability causing inability to perform usual social & functional activities OR Specialized resources on a full-time basis indicated	Disability causing inability to perform basic self-care functions OR Institutionalization indicated
Developmental Delay *< 18 years of age* *Specify type, if applicable*	Mild developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting	Moderate developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting	Severe developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting	Developmental regression, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting
Headache	Symptoms causing no or minimal interference with usual social & functional activities	Symptoms causing greater than minimal interference with usual social & functional activities	Symptoms causing inability to perform usual social & functional activities	Symptoms causing inability to perform basic self-care functions OR Hospitalization indicated OR Headache with significant impairment of alertness or other neurologic function

Neurologic

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Neuromuscular Weakness (includes myopathy and neuropathy) *Specify type, if applicable*	Minimal muscle weakness causing no or minimal interference with usual social & functional activities OR No symptoms with decreased strength on examination	Muscle weakness causing greater than minimal interference with usual social & functional activities	Muscle weakness causing inability to perform usual social & functional activities	Disabling muscle weakness causing inability to perform basic self-care functions OR Respiratory muscle weakness impairing ventilation
Neurosensory Alteration (includes paresthesia and painful neuropathy) *Specify type, if applicable*	Minimal paresthesia causing no or minimal interference with usual social & functional activities OR No symptoms with sensory alteration on examination	Sensory alteration or paresthesia causing greater than minimal interference with usual social & functional activities	Sensory alteration or paresthesia causing inability to perform usual social & functional activities	Disabling sensory alteration or paresthesia causing inability to perform basic self-care functions
Seizures ***New Onset Seizure*** *≥ 18 years of age*	NA	NA	1 to 3 seizures	Prolonged and repetitive seizures (e.g., status epilepticus) OR Difficult to control (e.g., refractory epilepsy)
< 18 years of age (includes new or pre-existing febrile seizures)	Seizure lasting < 5 minutes with < 24 hours postictal state	Seizure lasting 5 to < 20 minutes with < 24 hours postictal state	Seizure lasting ≥ 20 minutes OR > 24 hours postictal state	Prolonged and repetitive seizures (e.g., status epilepticus) OR Difficult to control (e.g., refractory epilepsy)
Pre-existing Seizure	NA	Increased frequency from previous level of control without change in seizure character	Change in seizure character either in duration or quality (e.g., severity or focality)	Prolonged and repetitive seizures (e.g., status epilepticus) OR Difficult to control (e.g., refractory epilepsy)
Syncope	Near syncope without loss of consciousness (e.g., pre-syncope)	Loss of consciousness with no intervention indicated	Loss of consciousness AND Hospitalization or intervention required	NA

Pregnancy, Puerperium, and Perinatal

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Stillbirth (report using mother's participant ID) *Report only one*	NA	NA	Fetal death occurring at ≥ 20 weeks gestation	NA
Preterm Birth (report using mother's participant ID)	Live birth at 34 to < 37 weeks gestational age	Live birth at 28 to < 34 weeks gestational age	Live birth at 24 to < 28 weeks gestational age	Live birth at < 24 weeks gestational age
Spontaneous Abortion or Miscarriage[7] (report using mother's participant ID) *Report only one*	Chemical pregnancy	Uncomplicated spontaneous abortion or miscarriage	Complicated spontaneous abortion or miscarriage	NA

[7] Definition: A pregnancy loss occurring at < 20 weeks gestational age.

Psychiatric

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Insomnia	Mild difficulty falling asleep, staying asleep, or waking up early causing no or minimal interference with usual social & functional activities	Moderate difficulty falling asleep, staying asleep, or waking up early causing more than minimal interference with usual social & functional activities	Severe difficulty falling asleep, staying asleep, or waking up early causing inability to perform usual social & functional activities requiring intervention or hospitalization	NA
Psychiatric Disorders (includes anxiety, depression, mania, and psychosis) *Specify disorder*	Symptoms with intervention not indicated OR Behavior causing no or minimal interference with usual social & functional activities	Symptoms with intervention indicated OR Behavior causing greater than minimal interference with usual social & functional activities	Symptoms with hospitalization indicated OR Behavior causing inability to perform usual social & functional activities	Threatens harm to self or others OR Acute psychosis OR Behavior causing inability to perform basic self-care functions
Suicidal Ideation or Attempt *Report only one*	Preoccupied with thoughts of death AND No wish to kill oneself	Preoccupied with thoughts of death AND Wish to kill oneself with no specific plan or intent	Thoughts of killing oneself with partial or complete plans but no attempt to do so OR Hospitalization indicated	Suicide attempted

Respiratory

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Acute Bronchospasm	Forced expiratory volume in 1 second or peak flow reduced to ≥ 70 to < 80% OR Mild symptoms with intervention not indicated	Forced expiratory volume in 1 second or peak flow 50 to < 70% OR Symptoms with intervention indicated OR Symptoms causing greater than minimal interference with usual social & functional activities	Forced expiratory volume in 1 second or peak flow 25 to < 50% OR Symptoms causing inability to perform usual social & functional activities	Forced expiratory volume in 1 second or peak flow < 25% OR Life-threatening respiratory or hemodynamic compromise OR Intubation
Dyspnea or Respiratory Distress *Report only one*	Dyspnea on exertion with no or minimal interference with usual social & functional activities OR Wheezing OR Minimal increase in respiratory rate for age	Dyspnea on exertion causing greater than minimal interference with usual social & functional activities OR Nasal flaring OR Intercostal retractions OR Pulse oximetry 90 to < 95%	Dyspnea at rest causing inability to perform usual social & functional activities OR Pulse oximetry < 90%	Respiratory failure with ventilator support indicated (e.g., CPAP, BPAP, intubation)

Sensory

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Hearing Loss *≥ 12 years of age*	NA	Hearing aid or intervention not indicated	Hearing aid or intervention indicated	Profound bilateral hearing loss (> 80 dB at 2 kHz and above) OR Non-serviceable hearing (i.e., >50 dB audiogram and <50% speech discrimination)
< 12 years of age (based on a 1, 2, 3, 4, 6 and 8 kHz audiogram)	> 20 dB hearing loss at ≤ 4 kHz	> 20 dB hearing loss at > 4 kHz	> 20 dB hearing loss at ≥ 3 kHz in one ear with additional speech language related services indicated (where available) OR Hearing loss sufficient to indicate therapeutic intervention, including hearing aids	Audiologic indication for cochlear implant and additional speech-language related services indicated (where available)
Tinnitus	Symptoms causing no or minimal interference with usual social & functional activities with intervention not indicated	Symptoms causing greater than minimal interference with usual social & functional activities with intervention indicated	Symptoms causing inability to perform usual social & functional activities	NA
Uveitis	No symptoms AND Detectable on examination	Anterior uveitis with symptoms OR Medical intervention indicated	Posterior or pan-uveitis OR Operative intervention indicated	Disabling visual loss in affected eye(s)
Vertigo	Vertigo causing no or minimal interference with usual social & functional activities	Vertigo causing greater than minimal interference with usual social & functional activities	Vertigo causing inability to perform usual social & functional activities	Disabling vertigo causing inability to perform basic self-care functions
Visual Changes (assessed from baseline)	Visual changes causing no or minimal interference with usual social & functional activities	Visual changes causing greater than minimal interference with usual social & functional activities	Visual changes causing inability to perform usual social & functional activities	Disabling visual loss in affected eye(s)

Systemic

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Acute Allergic Reaction	Localized urticaria (wheals) with no medical intervention indicated	Localized urticaria with intervention indicated OR Mild angioedema with no intervention indicated	Generalized urticaria OR Angioedema with intervention indicated OR Symptoms of mild bronchospasm	Acute anaphylaxis OR Life-threatening bronchospasm OR Laryngeal edema
Chills	Symptoms causing no or minimal interference with usual social & functional activities	Symptoms causing greater than minimal interference with usual social & functional activities	Symptoms causing inability to perform usual social & functional activities	NA
Cytokine Release Syndrome[8]	Mild signs and symptoms AND Therapy (i.e., antibody infusion) interruption not indicated	Therapy (i.e., antibody infusion) interruption indicated AND Responds promptly to symptomatic treatment OR Prophylactic medications indicated for ≤ 24 hours	Prolonged severe signs and symptoms OR Recurrence of symptoms following initial improvement	Life-threatening consequences (e.g., requiring pressor or ventilator support)
Fatigue or Malaise *Report only one*	Symptoms causing no or minimal interference with usual social & functional activities	Symptoms causing greater than minimal interference with usual social & functional activities	Symptoms causing inability to perform usual social & functional activities	Incapacitating symptoms of fatigue or malaise causing inability to perform basic self-care functions
Fever (non-axillary temperatures only)	38.0 to < 38.6°C or 100.4 to < 101.5°F	≥ 38.6 to < 39.3°C or ≥ 101.5 to < 102.7°F	≥ 39.3 to < 40.0°C or ≥ 102.7 to < 104.0°F	≥ 40.0°C or ≥ 104.0°F
Pain[9] (not associated with study agent injections and not specified elsewhere) *Specify location*	Pain causing no or minimal interference with usual social & functional activities	Pain causing greater than minimal interference with usual social & functional activities	Pain causing inability to perform usual social & functional activities	Disabling pain causing inability to perform basic self-care functions OR Hospitalization indicated

[8] Definition: A disorder characterized by nausea, headache, tachycardia, hypotension, rash, and/or shortness of breath.
[9] For pain associated with injections or infusions, see the *Site Reactions to Injections and Infusions* section (page 23).

Systemic

Serum Sickness[10]	Mild signs and symptoms	Moderate signs and symptoms AND Intervention indicated (e.g., antihistamines)	Severe signs and symptoms AND Higher level intervention indicated (e.g., steroids or IV fluids)	Life-threatening consequences (e.g., requiring pressor or ventilator support)
Underweight[11] *> 5 to 19 years of age*	WHO BMI z-score < -1 to -2	WHO BMI z-score < -2 to -3	WHO BMI z-score < -3	WHO BMI z-score < -3 with life-threatening consequences
2 to 5 years of age	WHO Weight-for-height z-score < -1 to -2	WHO Weight-for-height z-score < -2 to -3	WHO Weight-for-height z-score < -3	WHO Weight-for-height z-score < -3 with life-threatening consequences
< 2 years of age	WHO Weight-for-length z-score < -1 to -2	WHO Weight-for-length z-score < -2 to -3	WHO Weight-for-length z-score < -3	WHO Weight-for-length z-score < -3 with life-threatening consequences
Unintentional Weight Loss (excludes postpartum weight loss)	NA	5 to < 9% loss in body weight from baseline	≥ 9 to < 20% loss in body weight from baseline	≥ 20% loss in body weight from baseline OR Aggressive intervention indicated (e.g., tube feeding, total parenteral nutrition)

[10] Definition: A disorder characterized by fever, arthralgia, myalgia, skin eruptions, lymphadenopathy, marked discomfort, and/or dyspnea.

[11] WHO reference tables may be accessed by clicking the desired age range or by accessing the following URLs: http://www.who.int/growthref/who2007_bmi_for_age/en/ for participants > 5 to 19 years of age and http://www.who.int/childgrowth/standards/chart_catalogue/en/ for those ≤ 5 years of age.

Urinary

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Urinary Tract Obstruction	NA	Signs or symptoms of urinary tract obstruction without hydronephrosis or renal dysfunction	Signs or symptoms of urinary tract obstruction with hydronephrosis or renal dysfunction	Obstruction causing life-threatening consequences

Site Reactions to Injections and Infusions

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Injection Site Pain or Tenderness *Report only one*	Pain or tenderness causing no or minimal limitation of use of limb	Pain or tenderness causing greater than minimal limitation of use of limb	Pain or tenderness causing inability to perform usual social & functional activities	Pain or tenderness causing inability to perform basic self-care function OR Hospitalization indicated
Injection Site Erythema or Redness[12] *Report only one* *> 15 years of age*	2.5 to < 5 cm in diameter OR 6.25 to < 25 cm^2 surface area AND Symptoms causing no or minimal interference with usual social & functional activities	≥ 5 to < 10 cm in diameter OR ≥ 25 to < 100 cm^2 surface area OR Symptoms causing greater than minimal interference with usual social & functional activities	≥ 10 cm in diameter OR ≥ 100 cm^2 surface area OR Ulceration OR Secondary infection OR Phlebitis OR Sterile abscess OR Drainage OR Symptoms causing inability to perform usual social & functional activities	Potentially life-threatening consequences (e.g., abscess, exfoliative dermatitis, necrosis involving dermis or deeper tissue)
≤ 15 years of age	≤ 2.5 cm in diameter	> 2.5 cm in diameter with < 50% surface area of the extremity segment involved (e.g., upper arm or thigh)	≥ 50% surface area of the extremity segment involved (e.g., upper arm or thigh) OR Ulceration OR Secondary infection OR Phlebitis OR Sterile abscess OR Drainage	Potentially life-threatening consequences (e.g., abscess, exfoliative dermatitis, necrosis involving dermis or deeper tissue)
Injection Site Induration or Swelling *Report only one* *> 15 years of age*	Same as for **Injection Site Erythema or Redness,** *> 15 years of age*	Same as for **Injection Site Erythema or Redness,** *> 15 years of age*	Same as for **Injection Site Erythema or Redness,** *> 15 years of age*	Same as for **Injection Site Erythema or Redness,** *> 15 years of age*
≤ 15 years of age	Same as for **Injection Site Erythema or Redness,** *≤ 15 years of age*	Same as for **Injection Site Erythema or Redness,** *≤ 15 years of age*	Same as for **Injection Site Erythema or Redness,** *≤ 15 years of age*	Same as for **Injection Site Erythema or Redness,** *≤ 15 years of age*
Injection Site Pruritus	Itching localized to the injection site that is relieved spontaneously or in < 48 hours of treatment	Itching beyond the injection site that is not generalized OR Itching localized to the injection site requiring ≥ 48 hours treatment	Generalized itching causing inability to perform usual social & functional activities	NA

[12] Injection Site Erythema or Redness should be evaluated and graded using the greatest single diameter or measured surface area.

*Laboratory Values**
Chemistries

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Acidosis	NA	pH ≥ 7.3 to < LLN	pH < 7.3 without life-threatening consequences	pH < 7.3 with life-threatening consequences
Albumin, Low (g/dL; *g/L*)	3.0 to < LLN *30 to < LLN*	≥ 2.0 to < 3.0 *≥ 20 to < 30*	< 2.0 *< 20*	NA
Alkaline Phosphatase, High	1.25 to < 2.5 x ULN	2.5 to < 5.0 x ULN	5.0 to < 10.0 x ULN	≥ 10.0 x ULN
Alkalosis	NA	pH > ULN to ≤ 7.5	pH > 7.5 without life-threatening consequences	pH > 7.5 with life-threatening consequences
ALT or SGPT, High *Report only one*	1.25 to < 2.5 x ULN	2.5 to < 5.0 x ULN	5.0 to < 10.0 x ULN	≥ 10.0 x ULN
Amylase (Pancreatic) or Amylase (Total), High *Report only one*	1.1 to < 1.5 x ULN	1.5 to < 3.0 x ULN	3.0 to < 5.0 x ULN	≥ 5.0 x ULN
AST or SGOT, High *Report only one*	1.25 to < 2.5 x ULN	2.5 to < 5.0 x ULN	5.0 to < 10.0 x ULN	≥ 10.0 x ULN
Bicarbonate, Low (mEq/L; *mmol/L*)	16.0 to < LLN *16.0 to < LLN*	11.0 to < 16.0 *11.0 to < 16.0*	8.0 to < 11.0 *8.0 to < 11.0*	< 8.0 *< 8.0*
Bilirubin ***Direct Bilirubin[13], High*** *> 28 days of age*	NA	NA	> ULN with other signs and symptoms of hepatotoxicity.	> ULN with life-threatening consequences (e.g., signs and symptoms of liver failure)
≤ 28 days of age	ULN to ≤ 1 mg/dL	> 1 to ≤ 1.5 mg/dL	> 1.5 to ≤ 2 mg/dL	> 2 mg/dL
Total Bilirubin, High *> 28 days of age*	1.1 to < 1.6 x ULN	1.6 to < 2.6 x ULN	2.6 to < 5.0 x ULN	≥ 5.0 x ULN
≤ 28 days of age	See Appendix A. Total Bilirubin for Term and Preterm Neonates	See Appendix A. Total Bilirubin for Term and Preterm Neonates	See Appendix A. Total Bilirubin for Term and Preterm Neonates	See Appendix A. Total Bilirubin for Term and Preterm Neonates

*Reminder: An asymptomatic abnormal laboratory finding without an accompanying AE should not be reported to DAIDS in an expedited time frame unless it meets protocol-specific reporting requirements.

[13] Direct bilirubin > 1.5 mg/dL in a participant < 28 days of age should be graded as grade 2, if < 10% of the total bilirubin.

Chemistries

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Calcium, High (mg/dL; *mmol/L*)				
≥ *7 days of age*	10.6 to < 11.5 *2.65 to < 2.88*	11.5 to < 12.5 *2.88 to < 3.13*	12.5 to < 13.5 *3.13 to < 3.38*	≥ 13.5 ≥ *3.38*
< *7 days of age*	11.5 to < 12.4 *2.88 to < 3.10*	12.4 to < 12.9 *3.10 to < 3.23*	12.9 to < 13.5 *3.23 to < 3.38*	≥ 13.5 ≥ *3.38*
Calcium (Ionized), High (mg/dL; *mmol/L*)	> ULN to < 6.0 *> ULN to < 1.5*	6.0 to < 6.4 *1.5 to < 1.6*	6.4 to < 7.2 *1.6 to < 1.8*	≥ 7.2 ≥ *1.8*
Calcium, Low (mg/dL; *mmol/L*)				
≥ *7 days of age*	7.8 to < 8.4 *1.95 to < 2.10*	7.0 to < 7.8 *1.75 to < 1.95*	6.1 to < 7.0 *1.53 to < 1.75*	< 6.1 *< 1.53*
< *7 days of age*	6.5 to < 7.5 *1.63 to < 1.88*	6.0 to < 6.5 *1.50 to < 1.63*	5.50 to < 6.0 *1.38 to < 1.50*	< 5.50 *< 1.38*
Calcium (Ionized), Low (mg/dL; *mmol/L*)	< LLN to 4.0 *< LLN to 1.0*	3.6 to < 4.0 *0.9 to < 1.0*	3.2 to < 3.6 *0.8 to < 0.9*	< 3.2 *< 0.8*
Cardiac Troponin I, High	NA	NA	NA	Levels consistent with myocardial infarction or unstable angina as defined by the local laboratory
Creatine Kinase, High	3 to < 6 x ULN	6 to < 10x ULN	10 to < 20 x ULN	≥ 20 x ULN
Creatinine, High **Report only one*	1.1 to 1.3 x ULN	> 1.3 to 1.8 x ULN OR Increase to 1.3 to < 1.5 x participant's baseline	> 1.8 to < 3.5 x ULN OR Increase to 1.5 to < 2.0 x participant's baseline	≥ 3.5 x ULN OR Increase of ≥ 2.0 x participant's baseline
Creatinine Clearance[14] or eGFR, Low **Report only one*	NA	< 90 to 60 ml/min or ml/min/1.73 m^2 OR 10 to < 30% decrease from participant's baseline	< 60 to 30 ml/min or ml/min/1.73 m^2 OR 30 to < 50% decrease from participant's baseline	< 30 ml/min or ml/min/1.73 m^2 OR ≥ 50% decrease from participant's baseline or dialysis needed
Glucose (mg/dL; *mmol/L*)				
Fasting, High	110 to 125 *6.11 to < 6.95*	> 125 to 250 *6.95 to < 13.89*	> 250 to 500 *13.89 to < 27.75*	≥ 500 ≥ *27.75*
Nonfasting, High	116 to 160 *6.44 to < 8.89*	> 160 to 250 *8.89 to < 13.89*	> 250 to 500 *13.89 to < 27.75*	≥ 500 ≥ *27.75*

[14] Use the applicable formula (i.e., Cockcroft-Gault in mL/min or Schwartz, MDRD, CKD-Epi in mL/min/1.73m2). Sites should choose the method defined in their study and when not specified, use the method most relevant to the study population.

*Reminder: Choose the method that selects for the higher grade.

Chemistries

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Glucose, Low (mg/dL; *mmol/L*)				
≥ 1 month of age	55 to 64 *3.05 to <3.55*	40 to < 55 *2.22 to < 3.05*	30 to < 40 *1.67 to < 2.22*	< 30 *< 1.67*
< 1 month of age	50 to 54 *2.78 to < 3.00*	40 to < 50 *2.22 to < 2.78*	30 to < 40 *1.67 to < 2.22*	< 30 *< 1.67*
Lactate, High	ULN to < 2.0 x ULN without acidosis	≥ 2.0 x ULN without acidosis	Increased lactate with pH < 7.3 without life-threatening consequences	Increased lactate with pH < 7.3 with life-threatening consequences
Lipase, High	1.1 to < 1.5 x ULN	1.5 to < 3.0 x ULN	3.0 to < 5.0 x ULN	≥ 5.0 x ULN
Lipid Disorders (mg/dL; *mmol/L*)				
Cholesterol, Fasting, High *≥ 18 years of age*	200 to < 240 *5.18 to < 6.19*	240 to < 300 *6.19 to < 7.77*	≥ 300 *≥ 7.77*	NA
< 18 years of age	170 to < 200 *4.40 to < 5.15*	200 to < 300 *5.15 to < 7.77*	≥ 300 *≥ 7.77*	NA
LDL, Fasting, High *≥ 18 years of age*	130 to < 160 *3.37 to < 4.12*	160 to < 190 *4.12 to < 4.90*	≥ 190 *≥ 4.90*	NA
> 2 to < 18 years of age	110 to < 130 *2.85 to < 3.34*	130 to < 190 *3.34 to < 4.90*	≥ 190 *≥ 4.90*	NA
Triglycerides, Fasting, High	150 to 300 *1.71 to 3.42*	>300 to 500 *>3.42 to 5.7*	>500 to < 1,000 *>5.7 to 11.4*	> 1,000 *> 11.4*
Magnesium[15], Low (mEq/L; *mmol/L*)	1.2 to < 1.4 *0.60 to < 0.70*	0.9 to < 1.2 *0.45 to < 0.60*	0.6 to < 0.9 *0.30 to < 0.45*	< 0.6 *< 0.30*
Phosphate, Low (mg/dL; *mmol/L*)				
> 14 years of age	2.0 to < LLN *0.65 to < LLN*	1.4 to < 2.0 *0.45 to < 0.65*	1.0 to < 1.4 *0.32 to < 0.45*	< 1.0 *< 0.32*
1 to 14 years of age	3.0 to < 3.5 *0.97 to < 1.13*	2.5 to < 3.0 *0.81 to < 0.97*	1.5 to < 2.5 *0.48 to < 0.81*	< 1.5 *< 0.48*
< 1 year of age	3.5 to < 4.5 *1.13 to < 1.45*	2.5 to < 3.5 *0.81 to < 1.13*	1.5 to < 2.5 *0.48 to < 0.81*	< 1.5 *< 0.48*
Potassium, High (mEq/L; *mmol/L*)	5.6 to < 6.0 *5.6 to < 6.0*	6.0 to < 6.5 *6.0 to < 6.5*	6.5 to < 7.0 *6.5 to < 7.0*	≥ 7.0 *≥ 7.0*
Potassium, Low (mEq/L; *mmol/L*)	3.0 to < 3.4 *3.0 to < 3.4*	2.5 to < 3.0 *2.5 to < 3.0*	2.0 to < 2.5 *2.0 to < 2.5*	< 2.0 *< 2.0*

[15] To convert a magnesium value from mg/dL to mmol/L, laboratories should multiply by 0.4114.

Chemistries

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Sodium, High (mEq/L; *mmol/L*)	146 to < 150 *146 to < 150*	150 to < 154 *150 to < 154*	154 to < 160 *154 to < 160*	≥ 160 *≥ 160*
Sodium, Low (mEq/L; *mmol/L*)	130 to < 135 *130 to < 135*	125 to < 130 *125 to < 130*	121 to < 125 *121 to < 125*	≤ 120 *≤ 120*
Uric Acid, High (mg/dL; *mmol/L*)	7.5 to < 10.0 *0.45 to < 0.59*	10.0 to < 12.0 *0.59 to < 0.71*	12.0 to < 15.0 *0.71 to < 0.89*	≥ 15.0 *≥ 0.89*

Hematology

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Absolute CD4+ Count, Low (cell/mm^3; *cells/L*)				
> 5 years of age (not HIV infected)	300 to < 400 *300 to < 400*	200 to < 300 *200 to < 300*	100 to < 200 *100 to < 200*	< 100 *< 100*
Absolute Lymphocyte Count, Low (cell/mm^3; *cells/L*)				
> 5 years of age (not HIV infected)	600 to < 650 *0.600 x 10^9 to < 0.650 x 10^9*	500 to < 600 *0.500 x 10^9 to < 0.600 x 10^9*	350 to < 500 *0.350 x 10^9 to < 0.500 x 10^9*	< 350 *< 0.350 x 10^9*
Absolute Neutrophil Count (ANC), Low (cells/mm^3; *cells/L*)				
> 7 days of age	800 to 1,000 *0.800 x 10^9 to 1.000 x 10^9*	600 to 799 *0.600 x 10^9 to 0.799 x 10^9*	400 to 599 *0.400 x 10^9 to 0.599 x 10^9*	< 400 *< 0.400 x 10^9*
2 to 7 days of age	1,250 to 1,500 *1.250 x 10^9 to 1.500 x 10^9*	1,000 to 1,249 *1.000 x 10^9 to 1.249 x 10^9*	750 to 999 *0.750 x 10^9 to 0.999 x 10^9*	< 750 *< 0.750 x 10^9*
≤ 1 day of age	4,000 to 5,000 *4.000 x 10^9 to 5.000 x 10^9*	3,000 to 3,999 *3.000 x 10^9 to 3.999 x 10^9*	1,500 to 2,999 *1.500 x 10^9 to 2.999 x 10^9*	< 1,500 *< 1.500 x 10^9*
Fibrinogen, Decreased (mg/dL; *g/L*)	100 to < 200 *1.00 to < 2.00* OR 0.75 to < 1.00 x LLN	75 to < 100 *0.75 to < 1.00* OR ≥ 0.50 to < 0.75 x LLN	50 to < 75 *0.50 to < 0.75* OR 0.25 to < 0.50 x LLN	< 50 *< 0.50* OR < 0.25 x LLN OR Associated with gross bleeding
Hemoglobin[16], Low (g/dL; *mmol/L*)[17]				
≥ 13 years of age (male only)	10.0 to 10.9 *6.19 to 6.76*	9.0 to < 10.0 *5.57 to < 6.19*	7.0 to < 9.0 *4.34 to < 5.57*	< 7.0 *< 4.34*
≥ 13 years of age (female only)	9.5 to 10.4 *5.88 to 6.48*	8.5 to < 9.5 *5.25 to < 5.88*	6.5 to < 8.5 *4.03 to < 5.25*	< 6.5 *< 4.03*

[16] Male and female sex are defined as sex at birth. For transgender participants ≥13 years of age who have been on hormone therapy for more than 6 consecutive months, grade hemoglobin based on the gender with which they identify (i.e., a transgender female should be graded using the female sex at birth hemoglobin laboratory values).

[17] The most commonly used conversion factor to convert g/dL to mmol/L is 0.6206. For grading hemoglobin results obtained by an analytic method with a conversion factor other than 0.6206, the result must be converted to g/dL using appropriate conversion factor for the particular laboratory.

Hematology

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
57 days of age to < 13 years of age (male and female)	9.5 to 10.4 *5.88 to 6.48*	8.5 to < 9.5 *5.25 to < 5.88*	6.5 to < 8.5 *4.03 to < 5.25*	< 6.5 *< 4.03*
36 to 56 days of age (male and female)	8.5 to 9.6 *5.26 to 5.99*	7.0 to < 8.5 *4.32 to < 5.26*	6.0 to < 7.0 *3.72 to < 4.32*	< 6.0 *< 3.72*
22 to 35 days of age (male and female)	9.5 to 11.0 *5.88 to 6.86*	8.0 to < 9.5 *4.94 to < 5.88*	6.7 to < 8.0 *4.15 to < 4.94*	< 6.7 *< 4.15*
8 to ≤ 21 days of age (male and female)	11.0 to 13.0 *6.81 to 8.10*	9.0 to < 11.0 *5.57 to < 6.81*	8.0 to < 9.0 *4.96 to < 5.57*	< 8.0 *< 4.96*
≤ 7 days of age (male and female)	13.0 to 14.0 *8.05 to 8.72*	10.0 to < 13.0 *6.19 to < 8.05*	9.0 to < 10.0 *5.59 to < 6.19*	< 9.0 *< 5.59*
INR, High (not on anticoagulation therapy)	1.1 to < 1.5 x ULN	1.5 to < 2.0 x ULN	2.0 to < 3.0 x ULN	≥ 3.0 x ULN
Methemoglobin (% hemoglobin)	5.0 to < 10.0%	10.0 to < 15.0%	15.0 to < 20.0%	≥ 20.0%
PTT, High (not on anticoagulation therapy)	1.1 to < 1.66 x ULN	1.66 to < 2.33 x ULN	2.33 to < 3.00 x ULN	≥ 3.00 x ULN
Platelets, Decreased (cells/mm^3; *cells/L*)	100,000 to < 125,000 *100.000 x 10^9 to < 125.000 x 10^9*	50,000 to < 100,000 *50.000 x 10^9 to < 100.000 x 10^9*	25,000 to < 50,000 *25.000 x 10^9 to < 50.000 x 10^9*	< 25,000 *< 25.000 x 10^9*
PT, High (not on anticoagulation therapy	1.1 to < 1.25 x ULN	1.25 to < 1.50 x ULN	1.50 to < 3.00 x ULN	≥ 3.00 x ULN
WBC, Decreased (cells/mm^3; *cells/L*)				
> 7 days of age	2,000 to 2,499 *2.000 x 10^9 to 2.499 x 10^9*	1,500 to 1,999 *1.500 x 10^9 to 1.999 x 10^9*	1,000 to 1,499 *1.000 x 10^9 to 1.499 x 10^9*	< 1,000 *< 1.000 x 10^9*
≤ 7 days of age	5,500 to 6,999 *5.500 x 10^9 to 6.999 x 10^9*	4,000 to 5,499 *4.000 x 10^9 to 5.499 x 10^9*	2,500 to 3,999 *2.500 x 10^9 to 3.999 x 10^9*	< 2,500 *< 2.500 x 10^9*

Urinalysis

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Glycosuria (random collection tested by dipstick)	Trace to 1+ or ≤ 250 mg	2+ or > 250 to ≤ 500 mg	> 2+ or > 500 mg	NA
Hematuria (not to be reported based on dipstick findings or on blood believed to be of menstrual origin)	6 to < 10 RBCs per high power field	≥ 10 RBCs per high power field	Gross, with or without clots OR With RBC casts OR Intervention indicated	Life-threatening consequences
Proteinuria (random collection tested by dipstick)	1+	2+	3+ or higher	NA

Appendix A.
Total Bilirubin Table for Term and Preterm Neonates

PARAMETER	GRADE 1 MILD	GRADE 2 MODERATE	GRADE 3 SEVERE	GRADE 4 POTENTIALLY LIFE-THREATENING
Total Bilirubin[18], High (mg/dL; *µmol/L*)[19]				
Term Neonate[20] *< 24 hours of age*	4 to < 7 *68.4 to < 119.7*	7 to < 10 *119.7 to < 171*	10 to < 17 *171* to < *290.7*	≥ 17 ≥ *290.7*
24 to < 48 hours of age	5 to < 8 *85.5 to < 136.8*	8 to < 12 *136.8 to < 205.2*	12 to < 19 *205.2* to < *324.9*	≥ 19 ≥ *324.9*
48 to < 72 hours of age	8.5 to < 13 *145.35 to < 222.3*	13 to < 15 *222.3 to < 256.5*	15 to < 22 *256.5* to < *376.2*	≥ 22 ≥ *376.2*
72 hours to < 7 days of age	11 to < 16 *188.1 to < 273.6*	16 to < 18 *273.6 to < 307.8*	18 to < 24 *307.8* to < *410.4*	≥ 24 ≥ *410.4*
7 to 28 days of age (breast feeding)	5 to < 10 *85.5 to < 171*	10 to < 20 *171 to < 342*	20 to < 25 *342 to < 427.5*	≥ 25 ≥ *427.5*
7 to 28 days of age (not breast feeding)	1.1 to < 1.6 x ULN	1.6 to < 2.6 x ULN	2.6 to < 5.0 x ULN	≥ 5.0 x ULN
Preterm Neonate[20] *35 to < 37 weeks gestational age*	Same as for ***Total Bilirubin, High, Term Neonate*** (based on days of age).	Same as for ***Total Bilirubin, High, Term Neonate*** (based on days of age).	Same as for ***Total Bilirubin, High, Term Neonate*** (based on days of age).	Same as for ***Total Bilirubin, High, Term Neonate*** (based on days of age).
32 to < 35 weeks gestational age and < 7 days of age	NA	NA	10 to < 14 *171 to < 239.4*	≥ 14 ≥ *239.4*
28 to < 32 weeks gestational age and < 7 days of age	NA	NA	6 to < 10 *102.6 to < 171*	≥ 10 ≥ *171*
< 28 weeks gestational age and < 7 days of age	NA	NA	5 to < 8 *85.5 to < 136.8*	≥ 8 ≥ *136.8*
7 to 28 days of age (breast feeding)	5 to < 10 *85.5 to < 171*	10 to < 20 *171 to < 342*	20 to < 25 *342 to < 427.5*	≥ 25 ≥ *427.5*
7 to 28 days of age (not breast feeding)	1.1 to < 1.6 x ULN	1.6 to < 2.6 x ULN	2.6 to < 5.0 x ULN	≥ 5.0 x ULN

[18] Severity grading for total bilirubin in neonates is complex because of rapidly changing total bilirubin normal ranges in the first week of life followed by the benign phenomenon of breast milk jaundice after the first week of life. Severity grading in this appendix corresponds approximately to cut-offs for indications for phototherapy at grade 3 and for exchange transfusion at grade 4.

[19] A laboratory value of 1 mg/dL is equivalent to 17.1 µmol/L.

[20] Definitions: Term is defined as ≥ 37 weeks gestational age; near-term, as ≥ 35 weeks gestational age; preterm, as < 35 weeks gestational age; and neonate, as 0 to 28 days of age.

Appendix IV

Declaration of Helsinki

WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects

Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964
and amended by the:
29th WMA General Assembly, Tokyo, Japan, October 1975
35th WMA General Assembly, Venice, Italy, October 1983
41st WMA General Assembly, Hong Kong, September 1989
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996
52nd WMA General Assembly, Edinburgh, Scotland, October 2000
53rd WMA General Assembly, Washington DC, USA, October 2002 (Note of Clarification added)
55th WMA General Assembly, Tokyo, Japan, October 2004 (Note of Clarification added)
59th WMA General Assembly, Seoul, Republic of Korea, October 2008
64th WMA General Assembly, Fortaleza, Brazil, October 2013

Preamble

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data.

The Declaration is intended to be read as a whole and each of its constituent paragraphs should be applied with consideration of all other relevant paragraphs.

2. Consistent with the mandate of the WMA, the Declaration is addressed primarily to physicians. The WMA encourages others who are involved in medical research involving human subjects to adopt these principles.

General Principles

3. The Declaration of Geneva of the WMA binds the physician with the words,

“The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician shall act in the patient's best interest when providing medical care.”

4. It is the duty of the physician to promote and safeguard the health, well-being and rights of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment of this duty.

5. Medical progress is based on research that ultimately must include studies involving human subjects.

6. The primary purpose of medical research involving human subjects is to understand the causes, development and effects of diseases and improve preventive, diagnostic and therapeutic interventions (methods, procedures and treatments). Even the best proven interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility and quality.

7. Medical research is subject to ethical standards that promote and ensure respect for all human subjects and protect their health and rights.

8. While the primary purpose of medical research is to generate new knowledge, this goal can never take precedence over the rights and interests of individual research subjects.

9. It is the duty of physicians who are involved in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects. The responsibility for the protection of research subjects must always rest with the physician or other health care professionals and never with the research subjects, even though they have given consent.

10. Physicians must consider the ethical, legal and regulatory norms and standards for research involving human subjects in their own countries as well as applicable international norms and standards. No national or international ethical, legal or regulatory requirement should reduce or eliminate any of the protections for research subjects set forth in this Declaration.

11. Medical research should be conducted in a manner that minimises possible harm to the environment.

12. Medical research involving human subjects must be conducted only by

individuals with the appropriate ethics and scientific education, training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional.

13. Groups that are underrepresented in medical research should be provided appropriate access to participation in research.

14. Physicians who combine medical research with medical care should involve their patients in research only to the extent that this is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

15. Appropriate compensation and treatment for subjects who are harmed as a result of participating in research must be ensured.

Risks, Burdens and Benefits

16. In medical practice and in medical research, most interventions involve risks and burdens.

Medical research involving human subjects may only be conducted if the importance of the objective outweighs the risks and burdens to the research subjects.

17. All medical research involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and groups involved in the research in comparison with foreseeable benefits to them and to other individuals or groups affected by the condition under investigation.

Measures to minimise the risks must be implemented. The risks must be continuously monitored, assessed and documented by the researcher.

18. Physicians may not be involved in a research study involving human subjects unless they are confident that the risks have been adequately assessed and can be satisfactorily managed.

When the risks are found to outweigh the potential benefits or when there is conclusive proof of definitive outcomes, physicians must assess whether to continue, modify or immediately stop the study.

Vulnerable Groups and Individuals

19. Some groups and individuals are particularly vulnerable and may have an increased likelihood of being wronged or of incurring additional harm.

All vulnerable groups and individuals should receive specifically considered protection.

20. Medical research with a vulnerable group is only justified if the research is responsive to the health needs or priorities of this group and the research cannot be carried out in a non-vulnerable group. In addition, this group should stand to benefit from the knowledge, practices or interventions that result from the research.

Scientific Requirements and Research Protocols

21. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

22. The design and performance of each research study involving human subjects must be clearly described and justified in a research protocol.

The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, potential conflicts of interest, incentives for subjects and information regarding provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study.

In clinical trials, the protocol must also describe appropriate arrangements for post-trial provisions.

Research Ethics Committees

23. The research protocol must be submitted for consideration, comment, guidance and approval to the concerned research ethics committee before the study begins. This committee must be transparent in its functioning, must be independent of the researcher, the sponsor and any other undue influence and must be duly qualified. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and

standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration.

The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No amendment to the protocol may be made without consideration and approval by the committee. After the end of the study, the researchers must submit a final report to the committee containing a summary of the study's findings and conclusions.

Privacy and Confidentiality

24. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information.

Informed Consent

25. Participation by individuals capable of giving informed consent as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no individual capable of giving informed consent may be enrolled in a research study unless he or she freely agrees.

26. In medical research involving human subjects capable of giving informed consent, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, post-study provisions and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information.

After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject's freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

All medical research subjects should be given the option of being informed about the general outcome and results of the study.

27. When seeking informed consent for participation in a research study the physician must be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent must be sought by an appropriately qualified individual who is completely independent of this relationship.

28. For a potential research subject who is incapable of giving informed consent, the physician must seek informed consent from the legally authorised representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the group represented by the potential subject, the research cannot instead be performed with persons capable of providing informed consent, and the research entails only minimal risk and minimal burden.

29. When a potential research subject who is deemed incapable of giving informed consent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorised representative. The potential subject's dissent should be respected.

30. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research group. In such circumstances the physician must seek informed consent from the legally authorised representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research must be obtained as soon as possible from the subject or a legally authorised representative.

31. The physician must fully inform the patient which aspects of their care are related to the research. The refusal of a patient to participate in a study or the patient's decision to withdraw from the study must never adversely affect the patient-physician relationship.

32. For medical research using identifiable human material or data, such as research on material or data contained in biobanks or similar repositories, physicians must seek informed consent for its collection, storage and/or reuse. There may be exceptional situations where consent would be impossible or impracticable to obtain

for such research. In such situations the research may be done only after consideration and approval of a research ethics committee.

Use of Placebo

33. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best proven intervention(s), except in the following circumstances:

Where no proven intervention exists, the use of placebo, or no intervention, is acceptable; or

Where for compelling and scientifically sound methodological reasons the use of any intervention less effective than the best proven one, the use of placebo, or no intervention is necessary to determine the efficacy or safety of an intervention

and the patients who receive any intervention less effective than the best proven one, placebo, or no intervention will not be subject to additional risks of serious or irreversible harm as a result of not receiving the best proven intervention.

Extreme care must be taken to avoid abuse of this option.

Post-Trial Provisions

34. In advance of a clinical trial, sponsors, researchers and host country governments should make provisions for post-trial access for all participants who still need an intervention identified as beneficial in the trial. This information must also be disclosed to participants during the informed consent process.

Research Registration and Publication and Dissemination of Results

35. Every research study involving human subjects must be registered in a publicly accessible database before recruitment of the first subject.

36. Researchers, authors, sponsors, editors and publishers all have ethical obligations with regard to the publication and dissemination of the results of research. Researchers have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. All parties should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results must be published or otherwise made

publicly available. Sources of funding, institutional affiliations and conflicts of interest must be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.

Unproven Interventions in Clinical Practice

37. In the treatment of an individual patient, where proven interventions do not exist or other known interventions have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorised representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. This intervention should subsequently be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information must be recorded and, where appropriate, made publicly available.

Appendix V

Sponsor's Signature Page

PROTOCOL APPROVAL PAGE

Protocol No.:ICMR/SII-COVOVAX

Version No.: 6.0

Date: 18 May 2021

Amendment No.: 05

Study Title: A phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults

	[redacted]
Signature and Date	
Name	[redacted]

Appendix VI

Investigator’s statement of compliance

STATEMENT OF COMPLIANCE

Study Title: A phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults

Protocol No.: ICMR/SII-COVOVAX

Version: 6.0 Dated 18 May 2021

This study will be conducted in compliance with the approved clinical trial protocol, institution ethics committee and informed consent regulations and ICH GCP guidelines. The study will be conducted according to current revision of the Declaration of Helsinki (Revised Fortaleza, 2013). In addition, most current version of local regulatory and ethical requirements 'Guidelines for Clinical Trials on Pharmaceutical Products in India – GCP Guidelines' issued by Central Drugs Standard Control Organization (CDSCO), Ministry of Health, Government of India in 2005, 'Requirements and guidelines for permission to import and / or manufacture of new drugs for sale or to undertake clinical trials' (New Drugs and Clinical Trials Rules, 2019) and it's amended rules and 'Ethical Guidelines for Biomedical Research on Human Subjects' issued by Indian Council of Medical Research will be adhered to.

Principal Investigator	Signature	Date

Appendix VII

Study Sites and Principal Investigator Information

GENERAL INFORMATION: PRINCIPAL INVESTIGATORS AND STUDY SITES

Title	A phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults
Protocol No.	ICMR/SII-COVOVAX
Version and Date	Version: 6.0 Dated 18 May 2021
Phase	2/3
Sponsor	**SERUM INSTITUTE OF INDIA PVT. LTD.** 212/2, Off Soli Poonawalla Road, Hadapsar,Pune, Maharashtra-411028, India [redacted] **INDIAN COUNCIL OF MEDICAL RESEARCH** V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi - 110029, India
Principal Investigators and study sites	[redacted]

[redacted]	[redacted]
	[redacted]
[redacted]	[redacted]
	[redacted]
	[redacted]
	[redacted]
	[redacted]
	[redacted]

	[redacted]
	[redacted]
	[redacted]
	[redacted]
	[redacted]
	[redacted]
	[redacted]
	[redacted]